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First described in 1950 as a phytopathogen, Burkholderia cepacia possesses inherent
resistance to most classes of antibiotics and extraordinary metabolic abilities. In the last
five years, polyphasic taxonomic studies have revealed considerable diversity within
clinical and environmental isolates ofB. cepacia. Presently, the B. cepacia complex
comprises at least seven genomovars, a term that describes distinct genomic species
without a recognisable phenotype. Phenotypic characteristics distinguishing several
genomovars have now been identified and the genomovars renamed. Thus, the B.
cepacia complex currently consists ofB. cepacia genomovar I, B multivorans (formerly
genomovar II), B. cepacia genomovar III, B. stabilis (formerly genomovar IV), B.
vietnamiensis (formerly genomovar V), B. cepacia genomovar VI and B. ambifaria {B.
cepacia genomovar VII). During the 1980s members of the B. cepacia complex
emerged as life-threatening pathogens of immunocompromised individuals, particularly
patients with cystic fibrosis. Ironically, at the same time, the organisms' antifungal
properties led to increasing agricultural interest in the B. cepacia complex as
biopesticides to improve crop yields. The aims of this thesis were to investigate the
biological properties of both clinical and environmental isolates of the B. cepacia
complex, with particular relevance to their pathogenicity and potential biotechnological
exploitation.
B. vietnamiensis strains were more sensitive to ceftazidime and chloramphenicol than
strains from the other genomovars, and environmental B. cepacia genomovar III strains
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were more sensitive to ciprofloxacin and chloramphenicol than clinical isolates of the
same genomovar. Although resistance to antibiotics is not uniform across all the
subgroups of the B. cepacia complex, the antibiotic-sensitive strains can readily mutate
to high levels of resistance. With the exception of catalase and melanin that were only
produced by clinical strains, other putative virulence factors were detected in both
clinical and environmental isolates. Certain factors including genetic markers for
epidemic spread, were also detected in candidate biopesticide strains. The
phytopathogenicity of clinical and environmental isolates was also found to be similar.
Lack of knowledge regarding the fate of the B. cepacia complex strains introduced to the
environment is a major obstruction to the organisms' commercial exploitation. Ofmajor
concern is the possibility of genetic exchange between different B. cepacia complex
strains and between the B. cepacia complex and other soil microflora. Natural
transformation ofB. cepacia complex strains was demonstrated with DNA from the
well-characterised epidemic lineage ET12, represented by the Edinburgh isolate J2315.
The transformed bacteria included candidate biopesticide strains. The exchange of
genes was also observed through B. cepacia transducing phages NS1 and NS2, recently
identified in this thesis. Interestingly, the host spectrum of both phages spanned
environmental and clinical isolates, several sub-populations within the B. cepacia
complex and candidate biopesticide strains. The host range of the phages also extended
to P. aeruginosa. Some B. cepacia complex strains were also sensitive to well-
characterised P. aeruginosa transducing phages. Thus, not only is there potential for
B. cepacia DNA being exchanged between different sub-populations of the B. cepacia
xii
complex but also to P. aeruginosa. Sensitivity ofB. cepacia complex strains to
P. aeruginosa transducing phages could also facilitate the importation of foreign genes.
The similarity ofputative B. cepacia complex virulence factors produced by clinical,
environmental and candidate biopesticide strains, as well as the natural exchange of
genes between all subgroups suggests that caution should be exercised on the
commercial application ofmembers of the B. cepacia as biopesticides.
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Burkholderia cepacia, originally named Pseudomonas cepacia, was first described in
1950 as a phytopathogen causing 'sour skin', a bacterial rot which attacks the outer
fleshy scales of damaged onion bulbs (Burkholder, 1950). Between 1951 and 1965,
several clinical bacterial isolates designated as Eugonic oxidiser 1 (King, 1964), later
renamed Pseudomonas kingii (Jonsson, 1970), were submitted to the National
Communicable Disease Centre. In 1966, a group ofbacteria isolated from soil, water
and the hospital environments was described and named Pseudomonas multivorans
(eater of everything), to emphasize the organisms' extraordinary nutritional versatility
(Stanier, Palleroni, et al, 1966). In 1970, it was established that P. cepacia and P.
multivorans were synonyms for the same group ofbacteria (Ballard, Palleroni, et al,
1970). A few years later, P. kingii and P. cepacia were recognised as synonymous
(Snell, Hill, et al, 1972).
1.1.1. General characteristics
B. cepacia is a Gram negative, aerobic, non-spore-forming bacillus. It is motile by
means of one or more polar flagella, typically oxidase and catalase positive, may
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produce various non-fluorescent pigments and poly-13-hydroxyalkanoates can be
accumulated as intracellular reserve material. It has an optimum growth temperature of
30-35°C, a maximum growth temperature of 41°C and does not grow at 4°C (Burkholder,
1950, Palleroni, 1984).
1.1.2. Taxonomy of the B. cepacia complex
In the early 1970s, a taxonomic study of the aerobic pseudomonads revealed that the
organisms formally known as P. cepacia, Pseudomonas marginata and Pseudomonas
caryophylii shared many phenotypic characteristics with Pseudomonas pseudomallei and
Pseudomonas mallei. In addition, DNA-DNA hybridisation showed varying degrees of
genetic homology among all the five species which was not present with the other
pseudomonads tested, including Pseudomonas aeruginosa (Ballard, Palleroni, et al,
1970). This study resulted in these five species being provisionally named 'the
pseudomallei group'. Much later, bacterial whole cell protein profiles showed that
members of the rRNA group II pseudomonads, ofwhich 'the pseudomallei group' is a
part, were distinct from other non-fluorescent and fluorescent pseudomonads (Li and
Hayward, 1994).
In 1992, a new genus Burkholderia was formed from the rRNA homology group II of
the genus Pseudomonas with B. cepacia as the type species, and NCTC 10743 (ATCC
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24516) as the type strain (Yabuuchi, Kosako, et al, 1992). The new genus contained
seven species Burkholderia cepacia, Burkholderia mallei, Burkholderia pseudomallei,
Burkholderia caryophylli, Burkholderia gladioli, Burkholderia pickettii and
Burkholderia solanacearum.
Within collections of isolates presumptively identified as B. cepacia, five major
subgroups were later identified (Vandamme, Holmes, et al, 1997) and named
genomovars I-V; the term denotes a group of organisms which are genotypically distinct
but cannot be differentiated phenotypically (Ursing, Rossello-Mora, et al 1995). A
group of nitrogen-fixing bacteria isolated from the rhizosphere of rice cultivated in
Vietnam was shown to constitute a single cluster together with two strains of clinical
origin (Gillis, Van, et al, 1995). The name Burkholderia vietnamiensis was proposed for
this, the fifth genomovar ofB. cepacia. Genomovar II was later proposed to constitute a
new species Burkholderia multivorans (Vandamme, Holmes, et al, 1997) and
genomovar IV was re-named Burkholderia stabilis (Vandamme, Mahenthiralingam, et
al, 2000). More recent studies have identifed the additive genomovars VI and VII (Dr P.
Vandamme, personal communication). At present, all seven genomovars constitute the
B. cepacia complex. For the purpose of this thesis the terms B. cepacia and B. cepacia
complex are synonymous. B. cepacia genomovars II, IV and V will be referred to as B.
multivorans, B. stabilis and B. vietnamiensis respectively.
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While the taxonomy ofB. cepacia is an interesting and challenging subject in its own
respect, it was the life-threatening infections caused by B. cepacia, which primarily drew
attention to this group of organisms.
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1.1.3. Early cases of/?, cepacia infections
The first report ofB. cepacia infection was in 1966 when a Pseudomonas sp. was
identified as the cause of several cases ofpost-operative urinary tract infection in a UK
hospital (Mitchell and Hayward, 1966). The organism was reported as being unusual in
utilising an exceptionally wide range of carbohydrates. When epidemiological
investigations were conducted, the source of infection was traced to the disinfectant,
hibitane, which was used to disinfect the water tank which was then filled with the
sterile water used for bladder irrigation (Mitchell and Hayward, 1966).
This initial report was followed by sporadic reports of nosocomial B. cepacia infections.
B. cepacia was isolated from wounds (Bassett, Stokes, et al, 1970), the urinary and
respiratory tracts, blood (Ederer and Matsen, 1972), and the heart (Noriega, Rubinstein,
et al, 1975). In all these reports, the infection was traced to seemingly unlikely sources
such as contaminated antiseptics and disinfectants (Bassett, Stokes, et al, 1970),
benzylchloride solution in commercially packaged urinary catheter kits (Ederer and
Matsen, 1972) and distilled water, (Gelbart, Reinhardt, et al, 1976). A slightly different
cause of infection reported during this period was contamination of human serum
albumin during manufacture, which later led to bacteraemia (Steere, Terniey, et al,
1977).
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In summary, during the 60s and 70s infections caused by B. cepacia were sporadic and
could be generally traced to the use of contaminated solutions. It was only in the 1980s
that B. cepacia emerged as a major cause for concern in individuals with cystic fibrosis.
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1.2. Cystic fibrosis
Originally described in 1938 as cystic fibrosis of the pancreas, cystic fibrosis (CF) has
subsequently emerged to be the most common, potentially lethal, autosomal recessive
disease in Caucasians. In most human populations, CF affects between lin 2 000 and 1
in 4 500 individuals (Koch and Hoiby, 1993). The incidence is much higher in some
populations such as the Alberta Hutterites where it is 1 in 313 (Fujiwara, Morgan, et al,
1989), the South West African Afrikaner population where it is lin 622 (Super, 1975)
and lin 895 in the French-Canadian population of the Saguanay-Lac St. Jean region
(Rozen, Schwartz, et al, 1990). The unusually high incidences ofCF in these
populations are thought to be due to a founder effect in which the closely knit
communities grew from a small number of ancestors, some ofwhom were carriers,
followed by subsequent isolation of the population.
1.2.1. Clinical features ofCF
The clinical features ofCF are dominated by involvement of the respiratory tract and in
approximately 50% of CF patients, the diagnosis is first considered because of
pulmonary symptoms (Fitzsimmons, 1993). The symptoms include airway obstruction
by thick, sticky mucus, chronic cough and sputum production, persistent chest
radiograph abnormalities and persistent colonisation and/or infection with a narrow
spectrum of typical CF pathogens (Collins, 1992; Rosenstein and Cutting, 1998).
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Involvement of the gastrointestinal tract is also a common occurrence in most CF
patients. Approximately 18% of newborns with CF have a form of intestinal obstruction
called meconium ileus (Fitzsimmons, 1993). In addition, approximately 85%ofCF
patients, show pancreatic insufficiency as a result of obstruction of the pancreatic ducts
and subsequent scarring, leading to destruction of the organ's exocrine function (Collins,
1992; Fitzsimmons, 1993). Without the intake of dietary supplements, a large
proportion of ingested food would be lost in the stools with the loss of fat being
especially striking (Andersen, 1938).
The discovery that there is a high concentration ofNa+, K+ and CI" ions in the sweat of
CF patients (DiSanfAgnese, Darling, et al, 1953) led to the development of a sweat test
(Gibson and Cooke, 1959). 'The sweat test' remained the standard of confirmation or
exclusion of the diagnosis ofCF before the advent of genetic testing. This increased
amount of salts in the sweat is not decreased by a low-salt diet (DiSanfAgnese, Darling,
et al, 1953).
Reproductive fitness in females with CF is reduced and infertility is almost universal in
males. Infertility of adult males with CF is usually due to absence of the vas deferans
(Kaplan, Shwachman, et al, 1968) with most patients having aspermia, although
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spermatogenesis has been shown to occur. Other factors contributing to infertility
include a small semen volume which is acidic, testes that are diminished in size and a
reduced epididymus (Kaplan, Shwachman, et al, 1968). In contrast, women with CF
frequently give birth to healthy children although their fertility is reduced compared to
healthy females.
1.2.2. The CF gene and its product
A major advance in understanding CF occurred in 1989 when the CF gene was identified
and cloned through the use of chromosome walking, jumping and complementary DNA
hybridisation (Kerem, Rommens, et al, 1989, Rommens, Ianuzzi, et al, 1989, Riordan,
Rommens, et al, 1989). The 250kb of genomic DNA was found to encode a protein of
480 amino acids which was named the cystic fibrosis transmembrane conductance
regulator (CFTR).
On the basis of its predicted amino acid sequence, a potential structure for CFTR was
proposed (Riordan, Rommens, et al, 1989). The predictions were mainly based on the
striking homology of the CFTR primary sequence to a family ofproteins referred to as
the traffic adenosine triphosphatases (ATPases), or the ABC (ATP-binding cassette)
family (Hyde, Emsley, et al\ 1990). This family now includes over thirty proteins, some
ofwhich are not associated with transport, sharing approximately 30% sequence
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identification over a cassette of about 200 amino acids (Hyde, Emsley, et al. 1990).
Structurally, this family of proteins has one or two hydrophobic transmembrane
domains (TMDs), each usually involving six loops that span the membrane and one or
two nucleotide-binding domains (NBDs) that bind and cleave ATP (Figure 1.1) (Hyde,
Emsley, et al. 1990, Collins, 1992). In additions to the two TMDs and two NBDs,
CFTR contains a unique site called the R (regulatory) domain (Riordan, Rommens, et
al, 1989). The R domain is rich in serine residues that were predicted to be
phosphokinase A (PKA)-mediated phosphorylation sites (Riordan, Rommens, et al,
1989).
TMD1 TMD2
TMD, transmembrane domain; NBD, nucleotide-binding domain; R, regulatory domain
Fig 1.1. Schematic representation of the structure ofCFTR (Welsh, Anderson, et al,
1992)
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1.2.3. Expression of CFTR
Immunocytochemistry and in situ hybridisation studies revealed that CFTR is abundant
in the epithelial cells lining the pancreas, sweat ducts, salivary glands, lungs, intestinal
crypts, vas deferans and uterus (Crawford, Maloney, et al, 1991, Trezise and Buchwald,
1991). Surprisingly, the levels ofCFTR expression are relatively low in the epithelium
lining the respiratory tract (Crawford, Maloney, et al, 1991, Trezise and Buchwald,
1991), whereas kidney tubules (Crawford, Maloney, et al, 1991), and the serus tubules
of sub-mucosal glands show high expression of localised CFTR (Engelhardt and Wilson,
1992). Expression is restricted to apical rather than basolateral regions of epithelial cells
and at least a portion ofCFTR is associated with the plasma membrane (Crawford,
Maloney, et al, 1991).
1.2.4. Mutations associated with CF
The first of the CF mutations to be described was a deletion of three adjacent base pairs
leading to absence of the amino acid phenylalanine at position 508 in the first NBD
(Riordan, Rommens, et al, 1989). This mutation, AF508, accounts for approximately
70% of all CF mutations but its relative frequency varies between different ethnic or
geographic groups. AF508 is closely associated with pancreatic insufficiency, while
patients with one or two other mutations often have normal pancreatic function
(Kristidis, Bozon, et al, 1992).
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Since a single mutation is responsible for about 70% ofmutant CF chromosomes, it
would be expected that the total number ofmutations would be very small. However,
since 1989, more than 600 mutations have been identified in the CFTR gene although
only five have a world frequency of higher than 1% (Estivill, Bancells, et al, 1997).
These are AF508 (66%), G542X (2.6%), N1303K (1.6%), G551D (1.5%), and W1282X
(1.0%) (Estivill, Bancells, et al, 1997). The three most common CF mutations AF508,
G542X and N1303K are present in most countries and regions ofEurope (Estivill,
Bancells, et al, 1997), suggesting an ancient origin and spread of these mutations. The
different mutations affect the transport of several ions including CI" and Na+ across the
epithelium.
Four general mechanisms have been proposed to explain how the different CFTR
mutations affect chloride transport across the epithelium and these are reviewed by
Welsh and Smith, 1993.
❖ Class 1 mutations affect protein production by encoding truncated or aberrant forms
of protein. They constitute nonsense, frameshift and splice mutations such as
G542X and R553X and are associated with pancreatic insufficiency.
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❖ Class 2 mutations, the most common of all CFTR mutations, are processing
mutations and produce protein that is incompletely glycosylated and retained within
the endoplasmic reticulum. They include AF508 and are associated with severe
pancreatic insufficiency.
❖ Class 3 mutations encode proteins that are defective in channel regulation. The
defect may be mild as in G551S in which case the patients would be pancreatic
sufficient or it can result in complete loss of regulation as in G551D (Cutting, Kasch,
et al, 1990) resulting in pancreatic insufficiency.
❖ Class 4 mutations such as R117H affect the conduction properties of the channel and
usually occur in the trans-membrane domains (TMDs) (Welsh and Smithl993, Ma
and Davies, 1998).
1.2.5. Functions of CFTR
An indication of the function of CFTR came firstly from observing which tissues were
affected in CF and secondly from its localisation to the apical region of epithelia
(Crawford, Maloney, et al, 1991). It was postulated that CF involved an alteration of the
fluid in the epithelial tissue and this was supported by the observation that the sweat
from CF patients has an abnormal concentration of CI" (DiSant'Agnese, Darling, et al,
1953).
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Although expression ofnormal CFTR in cultured CF airway epithelial cells was shown
to correct the CI" channel defect (Rich, Anderson, et al, 1990), it was not initially clear
whether CFTR was a CI" channel or a regulator of a channel. On the basis of
understanding ofABC transporters, it was initially believed that CFTR could not itself
be a chloride channel (Crawford, Maloney, et al, 1991), for reasons that included the fact
that ABC transporters accumulate substrates against concentration gradients, requiring
ATP hydrolysis but chloride channels do not
Evidence that CFTR is a chloride channel was provided by an experiment in mice in
which the cAMP-activated CI" secretory response was found to be absent from CFTR
(-/-) mice as compared to littermate controls (Clarke, Grubb, et al, 1992). These
findings not only indicated that CFTR functions as a cAMP-regulated CI" conductance
pathway in murine epithelia but also that mice do not express an alternative cAMP-
mediated CI" conductance that might protect them from the effects of CFTR gene
disruption. Further evidence came from an experiment showing that when a basic amino
acid, lysine 95 or 335, in the TMD was altered to an acidic one, the anion selectivity of
cAMP-regulated channels containing either endogenous or recombinant CFTR was
altered from Br>Cl>I>Fl to I>Br>Cl>Fl (Anderson, Gregory et al, 1991). This showed
that CFTR is a chloride channel rather than a channel regulator and that either lysine 95
or 335 determine anion selectivity. However, the data did not exclude the possibility
that CFTR could have other functions. Shortly afterwards Bear and co-workers, purified
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and reconstituted CFTR from a cell line. When it was incorporated, the purified CFTR
exhibited regulated CI" channel activity, providing conclusive evidence that the protein
itself is the channel (Bear, Li, et al, 1992).
Having established that CFTR is indeed a chloride channel, the next challenge was to
understand how it functions. In proposing the structure of CFTR, Riordan and co¬
workers, had noted that the R domain is rich in serine residues which they predicted to
be sites ofphosphokinase A (PKA)-mediated phosphorylation (Riordan, Rommens, et
al, 1989). Two years later, it was shown that four serine residues 660,737,795 and 813
on the R domain are phosphorylated by PKA (Cheng, Rich, et al, 1991) and mutagenesis
of any one of these sites does not affect CI" channel activity. In fact, phosphorylation at
serine 660 alone is sufficient for the regulation ofCI" channel activity. The fact that
CFTR is poly phosphorylated on the R domain by PKA led to the suggestion that
phosphorylation could open the channel by providing an electrostatic force to repel the R
domain away from the membrane and prevent it from otherwise plugging the pore
(Welsh, Anderson, et al. 1992). While this hypothesis provided a role for the R domain
in CFTR, it did not provide an explanation for the role ofNBDs.
The role for NBDs was provided by a group ofworkers who demonstrated that
nucleoside triphosphates were required to open the CFTR CI" channel (Anderson, Berger
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et al, 1991). Using two different cell types, this group found that once phosphorylated
by cAMP-dependent PKA, the channels required cytosolic ATP to open.
Phosphorylated channels were reversibly activated by several hydrolysable nucleotides
but not with non-hydrolysable analogues or Mg 2+ free ATP. Their studies on CFTR
mutants indicated that ATP controls channel activity independent of the R domain and
suggested that hydrolysis ofATP at NBD1 may be sufficient for channel opening. They
concluded that nucleoside triphosphates regulate the CFTR CI" channel and that this
regulation most likely occurs through the NBDs and may require hydrolysis since only
hydrolysable nucleotides activate the channel F1 (Anderson, Gregory et al, 1991). The
discovery that ATP opens CFTR indicated that there may be at least two mechanisms to
regulate that channel, the first ofwhich involves PKA-dependent phosphorylation of the
R domain (Cheng, Rich, et al, 1991) and the second involving interaction ofnucleotides
with the NBDs F1 (Anderson, Gregory et al, 1991). In wild type CFTR, both processes
are required to open the channel and neither one alone is sufficient.
In summary, CFTR is a CI" channel located in the apical cell membrane. The channel is
activated by PKA-mediated phosphorylation of the serine residues on the R domain and
ATP hydrolysis in the NBDs. Phosphorylation on the R domain causes channel opening
by increasing negative charges which repel the R domain away from the membrane
(Cheng, Rich, et al, 1991; Wilkinson, Strong, et al, 1997). Parts of the TMDs constitute
the pore and the R domain functions as a channel inhibitor until it is phosphorylated by
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PKA. The closed state of the molecule can be secured by dephosphorylation of the R
domain (Ma and Davies, 1998).
CFTR has other functions in addition to being a chloride channel. It may also partly
regulate acidification of intracellular organelles by pumping H+ ions (Barasch, Kiss, et
al, 1991) and partly control cell endocytosis and exocytosis (Moss, 1995). It also
controls the efflux ofATP and concomitant regulation of the outwardly rectified
chloride channel (ORCC) and cAMP-dependent negative regulator of the epithelial Na+
channel (EnaC) (Mickle and Cutting, 1998).
Correction of the phenotypic defect by expression ofCFTR in cultured CF epithelial
cells (Rich, Anderson, et al, 1990), not only demonstrated a causal relationship between
mutations in the CFTR gene and defective CI" transport but also suggested the feasibility
of a therapeutic approach based on correcting the underlying defect. There are now
major human trials in progress using a variety of viral and non-viral vectors to test the
safety and efficiency ofCF gene therapy (Rosenfeld, Yoshimura et al, 1992, Caplen,
Alton, et al, 1995).
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1.2.6. Effects of CFTR dysfunction on the respiratory system
The normal mucociliary clearance system that cleanses the bronchopulmonary
epithelium of inhaled particles depends on the upward directional flow of a mucus layer
positioned at the tips of cilia that move freely in an underlying watery layer (the airway
surface fluid, ASF) (Mortesen, Hansen, et al, 1993). In conditions such as CF, the
mucociliary clearance system fails to function efficiently.
Two models that attempt to explain the failure ofCF airways to clear potential
pathogens by mucociliary clearance now been described. The first, proposed in 1988
(Boucher, Cotton, et al, 1988), is called the isotonic model of CFTR dysfunction.
Isotonic model
This model assumes that in people without CF the airway epithelium is a volume buffer
that controls the height of the ASF. If fluid is lost from the ASF by evaporation or
coughing, water flows across the epithelium into the ASF to restore the ASF volume.
The height of the ASF is critical for the normal mucociliary clearance of the
bronchopulmonary system. If the level is too high, then the tips of cilia fail to reach the
bottom of the mucus layer and are unable to move it. If on the other hand, the height is
too low then the cilia become enmeshed in the mucus and fail to function. The volume
of the ASF is controlled by the concentration of ions and by osmosis.
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The respiratory epithelium ofCF patients has a high potential difference due to increased
Na+ absorption in addition to lower CI" permeability (Boucher, Stutts, et al, 1986; Clarke,
Grubb, et al, 1992). It is thought that in CF, the major apical Na+ channel is open for an
abnormally large fraction of time, moving Na+ ions back into the epithelial cells to
compensate for the inefficient or absent CFTR which can not pump chloride out of the
epithelial cells into the ASF. Excessive absorption ofNa+ and CI" results in depletion of
water on airway surfaces since the osmotic potential of the ASF is not high enough to
attract water by osmosis. The lowered volume of the ASF means the cilia get tangled in
mucus leading to diminished immunity in the CF lung. Thus, according to this model,
the airway epithelium is a volume buffer and controls the height of the ASF, which is
critical for normal functioning of cilia.
Hypotonic model
The second model ofCFTR dysfunction is called the hypotonic model and was proposed
by workers at the University of Iowa College ofMedicine (Smith, Travis, et al, 1996).
This model suggests that the ASF in non-CF airways has a low, hypotonic salt
concentration and that a low NaCl concentration allows defensin-mediated antimicrobial
action to protect the airways. This model is supported by Goldman and co-workers who
demonstrated that a novel antimicrobial peptide called human P-defensin l(hBDl),
which is expressed in human epithelial cells, confers salt-dependent antimicrobial
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activity in ASF (Goldman, Anderson, et al, 1997) which is reduced or eliminated in high
salt concentrations.
A hypotonic salt gradient is formed by pumping sodium ions from the ASF into the
epithelium, leading to the passive flow of chloride ions back into the epithelium through
CFTR. In people with CF, this passive flow of chloride ions through CFTR can not
occur, the hypotonic gradient can not be formed, thus leading to elevated salt levels in
the ASF which inactivates the antimicrobial defensins in the ASF and lowers the
immunity of the CF lung. Thus, the hypotonic model proposes that non-CF airways
have a hypotonic salt concentration which allows naturally occurring antimicrobial
peptides to contribute to the defense of the host against bacterial pathogens.
Despite these plausible models for the role ofCFTR dysfunction on the respiratory
system, CF lung disease is also greatly influenced by other factors, in particular, the
influence of life-threatening pulmonary infections caused by a surprisingly small
spectrum of bacterial pathogens (Mickle and Cutting, 1998). Pulmonary function can be
extremely variable even in individuals with the same CFTR genotype. Although studies
on monozygotic and dizygotic twins indicate that there are genetic factors that influence
the severity ofpulmonary disease (Santis, Osborne, et al, 1992), the influence of
bacterial pathogens probably exerts the greatest influence.
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1.2.7. Microbiology ofCF
Most morbidity and mortality in CF is associated with progressive pulmonary
deterioration caused by recurrent exacerbation of chronic endobronchial bacterial
infection. Surprisingly, the bacteriology of the infected CF airways shows a unique
specificity of colonising pathogens with a predictable progression of colonisation. In
younger patients, infections with Staphylococcus aureus and Haemophilus influenzae
predominate while chronic P. aeruginosa infection is typically delayed until early
adolescence. Evidence suggests that the mechanisms leading to bacterial attachment to
upper airways, and early colonisation, depend on adhesins on the surface ofbacteria
(Ramphal, 1990).
Recent research has provided an explanation for the persistence of CF pathogens in the
respiratory tract. The common CF pathogens P. aeruginosa and S. aureus are killed
when added to the apical surface of normal airway epithelia but multiply on CF epithelia
(Smith, Travis, et al, 1996). Although the bactericidal activity is present in the ASF of
both normal and CF epithelia, bacterial killing requires a low NaCl concentration and
since CF ASF is suggested to have a high NaCl concentration, CF epithelia fail to kill
bacteria. The ASF from normal cells also kills other organisms and hence has broad-
spectrum bactericidal activity.
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This bactericidal activity secreted into the ASF is dependent on a low salt concentration
and has been identified as the antimicrobial peptide human (3-defensin 1 (hBD-1)
(Goldman, Anderson, et al, 1997). The activity of defensins in the ASF forms the basis
of the hypotonic model of CF dysfunction discussed previously.
1.2.7.1. Staphylococcus aureus
S. aureus was the first organism to be recognised as a cause of chronic lung infections in
young CF patients and in the 1930s staphylococcal infection was considered to be the
major cause ofmortality (Anderson, 193 8). S. aureus is associated with both chronic and
sporadic infections in CF and patient-to-patient spread can occur (Goering, Bauernfeind,
et al, 1990).
The exact mechanisms through which S. aureus causes infection in the CF lung are
unclear. The organism produces various products some ofwhich, for example, the
enterotoxins, have been identified as causing disease. However, the majority of
products, which include coagulase, catalase and haemolysins, have no clear role in
human infections (Cohen, 1986). Products such as teichoic acid and exopolysaccharide
may play a role in adherence to the respiratory epithelium in CF patients (Aly and Levit,
1987).
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In the CF lung, chronic airway infection is typically exacerbated and characterised by an
inflammatory hyper-secretion of'sticky' tracheobronchial mucus; in non-CF individuals
'normal' mucus acts as a barrier and removal system for bacterial pathogens. In chronic
bacterial lung infection however, inflammation and excess mucus may contribute to the
inefficiency ofmucociliary clearance and be responsible for the persistence of bacterial
infection. S. aureus possesses surface proteins that bind to human mucins, the major
constituents ofmucus (Trivier, Houdret, et al, 1997). It is believed that this ability to
bind human mucins could explain the early colonisation of the CF respiratory tract by
S. aureus.
1.2.7.2. Haemophilus influenzae
The role ofH. influenzae in CF lung disease is currently unresolved and controversial.
This is because although non-capsulated strains ofH. influenzae colonise the lower
respiratory tracts ofpatients with CF, they may also be found in the lower respiratory
tracts of non-CF children (Hoiby, 1976). In children under 12 years of age with CF,
H. influenzae may be the most frequently isolated organism from patient sputum as a
pure culture (Rayner, Hiller, et al, 1990). However, increased isolation ofH. influenzae
often precedes the development of acute exacerbations in CF patients and clinical
improvement coincides with a reduction in the isolation rate after antimicrobial
treatment (Rayner, Hiller, et al, 1990). In addition, studies on the use ofC-reactive
23
protein as an indicator ofpulmonary inflammation provide evidence that the highest
levels ofC-reactive protein coincide with acute exacerbation and culture of
H. influenzae (Glass, Hayward, et al, 1988). Generally, the organism is eradicated by
treatment with amoxycillin or fluoroquinolones such as ciprofloxacin (Pressler, Szaff, et
al, 1984; Rayner, Hiller, et al, 1990), and thus does not present the same problems of
chronic infection experienced with S. aureus and P. aeruginosa.
I.2.7.3. Pseudomonas aeruginosa
Infection with P. aeruginosa exceeds that of all other pathogens with up to 90% of adult
CF patients eventually becoming infected. Initially, the P. aeruginosa infecting the
lower respiratory tract exhibits a non-mucoid colonial phenotype; chronic infection
coincides with the production ofbacterial alginate and the notorious mucoid phenotype
(Koch and Hoiby, 1993). A major reason for the persistence ofP. aeruginosa in CF
airways is growth in micro-colonies embedded in an alginate matrix or biofilm. As the
infection becomes established, the host produces specific but ineffective anti-
pseudomonal antibodies leading to bronchopulmonary inflammation and obstruction.
This immune-mediated inflammation leads to further tissue damage, loss of lung tissue
and eventually pulmonary failure (Koch and Hoiby, 1993). Inflammatory cells, mainly
neutrophil granulocytes, accumulate and degenerate releasing tissue-damaging elastase
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and DNA, which also increases the viscosity of the secretions thus making them more
difficult for removal by cilia.
A possible explanation for the presence ofP. aeruginosa in CF airways derives from
CFTR's role as a pH regulator within the Golgi complex. Mutations in CFTR result in
decreased acidification of the trans-Golgi complex (Barasch and Al-Awqati, 1993).
Sialylation of proteins requires an acidic pH and dysfunction or absence ofCFTR leads
to undersialylation. Apical surfaces of CF epithelial cells have undersialylated proteins
and a higher concentration of asialoganglioside 1 (aGM,) than membranes with wild
type CFTR (Imundo, Barasch, et al, 1995).
It has been suggested that the tetrasaccharide moiety of aGMi is a receptor for S. aureus
and the P. aeruginosa pilin (Saiman and Prince, 1993, Imundo, Barasch, et al, 1995).
Thus increased aGM! in the apical membrane ofCF epithelia makes it a likely
contributor to the pathogenesis ofbacterial infections (Imundo, Barasch, et al, 1995).
1.2.7.4. Aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) caused by Aspergillus fumigatus was
first described in patients with CF in 1965 (Meams, Young, et al, 1965). In many
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patients, the proliferation ofAspergillus in the lung does not appear to cause any
symptoms but in some individuals with CF, it may lead to significant lung disease in
which tissue damage due to the immune reaction of the host occurs (Hiller, 1990).
Although most patients make good recoveries either spontaneously (Simmonds,
Littlewood, et al, 1990) or with steroid treatment (Maguire, Moriarty, et al, 1988),
recurrences are quite common (Brueton, Ormerod, et al, 1980; Maguire, Moriarty, et al,
1988).
1.2.7.5. Emerging CF pathogens
The microbiology ofCF pulmonary infection has changed with the increased life
expectancy ofpatients. Of note is the increased recovery of antibiotic-resistant
organisms such as Stenotrophomonas maltophilia and Alcaligenes xylosoxidans (Burns,
Emerson, et al, 1998; Peltroche-Llacsahuanga and Hasse, 1998). At present, the
pathogenic role of these opportunistic pathogens remains unclear. Other emergent
potential pathogens include Ralstonia pickettii and Bordetella hinzii (usually associated
with poultry) which has been reported as causing pulmonary exacerbation in a CF
patient over an extended period (Funke, Hess, et al, 1996). Although the role of these
organisms in CF lung disease is currently controversial, they possess sufficient potential
to emerge as the next new threat to CF patients. LPS from these organisms upregulates
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the expression ofproinflammatory cytokines to a level comparable with B. cepacia
(Hutchison, Bonell, et al, 2000).
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1.3. Burkholderia cepacia in cystic fibrosis
In the 1980s, several CF centres reported an increase in the numbers of patients infected
with B. cepacia, with a few centres reporting an incidence as high as 20% (Isles,
Maclusky, et al, 1984; Thomassen, Demko, et al, 1985). Most isolates were found to be
resistant to the commonly used antibiotics with the exception of chloramphenicol and
trimethoprim-sulphamethoxazole (Isles, Maclusky, et al, 1984). In addition, B. cepacia
often persisted in the CF lung despite the use of antibiotics previously shown to have in
vitro activity (Gold, 1983). B. cepacia infection was thought to be associated with
hospitalisation since one study found that 56% of patients developed chronic infection
either during or immediately after a hospitalisation (Thomassen, Demko, et al, 1985).
The clinical outcomes ofB. cepacia infection were found to be different from symptoms
previously experienced with other CF pathogens. Three distinct clinical patterns were
identified among CF patients infected with B. cepacia; chronic asymptomatic carriage,
progressive deterioration over many months, and a rapid, usually fatal deterioration in
previously mildly affected patients (Isles, Maclusky, et al, 1984; Thomassen, Demko, et
al, 1985). Patients colonised with B. cepacia showed significantly greater impairment of
pulmonary function than those colonised with P. aeruginosa or with neither organism.
Several patients with moderate pre-existing lung disease developed a fulminant
B. cepacia pneumonia which was sometimes accompanied by septicaemia and died
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rapidly (Isles, Maclusky, et al, 1984; Thomassen, Demko, et al, 1985). This rapid
deterioration became known as the 'cepacia syndrome'. Some patients who
asymptomatically harboured B. cepacia for several years ultimately experienced a rapid
decline characterised by fever and frequent hospitalisation prior to death (Thomassen,
Demko, et al, 1985). Females in good clinical condition were found to be more likely
than males to experience a decline in clinical condition, thus B. cepacia worsened the
already poor prognosis for females with CF (Thomassen, Demko, et al, 1985).
An early epidemiologic investigation showed that the risk of colonisation of CF patients
with B. cepacia increased with; increased severity of underlying CF, increased age,
having a sibling with CF who was colonised with B. cepacia and previous
hospitalisation (Tablan, Martone, et al, 1987); however, the source and mode of
transmission remained unclear. Since B. cepacia infection was thought to be associated
with hospitalisation, some CF centres introduced infection control measures in order to
abate the spread of infection. These measures included the physical separation of
hospitalised patients colonised with B. cepacia from non-colonised patients, education of
staff and families ofpatients with CF regarding precautionary measures and holding
separate summer camps and facilities for the colonised and non-colonised individuals
(Thomassen, Demko, et al, 1985; Smith, Smith, et al, 1992) or barrier nursing for all CF
patients irrespective ofmicrobiological findings (Millar- Jones, Paull, et al, 1992).
These infection control practices were considered draconian and unnecessary by some
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patients and CF centres but unarguably led to a general decline in the numbers of newly
infected patients (Thomassen, Demko, et al, 1985; Whiteford, Wilkinson, et al, 1995).
The ensuing decline in the numbers ofnewly infected individuals suggested that patient-
to-patient transmission, either directly or indirectly, was an important mode of
transmission. This speculation was confirmed by later studies (LiPuma, Dasen, et al,
1990; Cazzola, Amalfitano, et al, 1996). Infection control measures did not, however,
totally prevent acquisition ofB. cepacia as some centres still had new cases which were
thought to be caused by environmental acquisition (Smith, Smith, et al, 1992).
Although it had not yet been unequivocally established whether or not B. cepacia caused
pulmonary damage or merely acted as a clinical marker ofprogressive lung damage,
studies continued to demonstrate its transmissibility among CF patients. In addition to
showing that 20% of non-colonised patients acquired B. cepacia from a chronically
colonised individual after four weeks of exposure, LiPuma and co workers reported that
B. cepacia colonisation could be inapparent for several months after acquisition of the
organism (LiPuma, Marksaustin, et al, 1994). This was supported by another group that
showed as much as a four-fold increase in antibody response to B. cepacia before the
first culture of the organism from sputum (Govan, Brown, et al, 1993). However,
neither group could ascertain whether or not such inapparently colonised individuals
posed a threat to non-colonised patients.
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A study showing the acquisition ofB. cepacia at summer camps was carried out in 1994
and showed that the prevalence of sputum conversion increased with the number of
infected campers and the duration of the camp (Pegues, Carson, et al, 1994).
Transmission ofB. cepacia through social contact outwith the CF clinic and summer
camps was demonstrated in the UK by the transmission of a single strain within and
between several regional CF centres (Govan, Brown, et al, 1993); the precise nature of
social contacts facilitating transmission was not determined but attendance at a weekly
exercise class held in a school gymnasium was strongly suspected.
The observation ofB. cepacia transmission during or immediately after hospitalisation
was not reported by all centres. Some studies reported no evidence ofB. cepacia
transmission in the hospital setting although colonised and non-colonised patients
interacted freely (Hardy, McGowan, et al, 1986; Simmonds, Conway, et al, 1990), and
the sputum cultures of the non-colonised group remained free ofB. cepacia at three and
six months after discharge (Hardy, McGowan, et al, 1986). These varied results led to
considerable controversy on the need and value of separating B. cepacia colonised from
non-colonised patients. The differences in findings were explained when data suggested
that not all isolates ofB. cepacia were equally transmissible between CF patients. A
highly transmissible clonal lineage (the gymnasium isolate referred to previously)
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expressing giant cable pili was identified as being responsible for epidemics in the North
American and British CF centres (Govan, 1995; Sun, Jiang, et al, 1995). At present,
there is consensus that not only does B. cepacia infection occasionally cause a rapid
decline in clinical condition but some strains appear to be particularly adept at
transmitting from person-to-person. Evidence from national CF databases also
emphasize the pathogenic role ofB. cepacia-, life expectancy has been measured as more
than 50 years for CF patients free ofP. aeruginosa and B. cepacia, reducing to 29 years
for P. aeruginosa and to 21 years for P. cepacia-positive patients (LiPuma, 1998).
The emergence ofB. cepacia as a CF pathogen, with the accompanying controversy on
its epidemiology, prevalence and pathogenic role, is closely mirrored by the current
situation regarding 'new' organisms such as Stenotrophomonas maltophilia. Whether or
not these organisms will be shown to cause future major problems in CF lung disease
remains to be seen.
It has been reported that Burkholderia gladioli, another organism which, like B. cepacia,
is primarily a plant pathogen, was isolated from the respiratory tracts of CF patients
attending different centres in North America (Christenson, Welch, et al, 1989), although
no deleterious effects on the condition of the patients were observed. A more intriguing
report was the revelation that multi-resistant isolates responsible for high mortality,
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morbidity and transmission in UK CF patients which had been previously identified as
B. cepacia actually possessed characteristics ofboth B. cepacia and B. gladioli
(Simpson, Finlay, et al, 1994). Later studies revealed that some of these strains
belonged to B. cepacia genomovar III and included the highly transmissible ET12
lineage (Vandamme, Hlomes, et al, 1997). Another report of a B. galdioli isolate
causing a cross-infection problem, rapid decline in respiratory status and fulminant
bacteremia in CF patients (Wilsher, Kolbe, et al, 1997), was also later shown to have
been a misidentification of a B. cepacia genomovar III isolate (Clode, Matherell, et al,
1999). This problem ofmisidentification casts some doubt on the role ofB. gladioli in
CF infections. However, there are still numerous reports ofB. gladioli infections in
different patient groups including patients with CF (Khan, Gordon, et al, 1996; Graves,
Robin, et al, 1997; Jones, Stanbridge, et al, 2001).
In contrast to the debatable contribution ofB. gladioli, the contribution ofB. cepacia to
CF lung disease has now been unequivocally established. What remains to be elucidated
are the organism's virulence factors and the bacteria/host interactions responsible for
pulmonary damage.
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1.4. Pathogenicity and Virulence of B. cepacia
In contrast to the clearly defined virulence factors ofP. aeruginosa, the virulence
determinants ofB. cepacia are yet to be established. However, several cellular and
extracellular components have been identified as putative virulence factors.
1.4.1. Protease
The reported frequency of protease production among isolates of the B. cepacia complex
is not consistent. Some workers report that most strains can produce extracellular
proteases (McKevitt and Woods, 1984; Nakazawa, Yamada, et al, 1987; Gessner and
Mortensen, 1990; Gilligan, 1991), whereas other groups have indicated that rhizosphere
isolates are deficient in proteases (Bevivino, Tabacchioni, et al, 1994). Differences
between the proteases ofB. cepacia and P. aeruginosa have also been reported with the
former being unable to degrade elastin (McKevitt and Woods, 1984).
The B. cepacia protease PSCP, is a zinc metalloprotease of 34kDa, with an optimum pH
of 6.0 and temperature of 45°C (McKevitt, Bajaksouzian, et al, 1989). Sera from mice
immunised with the protease show a rise in antibody to the enzyme (McKevitt,
Bajaksouzian, et al\ 1989, Kooi, 1994), and heat inactivation increases the
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immunogenicity of the protease. PSCP produces bronchopneumonia when instilled
intratracheally into rat lungs and production of anti-PSCP antibodies does not protect
against lung damage produced by the same strain ofB. cepacia from which the enzyme
was derived.
Interestingly, antibodies to B. cepacia PSCP cross-react with a B. pseudomallei
extracellular protease and the V. cholerae HA1 protease, as well as the elastase and
alkaline phosphatase from. P. aeruginosa (McKevitt, Bajaksouzian, et al, 1989; Kooi,
1994).
1.4.2. Lipase
Extracellular lipases probably play a physiological role in bacteria by hydrolyzing
exogenous triglycerides to produce free fatty acids which are used for energy generation
(Lonon, Woods, et al, 1988). In addition, lipases, particularly phospholipases, are
known to play an important role in the virulence of some bacterial pathogens. Examples
in Gram-positive bacteria include the lipase produced by S. aureus, which possibly
enhances the organism's colonisation of the skin by hydrolyzing the lipids on the human
epithelial surface (Willet, 1976) and the a-toxin of Clostridium perfringens. Gram-
negative organisms, including V. cholerae and various Pseudomonas species, also
produce lipases, the most notable ofwhich is phospholipase C (PLC) (Esselman and Liu,
1961). This enzyme is a lecithinase which catalyzes the hydrolysis of
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phosphatidylcholine, a phospholipid found in the membrane of animal cells, into
phosphocholine and diacylglycerol (Esselman and Liu, 1961). Evidence suggests that
this enzyme is a virulence factor in pulmonary infections caused by P. aeruginosa
(Southern, Mays, et al, 1970).
The lipolytic activity of the organism later to be designated as P. cepacia, was first
described in 1941 (Starr and Burkholder, 1941). Since then, various workers have
described different types of lipases including esterases and lecithinase (Lonon, Woods,
et al, 1988; Gessner and Mortensen, 1990; Vasil, Krieg, et al, 1990; Lonon and Hooke,
1991). One study found that 60% ofB. cepacia CF isolates tested produce a lecithinase
which is not PLC (Lonon, Woods, et al, 1988) and had a molecular weight of 25 000.
At least one strain ofB. cepacia (Pc224c) has been shown to produce PLC activity
which is non hemolytic, heat labile, not a lecithinase and is inhibited by inorganic
phosphate (Lonon and Hooke, 1991).
One of the ways in which lipases may contribute to bacterial virulence is through their
reduction of the phagocytic activity ofmacrophages (Straus, Lonon, et al, 1992). Thus
lipase may be an important virulence determinant by allowing B. cepacia to evade the
mammalian host defence system. This inhibitory effect is lost when the lipase is
inactivated by heat. B. cepacia lipase appears to exert its antiphagocytic effect on
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pulmonary rat alveolar macrophages by affecting their cell surface (Straus, Lonon, et al,
1992).
1.4.3. Haemolysin
Haemolysin is considered a virulence factor for several different bacteria. About 4% of
B. cepacia strains produce a heat-labile haemolysin that is most active against human
erythrocytes (Nakazawa, Yamada, et al, 1987). In contrast to P. aeruginosa, production
of haemolysin by B. cepacia strains does not correlate with phospholipase (PLC)
activity. Recently, an interesting 'haemolysin' ofB. cepacia was purified and found to
cause cause apoptosis and degranulation of human neutrophils, (Hutchison, Poxton, et
al, 1998), in addition to causing lysis of human erythrocytes.
1.4.4. Siderophores
Siderophores are iron-chelating compounds which are excreted by bacteria in iron-
limiting conditions to solubilize, transport and store iron (Stephan, Freund, et al, 1999).
Siderophores stimulate bacterial growth in iron-deficient media by enabling the cells to
compete with host iron-binding proteins, thus enhancing the pathogenic potential of an
organism. Several families of siderophores have been described in B. cepacia including
pyochelin (Sokol, 1986), cepabactin (Meyer, Hohnadel, et al, 1989), salicylic acid
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(Visca, Cierco, et al, 1999) and ornibactins (Stephan, Freund, et al, 1999). Salycylic
acid is not only a precursor of pyochelin synthesis but is an endogenous siderophore for
some B. cepacia, P. aeruginosa and P. fluorescens isolates (Visca, Cierco, et al, 1999).
Azurechelin has been identified as one of the siderophores produced by B. cepacia
(Bukovits, Mohr, et al, 1982) but has recently been shown to be identical to salicylic
acid (Visca, Cierco, et al, 1999).
There is evidence to suggest that pyochelin production by clinical strains ofB. cepacia is
associated with increased morbidity and mortality ofCF patients (Sokol, 1986). Most
strains (81%) causing mild to moderate infections did not produce pyochelin, whereas
the isolates from 'serious' infections were pyochelin-positive. It has been suggested that
the CF pathogens B. cepacia and P. aeruginosa are 'co-operative' in their pyochelin
usage, that is, if one does not produce pyochelin, it could use that of the other (Sokol,
1986), a process which renders both organisms excellent iron chelators.
1.4.5. Evasion of the immune system
In recent years, there has been growing evidence to suggest that B. cepacia's ability to
cause persistent and sometimes invasive infections may be due, at least in part, to its
ability to invade and survive intracellularly in humans. Burns and co-workers showed in
1996 that a CF isolate ofB. cepacia could invade and survive in cultured respiratory
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epithelial cells more efficiently than an environmental isolate (Burns, Jonas, et al, 1996).
So far, there is no evidence that B. cepacia causes destruction of respiratory epithelial
cells. Rather, organisms enter the eukaryotic cells where they remain, protected from
antibiotics and host defenses. The cells may also transcytose the epithelium and cause
bacteraemia in a sub-population ofCF patients.
Several genomovars ofB. cepacia, ofboth clinical and environmental origin, can survive
and replicate for several days within different strains of the free-living amoebae
Acanthamoeba (Marolda, Hauroda, et al, 1999). In addition, extracellular B. cepacia can
grow saprophytically on the by-products released by the amoeba and Acanthamoeba
strains periodically release membrane-bound vesicles containing bacteria (Marolda,
Hauroda, et al, 1999).
Following demonstration of the survival ofB. cepacia in respiratory epithelial cells and
amoeba, several groups have reported the invasion ofmacrophages (Tipper, Ingham, et
al, 1998; Saini, Galsworthy, et al, 1999; Martin, and Mohr, 2000). Although clinical
and environmental isolates can invade macrophages and epithelial cells with the same
frequency (Martin, and Mohr, 2000), in contrast to clinical isolates, environmental
isolates were unable to replicate intracellularly (Tipper, Ingham, et al, 1998; Martin, and
Mohr, 2000). Intracellular survival ofB. cepacia in macrophages was found to occur
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despite the fact that the macrophages were activated and releasing superoxides (Saini,
Galsworthy, et al, 1999). These repeated cycles ofphagocytosis and macrophage
activation without bacterial killing promote a deleterious inflammatory response causing
tissue destruction and decay of the lung. Thus intracellular survival and replication of B.
cepacia may contribute to the virulence potential of pathogenic strains and may play a
role in the pathogenesis ofCF lung infection.
Intracellular!ty ofB. cepacia also provides possible explanations for the organism's
survival in the environment in amoebae, transmission, persistence in the lungs,
macrophages, neutrophils and epithelial cells despite the use of antibiotics with
demonstrated in vitro activity, and induction of inflammation leading to CF lung disease.
1.4.6. Lipopolysaccharide (LPS)
LPS is a well-known bacterial virulence factor on account of its potent immuno-
stimulatory effects on granulocytes, macrophages and lymphocytes (Reitschel, Kirikae,
et al, 1993). Whereas, environmental isolates ofB. cepacia only possess smooth LPS,
clinical isolates possess either rough or smooth LPS, (Evans, Poxton, et al, 1999) which
is cross-reactive amongst different B. cepacia and with other Burkholderia species, such
as B. gladioli. Several studies indicate that B. cepacia LPS contributes to the organism's
pathogenicity in CF lung disease. In endotoxicity assays, LPS from both clinical and
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environmental isolates ofB. cepacia was more endotoxic than LPS from P. aeruginosa
(Shaw, Poxton, et al, 1995). B. cepacia and B. gladioli LPS produces at least a nine fold
higher activity in tumour necrosis factor (TNF) induction compared to both a CF isolate
ofP. aeruginosa and P. aeruginosa PA01 (Shaw, Poxton, et al, 1995), indicating that
B. cepacia LPS has greater potential than P. aeruginosa to cause sustained immune-
mediated damage in the lung. TNFa is a pro-inflammatory cytokine that plays a key
role in the regulation and secretion of other cytokines and thus amplifying and
diversifying the immune response (Manthey and Vogel, 1992). It was suggested that the
stimulation ofTNF by B. cepacia LPS may contribute to destructive pulmonary
inflammation since B. cepacia stimulates a pronounced inflammatory response in CF
mice (Davidson, Dorin, et al, 1995) and in CF patients as measured by levels of
neutrophil elastase (Elbom, Dodd, et al, 1994).
B. cepacia LPS is also a more potent priming agent of neutrophil respiratory burst than
P. aeruginosa LPS (Hughes, Stewart, et al, 1997). It is suggested that neutrophils
exposed to B. cepacia LPS may be involved in the recruitment of other neutrophils to the
lung or the LPS may prime neutrophils to increase the release of tissue-damaging
enzymes and reactive oxygen species from activated neutrophils.
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1.3.7. Pili and Flagella
Binding of a potential pathogen to the host's epithelium or mucosal surfaces is often
critical for the subsequent establishment of an infection. Analogous to P. aeruginosa,
B. cepacia has polar pili and flagella but there is no homology between the two
organisms' pilin structural genes, and B. cepacia is resistant to P. aeruginosa pilus-
specific phages (Saiman, Cacalano, et al, 1990). The binding capacity of the two
organisms also differs with P. aeruginosa binding to epithelial cell monolayers up to ten
times more than B. cepacia (Saiman, Cacalano, et al, 1990). Supernatants ofP.
aeruginosa increase the binding ofB. cepacia, suggesting that P. aeruginosa
exoproducts alter the epithelial cell surface and promote B. cepacia adherence.
Interestingly, mannose-binding lectins on the epithelium surface bind to B. cepacia, and
lead to complement activation, more strongly than they bind to P. aeruginosa (Davies,
Neth, et al, 2000). Thus, CF patients with mannose-binding lectin deficiency are at a
particular risk ofB. cepacia infection.
In B. cepacia isolates, the density of surface pili correlates with mucin-binding capacity
(Sajjan and Forstner, 1992); the major mucin-binding component being a 22kDa
doublet. Significantly, binding ofB. cepacia to mucin is highest for isolates from CF
patients with advanced lung disease (Sajjan and Forstner, 1992). Since mucin covers the
epithelial surface of the respiratory tract and is poorly cleared in CF, the 22kDa pilin
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adhesin formucin could be a potential colonisation and/or virulence factor in B. cepacia
infections.
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1.5. Resistance of B. cepacia to antibiotics
Treatment ofB. cepacia infections is difficult because of the organism's high intrinsic
resistance to most of the common antibacterial agents (Fass and Barnishan, 1980).
Although meropenem is more effective than other antibiotics (Lewin, Doherty, et al,
1993) therapeutic choices to treat most B. cepacia infections are chloramphenicol,
fluorinated quinolones, ceftazidime and co-trimoxazole (Blumer, Stern, et al, 1985,
Moore and Hancock, 1986). B. cepacia's susceptibility to various antimicrobial agents
varies widely between different isolates, including isolates with the same ribotype
pattern (Pitt, Kafmann, et al, 1996). Treatment ofB. cepacia infections is further
complicated by failure of antibiotics with demonstrated in vitro activity to have a
significant effect in patients with severe infections (Gold, Jin, et al, 1983; Isles,
Maclusky, et al, 1984). A number of possible explanations for this occurrence have
been suggested, including the failure of sufficient concentrations of antibiotic to
penetrate the bronchial mucosa and impaired phagocytic activity within the CF lung
(Thomassen, Boxerbaum, et al, 1979). Once effective antibiotics have been identified,
the development of further antibiotic resistance during therapy and the induction of
cross-resistance to other unrelated antimicrobial agents, adds to the already difficult task
ofmanaging B. cepacia infections.
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1.5.1. Cross-resistance between unrelated classes of antibiotics
Several workers have observed that strains ofB. cepacia show cross-resistance between
classes of unrelated antimicrobial compounds. Multiple drug resistance that crosses
drug class lines often involves a permeability change. Rajyaguru and Muszynski (1997)
found that chloramphenicol resistant mutants ofB. cepacia also expressed cross-
resistance to trimethoprim/sulphamethoxazole, nalidixic acid, ciprofloxacin, oxolinic
acid, ceftazidime and rifampicin. Cross-resistance seemed to be mediated by bacterial
LPS, as new higher molecular weight bands were seen in the resistant strains. In
addition to changes in their LPS profile, resistant mutants had lost a major outer
membrane protein in the 39-47 kDa range and also expressed additional outer membrane
proteins at 20-21 kDa or 75-77kDa (Rajyaguru and Muszynski, 1997).
Cross-resistance is not unique to B. cepacia and has also been reported in other
Gram-negative bacteria including Klebsiella pneumoniae (Sanders, Sanders, et al, 1984).
Mutants of a strain ofK. pneumoniae showing cross-resistance between quinolones and
B-lactams which is associated with changes in outer membrane proteins have been
reported. Changes in outer membrane proteins are also thought to be responsible for
B-lactam/ aminoglycoside resistance in Serratia marcescens (Sanders, Sanders, et al,
1984).
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1.5.2. Role of porins
Gram-negative bacteria have an outer membrane that acts as a permeability barrier and
offers various degrees of intrinsic resistance to antimicrobial agents. The natural level of
resistance created by the outer membrane can be increased by genetic or physiological
alterations that lower the permeability of this membrane (Nikaido, 1989). In clinical
isolates, this may be the result of stepwise mutations and may be reversible when
selective pressure of growth in antibiotic-containing medium is removed (Burns and
Clark, 1992).
Hydrophilic solutes most often cross the outer membrane through porins which are
water-filled transmembrane channels that allow hydrophilic solutes to penetrate the
membrane, subject to molecular size limits (Rosenbusch, 1974; Parr, Moore, et al,
1987). They are usually present as trimers, that are strongly but non-covalently linked to
the underlying peptidoglycan (Rosenbusch, 1974). The tertiary and quartenary
structures of porins are the ones that determine their function with neither lipids nor
lipopolysaccharides playing a part (Parr, Poole, et al, 1986). Most porins form channels
that function as sieves but a few that demonstrate substrate specificity have been
identified (Burns and Clark, 1992).
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B-lactams predominantly diffuse through the porins ofE. coli in order to reach their
target sites (Yoshimura, Nikaido, 1985). Other small hydrophilic agents, such as
tetracyclines, aminoglycosides and chloramphenicol, would also be expected to use the
same pathway. Porin-deficient mutants have lower permeability and thus greater
resistance to hydrophilic antibiotics (Harder, Nikaido, et al, 1981). One of the reasons
for P-lactam resistance in strains ofE. coli is their greatly diminished level of the porin
ompF (Harder, Nikaido, et al, 1981). However, lower outer membrane permeability is
not itself sufficient to result in increased resistance to antibiotics. A secondary
mechanism such as an inactivating enzyme may act in association with the impaired
uptake (Harder, Nikaido, et al, 1981).
The sizes and permeability ofporins differ between different bacteria. The outer
membrane permeability coefficient ofB. cepacia PC715j is about ten times less than that
for an E. coli control strain (Parr, Moore, et al, 1987), suggesting that B. cepacia has a
substantial outer membrane hydrophilic permeability barrier. The B. cepacia porin is
also 8-10 times smaller than that ofE. coli, which might explain the much lower
permeability ofB. cepacia outer membrane to the P-lactam nitrocefm (Parr, Moore, et
al, 1987). Parr and co-workers identified an 81kDa porin complex in the outer
membrane that dissociates on heating to form two proteins of 27 and 36kDa. The 27kDa
porin was found to be absent or partially lost in two CF isolates which showed decreased
P-lactam permeability and susceptibility (Aronoff, 1988). Thus, it has been suggested
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that the 27kDa outer membrane protein is either a major porin or a major protein
component of the porin complex in B. cepacia (Aronoff, 1988). Decreased expression of
this protein leads to decreased P-lactam diffusion across the outer membrane leading to
high level resistance to these antibiotics.
Since hydrophobic solutes cannot diffuse through porin channels rapidly, many
Gram- negative bacteria are resistant to a number of hydrophobic antibiotics and dyes
which are effective against Gram-positive bacteria (Nikaido, 1976). These antibiotics
include the macrolides, novobiocin, rifamycin SV and actinomycin D.
1.5.3. Active efflux
Decreased drug accumulation may result from impermeability or from active drug
efflux. A study by Burns and co-workers showed that the resistance ofB. cepacia to
chloramphenicol, trimethoprim and ciprofloxacin was due to active drug efflux. They
identified and sub-cloned a fragment coding for a 50kDa outer membrane protein
(Burns, Wadsworth, et al, 1996). The nucleotide sequence identified showed homology
to a portion of the multiple antibiotic resistance efflux operon mexA-mexB-oprM from
P. aeruginosa (Poole, Krebs, et al, 1993). Thus, in addition to restricting the entry of
antibiotics, B. cepacia porins can also actively remove the antibiotics accumulated
within the bacterial cell.
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1.5.4. Cationic antibiotics:- aminoglycosides and polymyxin B
Many Gram-negative bacteria are susceptible to P-lactams, aminoglycosides, polymyxin
B, colistin and tetracyclines, which are relatively small and hydrophilic and should
therefore readily diffuse through porins. B. cepacia is an exception to this general trend
in that it is inherently resistant to aminoglycosides and polymyxin B, in part because the
compounds can not permeabilize the organism's outer membrane, (Fass and Barnishan,
1980, Moore and Hancock, 1986). A possible explanation for this is that the LPS of
B. cepacia is arranged in the outer membrane in a way that masks the negative charges
found on the LPS molecule, thus making them unavailable for binding to polycationic
antibiotics (Moore and Hancock, 1986).
Polypeptides (polymyxin B, colistin) and aminoglycosides are absorbed by
Gram-negative bacteria through a self-promoted uptake (Moore and Hancock, 1986).
This mechanism has been described in P. aeruginosa in which these compounds aid
their own entry by disrupting the outer membrane structure (Rajyaguru and Muszynski,
1997). The crucial step is the interaction of the antibiotic with anionic sites at the
bacterial surface. The inability of cationic antibiotics to affect the permeability of
B. cepacia suggests that its LPS composition, structure and or function are distinctly
different from those ofP. aeruginosa and E. coli (Rajyaguru and Muszynski, 1997).
This difference in LPS structure is suggested by B. cepacia LPS being more endotoxic
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than LPS from P. aeruginosa (Shaw, Poxton et al, 1995). The LPS ofB. cepacia is low
in anions such as phosphates and 3-deoxyoct-2-ulosonic acid (KDO) (Cox and
Wilkinson, 1991) which means its cation-binding capacity is limited compared to other
Gram-negative bacteria. In addition, the LPS ofB. cepacia has 4-amino-deoxyarabinose
(Ara4N), a four amino sugar, as a substituent for lipid A (Cox and Wilkinson, 1991) and
this substitution is believed to further lower the affinity of the LPS for cationic
antibiotics.
1.5.5. Effect of Salicylates
Decreased porin-mediated outer membrane permeability is the most common antibiotic
resistance mechanism in B. cepacia. In some Gram negative bacteria, this form of
resistance can be induced by growth in the presence ofweak acids such as salicylates,
which suppress porin synthesis (Foulds, Murray, et al, 1989). E. coli grown in l-5mM
sodium salicylate show increased resistance to ampicillin, cephalexin cephaloridine,
chloramphenicol, nalidixic acid, tetracycline and cephalothin, (Rosner, 1985, Foulds,
Murray, et al, 1989). Since these antibiotics differ in their structure, targets and modes
of action, it is believed that the resistance is caused by an effect of the weak acids on
antibiotic uptake (Foulds, Murray, et al, 1989). When B. cepacia is grown in the
presence of salicylate, the MICs of chloramphenicol, trimethoprim and ciprofloxacin
increase but that of ceftazidime remains the same (Burns and Clark, 1992).
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Growth ofB. cepacia in lOmM sodium salicylate results in the loss of a minor outer
membrane protein ofmolecular weight 40 000 termed OpcS (Burns and Clark, 1992), or
decreased expression of the porin protein OmpF (Kunin, Hua, et al, 1995). Outer
membrane penetration of chloramphenicol is decreased while that of a (3-lactam
indicator compound, PADAC, is not. Thus, OpcS may function as a selective
antibiotic- permeable porin which can be suppressed by growth in salicylate. The effect
of salicylates on antibiotic resistance is reversible (Rosner, 1985), and its role in
B. cepacia infections is unknown.
1.5.6. Resistance to P-lactams
Increased resistance of bacteria to P-lactams may occur through mechanisms that
decrease the permeation of the outer membrane by the antibiotics or by increased
antibiotic hydrolysis by the P-lactamases found in the periplasmic space (Prince, Wood,
et al, 1988). Most CF and non-CF isolates ofB. cepacia contain a chromosomal
P-lactamase that focuses on isoelectric gels in the pH 7.9-8.1 range (Aronoff, 1988).
In B. cepacia strain 249, two separate p-lactamases have been reported; a penicillinase,
penA, responsible for about 80% of the total P-lactamase activity of the strain (Prince,
Wood, et al, 1988) and a second enzyme with primarily cephalosporinase activity
(Lessie and Gaffney, 1986). The P-lactamase of this strain is highly inducible by
penicillin G and is dependent on its continued presence. The penA P-lactamase has a
molecular weight of 33 500 and is unique amongst the P-lactamases in its association
with a metabolic pathway that allows B. cepacia to metabolise penicillin (Beckman and
Lessie, 1979). All wild type strains ofB. cepacia examined can use penicillin G as a
sole source of carbon and energy (Beckman and Lessie, 1979), however, they fail to
exhibit significant growth in the benzylpenicillin derivatives ampicillin and carbenicillin
even though they are resistant to these antibiotics. Extracts ofB. cepacia 249 grown in
penicillin G contain high levels of p-lactamase activity, although the activity itself is not
sufficient for growth in penicillin G, as seen in P. aeruginosa strains which have similar
P-lactamase activities (Beckman and Lessie, 1979). In B. cepacia 249, expression and
induction ofpenA is regulated by penR and resistance to imipenem is dependent on the
presence ofpenR (Trepanier, Prince, et al. 1997).
Since overall permeability ofB. cepacia and P. aeruginosa to P-lactam compounds has
been found to be very similar (Parr, Moore, et al, 1987), the ability to rapidly induce
P-lactamase expression may be an important selective advantage for B. cepacia. Pen A
P-lactamase differs significantly by physical properties, activity, and induction kinetics
and seems to be unrelated to the amp C-type P-lactamases of enterobacteria or P.
aeruginosa (Bergstrom, Olsson, et al, 1982).
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Incubation ofB. cepacia in an atmosphere of air and 5% carbon dioxide is reported to
result in the activity of (3-lactams being either lost or decreased but not eliminated
(Corkill, Deveney, et al, 1994). This effect is due to the fact that the production of
P-lactamases most active against first and second generation cephalosporins, increases at
least ten-fold in the presence of carbon dioxide. Interestingly, production of
P-lactamases showing greater activity toward third generation cephalosporins increases
180-fold when imipenem another P-lactam, is present in the growth medium (Corkill,
Deveney, et al, 1994). This implies that the presence ofdifferent p-lactams does not
always result in synergy but may actually reduce the effectiveness of individual
antibiotics.
1.5.7. Chloramphenicol Resistance
Chloramphenicol is a potent inhibitor ofbacterial protein synthesis and acts by
interacting with the 50S subunit ofbacterial ribosomes. Resistance to chloramphenicol is
usually conferred by chloramphenicol inactivation by 3-o-acetylation catalysed by the
intracellular enzyme acetyltransferase (CAT) (Shaw and Brodsky, 1968). In P.
aeruginosa and some other Gram-negative bacteria, a plasmid-specific permeability
barrier has been suggested as a mechanism of resistance not conferred by CAT (Gaffney,
Cundliffe, et al, 1981; Kono and O'Hara, 1976). This barrier is probably located on the
cytoplasmic membrane, thus preventing the drug from reaching its intracellular target
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and is possibly a protein that changes the structure of the membrane (Gaffney, Cundliffe,
et al, 1981). In P. aeruginosa, 50-85% of chloramphenicol resistant strains produce
CAT (Nitzan and Rushansky, 1981). Decreased permeability is probably the mechanism
of chloramphenicol resistance in B. cepacia, since no CAT or ribosomal resistance has
been detected (Burns, Hedin, et al, 1989; Rajyaguru and Muszynski, 1997). In the
strains studied, Burns and co-workers found that there were no structural alterations in
outer membrane proteins (including porins) nor were there any changes in LPS (Burns,
Hedin, et al, 1989). They concluded that the most likely mechanism is structural or
functional differences that are present in intact outer membranes.
1.5.8. Resistance to trimethoprim
Trimethoprim acts on the bacterial dihydrofolate enzyme and thus acts as an inhibitor of
folate utilisation (Bushby and Hitchings, 1968). Sulphonamides act by inhibiting the
biosynthesis of folic acid in the target organisms. A combination of trimethoprim and
sulphonamides such as sulphamethoxazole may be bactericidal where individual drugs
only produce bacterial stasis (Bushby and Hitchings, 1968). Resistance to trimethoprim
or the combination of trimethoprim/sulphamethoxazole has been documented as being
due to the production of a different dihydrofolate reductase which is either
chromosomally or plasmid encoded (Amyes, 1986). The dihydrofolate reductase
(DHFR) isolated from a trimethoprim-susceptible strain ofB. cepacia is more sensitive
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to trimethoprim than that from a trimethoprim-resistant strain, suggesting that the two
enzymes are different (Burns, Lien, et al, 1989). It has been suggested that the
differences between DHFR isolated from the susceptible and resistant strain are due to a
modification of the active site of the enzyme (Burns, Lien, et al, 1989).
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1.6. Biotechnological applications of B. cepacia
1.6.1. B. cepacia as a biopesticide
Intensive mono-culture of crops often leads to a decrease in crop yields and further loss
from root rot diseases may occur. One of the reasons for the increased incidence ofplant
crop diseases is the influence ofphytopathogenic fungal and bacterial populations
specific to the crop (Curl and Truelove, 1986). Chemical pesticides have been the main
weapons in controlling soil-bome pathogens. In recent years, ecological damage
resulting from the pollution of soil and ground water and pathogen resistance resulting
from the use of chemical compounds, have prompted research into alternative
approaches such as biological control. In addition, the use ofpesticides to control crop
diseases is increasingly threatened by consumer preferences and regulatory issues
concerning pesticide residues in food.
Biological control is based on plant-mediated interactions that occur between pathogens
and roots and between pathogens and antagonistic microorganisms in the rhizosphere
and rhizoplane (Cook and Baker, 1983). The use of natural antagonists lessens
agricultural dependence on synthetic agrochemical such as herbicides, insecticides and
fungicides. As oppossed to inundative chemical applications to control post-harvest
diseases, biocontrol agents can colonise plant tissues and lead to plant exudates that
protect sites within the plant. One focus ofbiological control is the use of antagonists
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and a major group ofnatural antagonists currently being investigated is phyloplane and
rhizosphere bacteria.
Microorganisms that grow in the rhizosphere are ideal for use as biological control
agents since the rhizosphere provides the front-line defense for roots against attack by
bacterial fungal pathogens. Such pathogens encounter antagonism from rhizosphere
organisms before and during primary infection and also during secondary spread of the
root. In the last few years several examples ofbacteria capable of providing substantial
disease control in the field have been reported. These recent successes in biological
control result in part from a greater understanding of the rhizosphere and from selection
of bacterial strains adapted to colonisation of the rhizosphere. Bacterial biopesticides
can improve plant growth by suppressing either major or minor pathogens.
The first successful biological control agent was Agrobacterium radiobacter which
controls crown gall caused by Agrobacterium tumefaciens (Kerr, 1972). Bacillus spp
were next to be studied intensely and tested on a wide variety of plant species for their
ability to control diseases. Bacillus spp are appealing as biocontrol agents because they
produce endospores that are tolerant to heat and desiccation. Currently, Pseudomonas
spp. and related organisms such as B. cepacia are receiving much attention as biocontrol
agents.
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B. cepacia isolated from crop plants has been demonstrated as a biological control agent
of fungal diseases of commercially-important food crops such as apples and pears
(Janisiewiez and Roitman, 1998), corn (Jayaswal, Fernandez, et al, 1990, Hebbar,
Martel, et al, 1998), peas (Parke, 1990), sunflowers (Hebbar, Berge, et al, 1991),
adzukibean (Hasegawa, Kondo, et al, 1991), and wheat. B. cepacia has also been used
to suppress several soil-borne plant pathogens when applied as a seed coating or root dip
(Homma, Sato et al, 1989, Parke, 1990). Some diseases such as Aphanomyces root rot
and Pythium damping off of peas cause seeds to rot before they germinate or seedlings to
be killed before or shortly after emergence (Parke, 1990; Parke and King, 1991), hence
the importance of seed treatment.
In addition to protecting food crops, B. cepacia also protects commercially important
plants such as protea (a flowering African shrub) against Phytophthora cinnamomi
which causes root and collar rot, leading to a major limitation of the cultivation of
proteas (Turnbull, Ogle, et al, 1991). In addition, compared to other closely related
organisms, B. cepacia has been found to be particularly effective in controlling
Rhizoctonia solani stem rot ofpoisenttia (a decorative plant associated with Christmas),
(Cartwright, 1995).
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In several tests, B. cepacia has performed comparably, over a wide range of
temperatures, with standard fungicide treatments such as captan and metalaxyl (Parke,
1990; Parke and King, 1991), and exceeded these fungicides in efficiency (Parke and
King, 1991).
Whilst most research on B. cepacia as a biocontrol agent has focussed on suppression of
fungal pathogens, few studies have been performed to measure the effect ofB. cepacia
on pathogenic nematodes. However, one group has reported that B. cepacia and
B. gladioli were the most predominant of Gram negative bacteria isolated from the
rhizospheres of different plants, which were antagonistic to soybean cyst {Heterodera
glycines) and root-knot (Meloidogyne incognita) nematodes (Kloepper, Rodriguez-
Kabana, et al, 1992).
Various mechanisms have been described to account for the biopesticide activity of
B. cepacia.
i) Production of antimicrobial agents
One of the reported mechanisms by which B. cepacia suppresses pathogens is through
the production of antibiotics such as pyrrolnitrin (3-chloro-4-(2-nitro-3-chlorophenyl)-
pyrrole (Janisiewiez and Roitman, 1998; Homma, Sato et al, 1989; Burkehead,
Schisler, et al, 1994) and pseudane derivatives 2-(2-heptenyl)-3-methyl-4-quinolinol
(HMQ) and 2-(2-nonenyl)-3-methyl-4-quinolonol (NMQ) (Homma, Sato et al, 1989).
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These antibiotics have higher antifungal activity than antibacterial activity (Homma,
Sato et al, 1989). Pyrrolnitrin, aminopyrrolnitrin and monochloroaminopyrrolnitrin
were isolated from a B. cepacia strain J82rif and protected sunflowers from the
sunflower wilt fungus Sclerotinia sclerotiorum (McLoughlin, Quinn, et al, 1992).
Sclerotinia wilt is one of the most important diseases of sunflowers as no effective
chemical control currently exists. The fungus survives in the soil as resistant sclerotia
and attacks the roots, resulting in root rot basal stem canker and plant wilt (McLoughlin,
Quinn, et al, 1992).
An antimicrobial agent produced by B. cepacia B5, active against the bacterial wilt
disease pathogen Pseudomonas solanacearum affecting tobacco and other plants in the
solanaceae family, was identified as 2-keto-D-gluconic acid (2KGA) (Aoki, Uehara, et
al, 1991). Since the pathogen can survive for long periods in the soil without the host
plant, B. cepacia was added to a contaminated soil suspension, together with either
wheat bran or glucose as nutrient additives. Pseudomonas spp, Acetobacter spp. and
related organisms such as B. cepacia can produce 2KGA from glucose (Isono,
Nakanishi, et al, 1968), which is thought to be the mechanism ofbacterial wilt disease
suppression by B. cepacia B5. B. cepacia B5 has been cultured on a large scale and after
long-term preservation, was still able to suppress disease in field tests (Aoki, Uehara, et
al, 1991) which makes it suitable for commercial application.
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B. cepacia also suppresses pathogenic fungi by producing the enzyme P-l,3-glucanase
(laminarase), (Friedlander, Inbar, et al, 1993) which degrades the fungal cell wall
component P-l,3-glucan. This enzyme is inducible and is excreted into the growth
medium only when other carbon sources are unavailable. A P-l,3-gliicanase-producing
B. cepacia was isolated on a synthetic medium with laminarin as the sole carbon source.
Enzyme induction by different fungal cell walls as sole carbon sources in synthetic
medium was found to correlate with the biological control of the respective fungi by
B. cepacia (Friedlander, Inbar, et al, 1993).
ii) Production of siderophores
Production of siderophores, which are low molecular weight, high affinity iron (III)
chelators that transport iron into the bacterial cell, allows B. cepacia biopesticides to
grow in iron-deficient conditions where other organisms would be unable to flourish (De
Freitas, Germida, et al, 1991).
iii) Competition
Bacterial antagonists with a broad spectrum of antibiosis, the ability to colonise plant
tissue rapidly and to survive for long periods in large numbers are potential candidates
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for microbial inoculation of seed or plants. These agents also compete with the pathogen
in diseased tissues. Substrate competition for nutrients supplied by the root and seed
exudates and niche exclusion have been suggested as a possible mechanism by which
B. cepacia suppresses pathogens (Parke, 1990).
Bacterial antagonists have an advantage over pathogenic fungi due to their rapid
multiplication and higher populations in the rhizosphere (Herbbar, Berge, et al, 1991).
B. cepacia strain 526 which suppresses maize soil-borne diseases colonises the roots and
rapidly multiplies on the maize roots and rhizosphere (Herbbar, Davey, et al, 1992).
Another strain which protects maize from soil-borne diseases, B. cepacia 64, has high
pectinase activity which enables it to penetrate maize root mucilage while strains with
low pectinase activity are unable to do so (Herbbar, Davey, et al, 1992).
iv) Chemotaxis
Once inoculated into the soil the ability to migrate towards the root system by
chemotaxis would be greatly advantageous to a biocontrol strain. Evidence shows that
B. cepacia migrates rapidly to root surfaces from the point of inoculation (Herbbar,
Davey, et al, 1992)
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In conclusion, the use ofmicroorganisms such as B. cepacia for the control of diseases
appears to be an appealing option when compared to more noxious chemical pesticides
which persist in the environment and whose residues remain in harvested foods,
sometimes with harmful effects. On the other hand, biological control agents have not
been unequivocally shown to have no effect on the normal microbial soil flora.
Furthermore, organisms such as B. cepacia could have potentially devastating effects on
susceptible human populations, in particular, individuals with CF and other
immunodeficiencies.
Conflicting evidence exists on the effects of introduced biocontrol agents on the normal
environmental microbial flora. When the biocontrol agent B. cepacia AMMDR1 was
applied to the rhizospheres of four pea cultivars, the total B. cepacia population fell to
levels present before the application, within about six weeks (King and Parke, 1993).
However, the population was elevated for several weeks after application.
Furthermore, experiments conducted to determine whether coating soybean seeds with
the biological control agent Bacillus cereus UW85 affected the bacterial community in
the rhizosphere of soybeans revealed that the communities of rhizosphere bacteria that
developed on non-treated plants and on plants grown from seeds treated with the
biocontrol agent were sometimes significantly different (Gilbert, Parke, et al, 1993).
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This population distinction occurred even when the introduced strain did not persist as a
common member of the bacterial community. The results from this study illustrate the
potential impact of introducing large populations of a single strain ofbacteria on the
indigenous rhizosphere flora.
Although B. cepacia was first described 50 years ago, much remains to be learned about
virtually every aspect of its biology including its pathogenicity, taxonomy, ecology and
epidemiology. This lack of adequate information makes it impossible to adequately
evaluate the commercial application ofB. cepacia as a biological control agent. In
recent years, concern has been expressed on the numerous patents being sought for the
commercial application of different B. cepacia strains. The regulations regarding the use
ofbiopesticides and bioremediation products, in both North America and the United
Kingdom, have been criticised as outdated and inadequate for the evaluation ofhighly
complex organisms such as the B. cepacia complex (LiPuma and Mahenthiralingham,
1998; Govan and Vandamme, 1998).
Although a great deal has been mentioned about 'clinical' and 'environmental' isolates
of the B. cepacia complex, available taxonomic data indicates that there is no clear
distinction between clinical and environmental or indeed, between pathogenic and non¬
pathogenic strains of the B. cepacia complex. Interestingly, new evidence has shown
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that clinical and environmental isolates of the B. cepacia complex can be clonally
related. Genotypic and phenotypic evidence of a clonal relationship between an
American strain isolated from onion (ATCC 25416) and a British strain isolated from a
CF patient (C1853) was obtained recently (Govan, Balendreau, et al 1998; Govan and
Vandamme, 1998).
As previously discussed in section 1.3, transmissible strains of the B. cepacia complex
have caused major epidemics in British and North American CF centres. Since genetic
changes conferring transmissibility in the B. cepacia complex are thought to occur at
random (Flolmes, Govan, et al, 1998) biopesticide strains could potentially become
highly transmissible. The large, complex and highly plastic genome of the B.
cepacia complex (Cheng and Lessie, 1994; Rodley, Romling, et al, 1995) has been cited
as making the organisms highly suited to rapid adaptation to environmental changes
(Holmes, Govan, et al, 1998). In addition, large-scale commercial application ofB.
cepacia complex strains to the environment could promote genetic exchange with
normal soil microflora and thus lead to the emergence ofpathogenic organisms with the
B. cepacia complex's inherent resistance to several antibiotics.
In view of the concerns raised and the lack of adequate information on the B. cepacia
complex, in its risk assessment ofB. cepacia biopesticides, the Scientific Advisory Panel
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to the Environmental Protection Agency advises caution on the use ofB. cepacia in
biological control programmes (http://www.ena.gov. 12 July 2000).
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1.6.2. Application ofB. cepacia in bioremediation of contaminated sites
Industrial chemicals, manufacturing wastes, herbicides and pesticides often contain
synthetic organic chemicals such as chlorinated aromatics. These compounds are
mineralised very slowly or not at all because natural microbial flora fail to degrade them
totally in order to derive their carbon and energy from the process. A few of these
compounds are toxic and some, although not toxic at concentrations found in soil and
water, are subject to biomagnification (Alexander, 1981).
The presence of recalcitrant compounds in water, land and crops is now deemed a serious
environmental pollution and health problem by the general public. In addition to
contaminating their sources, recalcitrant compounds can be transported some distance from
their source of introduction.
One of the major recalcitrant compounds found in most industrialised nations is 2,4,5-
Trichlorophenoxyacetic acid (2,4,5-T), a defoliating herbicide which is used to control
various broad-leafweeds and also as a growth regulator to delay colouration of lemons,
increase the size of citrus fruits and decrease deciduous fruit drop (Grant, 1979, Kilbane,
Chateijee, et al, 1982; Danganan, Ye, et al, 1994). Not only does 2,4,5-T persist in the
environment, it is also suspected of being genotoxic. An investigation of the rate ofbirth
malformations found a statistically significant association between the rate of spray of
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2,4,5-T and talipes (congenital deformity of the soles of feet), though no association with
malformations of the central nervous system was found (Hanify, Metcalf, et al, 1981).
Before 1982, no known microorganisms capable ofutilising 2,4,5-T as a source of carbon
and energy had been described (Alexander, 1981). In 1982, however, pure culture of
B. cepacia AC1100 capable of growing on 2,4,5-T was obtained from a mixed culture
where individual strains were incapable ofutilising the compound as a sole carbon source
(Kilbane, Chateijee, et al, 1982). Laboratory experiments demonstrated that B. cepacia
AC 1100 can significantly decontaminate soils heavily contaminated with 2,4,5-T. The
organism not only degrades the herbicide 2,4,5-T but also oxides a number of
chlorophenols that comprise major constituents of different toxic chemical dump sites
(Kilbane, Chateijee, et al, 1982). The cluster of genes involved in the metabolism of 2,4,5-
T by B. cepacia AC1100 has been identified and cloned, revealing it to be unique and not
related to other identified gene clusters (Daubarus, Saido, et al, 1995).
Application ofB. cepacia AC 1100 to contaminated sites is unlikely to lead to serious
ecological disturbance as it rapidly disappears after exhaustion of 2,4,5-T (Kilbane,
Chateijee, et al, 1982). Contaminated soil incapable of supporting the growth ofplants is
able to do so after treatment with B. cepacia AC1100. Although the quality ofplants in
these reclaimed sites is not as good as that of plants growing in virgin soils, treatment of
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contaminated sites with an appropriate microorganism virtually allows total restoration of
the original soil conditions.
B. cepacia has been successfully used in the bioremediation of sites contaminated by
several other recalcitrant compounds including trichloroethylene a consituent of the volatile
organics used in industry for degreasing (Shields and Reagin, 1992), and polycyclic
aromatics hydrocarbons, found amongst other things, in oil and wood preservation agents
(Juhasz, Britz, et al, 1997). Application of B. cepacia to sites contaminated by various
recalcitrant compounds, results in the detoxification of the parent compound to products
that are no longer hazardous to human health or the environment. B. cepacia's, unusual
metabolic versatility means that its exploitation in bioremediation is likely to increase.
69
1.7. Mechanisms of genetic exchange and genome alteration
Release of large amounts ofB. cepacia into the environment as biopesticides has the
potential to facilitate transfer of genetic information to other soil organisms and/ B. cepacia
strains of clinical interest. Although there is currently no experimental evidence showing
that this exchange does indeed occur, it has not been unequivocally shown that it cannot
occur. Based on currently available knowledge therefore, genetic exchange in soil between
different strains ofB. cepacia and also with other members of the normal soil flora should
be considered as possible.
Three principal ways by which bacteria can exchange genetic information are transduction,
conjugation and transformation.
1.7.1. Transduction and properties of bacteriophages
Genetic transduction is the transfer from one cell to another of non-viral genetic material
within a viral coat. Two types of transduction have been identified, generalised and
specialised, and these are mediated, respectively, by generalised transducing particles
which carry a fragment of host DNA and specialised transducing particles which contain
both host and viral particles as a single entity. The significant role played by bacteriophage
in different bacteria can not be over-emphasized. Phage typing is one of the most reliable
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methods currently used for classifying important pathogens such as Salmonella typhi
(Hickman-Brenner, Farmer, 1983), Vibrio cholerae (Guidolin and Manning, 1987),
Mycobacterium tuberculosis (Jones, Good , et al, 1982) and Klebsiella pneumoniae
(Rennie, Nord, et al, 1978).
Bacteriophages have been shown to be responsible for the transfer of virulence factors in
several bacterial pathogens. In V. cholerae bacteriophages are not only important for
typing but have been associated with virulence (Parker, Richardson, et al, 1970), induction
of toxinogenesis (Siddiqui and Bhattacharyya, 1987), biotype transition (Mitra, 1989) and
possibly also the evolution of epidemic strains (Mooi, and Bik, 1997). Thus, there is now
overwhelming evidence to support the concept that choleraphages play a major role in the
horizontal transmission of genetic information in V. cholerae. In other pathogenic genera,
lysogenic phages have been implicated in the transmission ofneurotoxigenicity from
toxigenic Clostridium butyricum strains to a harmless C. botulinum type E-like strain (Zhou
Sugiyama, et al, 1993).
The genes for two of the three pyrogenic exotoxins produced by Streptococcus pyogenes
are bacteriophage encoded (Kapur, Nelson, et al, 1992). Two distinct alleles of the gene
speC, which codes for the streptococcal pyrogenic toxin C, are present in natural
populations of S. pyogenes with each allele occurring in clones that are well differentiated
in overall chromosomal character (Kapur, Nelson, et al, 1992). It is believed that this toxin
71
allele-clone distribution pattern may be due to episodes ofhorizontal gene transfer and
recombination occuring by transduction. In E.coli, a nonlysogenic, nontoxigenic strain can
be converted to a lysogenic and heat labile enterotoxin-producing strain by infection with a
temperate phage (Takeda and Murphy, 1978).
Recent studies indicate that broad-host-range bacteriophages are more common than had
been thought previously (Jensen, Schrader, et al 1998). In their studies, Jensen and co¬
workers found that for two bacteriophage collections, 90% of the isolated phages had a
broad host range. Infection with these broad-host-range bacteriophages was not limited by
dependency on the presence of a specific plasmid and the phages were capable of infecting
a broad range of hosts.
Although plasmids are commonly implicated in the transmission ofantibiotic resistance,
some evidence suggests that bacteriophages can also be responsible for the spread of
antibiotic resistance. The resistance ofPseudomonas aeruginosa to single antibiotics such
as imipenem (Blahova, Kralikova, et al, 1998), and multiple antibiotic resistance (Knothe,
Lebek, et al, 1981, Blahova, Kralikova, et al, 1998, Blahova, Kralikova, et al, 1999) can be
transferred through transduction by wild-type as well as generalised transducing phages.
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Most studies on genetic exchange in soil are conducted on sterile soil with no competition
from the indigenous microbial flora. However, generalised transduction by phage PI does
occur in E. coli maintained in non-sterile soil (Germida and Khachatourians, 1987). When
microorganisms are introduced to the environment in large numbers, horizontal gene
transfer has the potential to occur not only in the soil but also on plant surfaces. Phage
F116-mediates gene transfer among P. aeruginosa strains on the same leaf surface
(Kidambi, Ripp, et al, 1994). In conditions ofhigh density planting, such as might occur in
intensive farming, transduction has been observed between bacterial strains on adjacent
plants.
As early as 1930, d'Herelle, one of the discoverers of bacteriophages suggested their use as
therapeutic agents for treatment of infectious disease. Despite this early enthusiasm, the
use ofbacteriophages as antibacterial agents was all but abandoned with the discovery of
antibiotics in the 1940s. The use ofbacteriophages as treatment agents actually dates back
to 1921 when it was initiated by Bruynoghe and Maisin in the treatment of staphylococcal
skin infections (Bruynoghe and Maisin, 1921). The process' initial lack of success, due to
misunderstanding of phage biology, coupled with the discovery of antibiotics, led to very
little research in subsequent years. Recently, the rise in antibiotic resistance in major
bacterial pathogens and the emergence in clinical practice of inherently multiple antibiotic
resistant organisms such as B. cepacia, has led to increased investigation into the
application of phages as treatment of life-threatening bacterial infections. Current opinion
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is that bacteriophage therapy is likely to be focused on veterinary practice, in the first
instance, perhaps paving the way for its later use in human infections (Dixon, 1987).
The range ofphage therapy applications is wide and this therapeutic strategy has found
particular favour in Eastern Europe. Phage therapy has been applied in the treatment of
infections induced by Staphylococcus, Klebsiella, Escherichia, Proteus and Pseudomonas
as well as infections in the digestive sytem caused by Salmonella and Shigella (Slopek,
Durlakowa, et al, 1983). Although oral and localised treatment seems to be the standard
method ofphage delivery (Slopek, Durlakowa, et al, 1983), even when oral treatment has to
be abandoned because of nausea and vomiting, direct application of phage to infected sites
has been enough to produce healing (Cislo, Dabrowski, et al, 1987).
In conclusion, bacteriophages are not only useful for typing bacterial strains, but they
function as vectors for the transmission of genetic material and show potential for use in the
treatment ofbacterial infections, a property which might be particularly relevant to the
treatment of infections caused by emerging multiresistant pathogens such as B. cepacia.
1.7.2. Conjugation
Conjugation accounts for most horizontal gene transfer between phylogenetically distant
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prokaryotes. The prime requirement for conjugation, as a system of genetic exchange, is
usually a plasmid that will promote chromosome transfer such as the F plasmid ofE.coli
K12. Although such plasmids have been difficult to detect in other organisms, clinical
strains ofP. aeruginosa frequently carry plasmids capable of acting as fertility factors
(Dean, Royle, et al, 1979; Holloway, 1998). Drug resistance plasmids have also been
shown to promote chromosome transfer (Sugino and Hirota, 1962). Of even greater interest
to the issue of genetic exchange are those plasmids that replicate in a range ofunrelated
Gram-negative bacteria and can be transferred freely among different genera (Lowbury,
Kidson, et al, 1969). Conjugal transfer ofbroad-host-range, incompatibility group P (IncP-
type) plasmids between Gram-negative bacteria is well known (Schafer, Kalinowski, et al,
1990), and is reviewed by Thomas and Smith (1987). These and similar groups ofplasmids
such as IncC, IncN, IncQ and IncW are self-transmissible at high frequency.
Incompatibility plasmids are those that share either replication control or partitioning
function and thus compete for stable inheritance (Thomas and Smith, 1987). The host
range of IncP type plasmids includes several Gram-negative bacteria, in fact, Bacteroides is
the only Gram-negative genus that has been documented as being non-permissive for IncP
plasmid maintenance (Guiney, Hasegawa, et al, 1984). It is not just plasmids that can be
transferred by conjugation, conjugative transposons have been isolated from a number of
Gram-positive and Gram-negative bacteria (Torres, Korman, et al, 1991, Bertram, Stratz, et
al, 1991). Conjugative transposons have broad host range and transpose into the genomes
of a wide variety of Gram-positive and some Gram-negative hosts.
75
For the transfer ofplasmids, stable cell to cell contact is required between bacterial cells in
the initial stages of conjugation. The donor cell contains the plasmid that has a transfer
(tra) locus that encodes the fertility pilus which attaches to the recipient cell and generates a
conjugal pore through which the DNA will enter. The donor cell's plasmid also encodes
mobilisation (mob) genes which promote the transfer ofDNA through interaction with
another region called the origin of transfer (or/7) (Buchanan-Wollaston, Passiatore, et al,
1987). During bacterial conjugation a linear single strand ofDNA is transferred from a
donor to a recipient cell where it is regenerated into a double-stranded DNA molecule.
Successful conjugation requires the plasmid to replicate either autonomously or to be
integrated into the replicon of the new host.
In a study of the survival, plasmid transfer and impact ofPseudomonas fluorescens
introduced into soil, it was found that although the introduced donor and recipient strains
showed a progressive decline in numbers in non-sterile soil, the strains still caused
stimulation of total numbers ofheterotrophic bacteria and selected physiological groups
(Kozdroj, 1997). Conjugation between the donor and recipient cell was observed as early
as within the first three days of the strains being introduced to the soil. Thus although
bacteria introduced to the soil may show limited survival, their potential for conjugation
and impact on soil microflora may still cause an ecological risk.
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Plasmids have been isolated from several B. cepacia strains (Gonzalez and Vidaver, 1979)
but in most cases, no phenotypic characteristics are assigned to them. From their work,
Gonzalez and Vidaver postulated that tetracycline resistance in B. cepacia may be plasmid-
determined. A different group isolated a plasmid pJW2 which conferred tetracycline
resistance to a clinical isolate ofB. cepacia (Williams, Yeggy, et al, 1979). The same group
also identified a plasmid pJW3 which was responsible for resistance ofB. cepacia to
ampicillin. Later work identified a 32 MDa IncP plasmid Rms45 in a clinical isolate B.
cepacia GN11131, which mediated resistance to streptomycin and mercury (Hirai, Iyobe, et
al, 1982). Interestingly, this plasmid could be transferred not only to other B. cepacia
isolates by transformation but also to P. aeruginosa and E .coli, as well as by conjugation
between isogenic strains ofP. aeruginosa and E. coli.
1.7.3. Transformation
Genetic transformation is a process by which a cell takes up naked DNA from the
surrounding medium and incorporates it to acquire an altered genotype that is heritable.
Bacteria and possibly some yeasts are the only organisms which can undergo natural
transformation (Smith, Danner, et al, 1981). Cells with this ability for DNA uptake are
described as competent; such cells express specialised proteins that allow them to bind and
take up large pieces ofDNA from their environment. In most microorganisms, natural
genetic competence is regulated, that is, expression of the proteins that form the DNA-
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uptake complex is switched on and off. Chromosomal and plasmid DNA released into the
environment after cell lysis is stabilised against nucleases degradation by adsorption to
particulate matter (Aardema, Lorenz, et al, 1983, Lorenz and Wackernagel, 1987) and this
protection from degradation depends on the type ofparticulate matter involved (Lorenz and
Wackernagel, 1987). DNA taken up during natural competence can efficiently replace
homologous regions of the chromosome (Solomon and grossman, 1996) and thus add to the
genetic plasticity of the host.
Although very little research on transformation in B. cepacia has been carried out,
B. cepacia plasmid DNA has been shown not only to transform other B. cepacia strains but
also to transform the major CF pathogen and soil inhabitant P. aeruginosa (Hirai, Iyobe, et
al, 1982, Sabate, Villanueva, et al, 1994). Thus, available evidence from in vitro
experiments indicates that B. cepacia complex strains could exchange genes between
themselves and with strains belonging to different genera, through transformation.
In conclusion, B. cepacia, an opportunistic pathogen of life-threatening and transmission in
compromised hosts such as CF patients, could be introduced into the environment in bulk
quantities as a biopesticide and bioremediation agent. B. cepacia also has a large, complex
and highly plastic genome (Cheng and Lessie, 1994; Rodley, Romling, et al, 1995).
Exchange of genetic material between the introduced B. cepacia complex isolates and soil
flora is a probable event with as yet unknown consequences.
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Aims of thesis
The B. cepacia complex, representing at least seven newly described genomovars
(.B. cepacia genomovar I, B. multivorans, B. cepacia genomovar III, B. stabilis,
B. vietnamiensis, B. cepacia genomovar VI and B. ambifaria) comprises nutritionally
adaptable, multiresistant, soil and water organisms. These organisms have a large genome
with several different transposable elements. The transposable elements impart a
considerable potential for re-arrangement of the B. cepacia complex genome. Although
previously known as a plant pathogen, B. cepacia complex bacteria are now recognised as a
major cause of fatal pulmonary infections and septicaemia in immuno-compromised
individuals, in particular, patients with cystic fibrosis and chronic granulomatous disease.
Highly transmissible strains responsible for major epidemics have been associated with
fatal or life-limiting infections in both CF and non-CF patients. The potential threat of the
B. cepacia complex to CF patients is particularly well recognised. In ironic contrast,
agricultural microbiologists are seeking commercial licenses to exploit the antifungal and
nutritional adaptability of these bacteria as biopesticides and agents for soil bioremediation.
At present, potential hazards of introducing large quantities of the B. cepacia complex to
the environment on the human population and on the normal microbial flora cannot be
assessed accurately, due to lack of adequate information on the pathogenicity, taxonomy,
ecology and epidemiology of these challenging and complex bacteria. The aims of this
thesis are four-fold and focus on the pathogenicity and virulence markers of the B. cepacia
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complex and the potential threat that biotechnological B. cepacia complex strains pose for
humans.
1. A study of the general characteristics and biological properties of the B. cepacia
complex, with emphasis on candidate biocontrol strains and strains of clinical interest.
2. Investigation of the prevalance of the different genomovars of the B. cepacia complex
in the natural environment. Despite B. cepacia genomovar III being isolated with the
highest frequency from the respiratory tracts of CF patients, prior to this thesis there
were no reports of the isolation of genomovar III from natural environments.
3. Evaluation of the putative virulence and epidemic strain markers ofB. cepacia and
comparison of the potential pathogenicity of environmental and candidate biopesticide
strains with that of clinical strains.
4. Investigation ofpotential mechanisms of genetic exchange and alteration, firstly within
the B. cepacia complex and secondly, between B. cepacia and other organisms. Of
particular interest, would be genetic exchange between candidate biopesticide strains,






The bacterial strains used are shown in Tables 2.1 and 2.2, and were obtained from the
Cystic Fibrosis Laboratory Collection (Department ofMedical Microbiology, University
ofEdinburgh) and included strains from the recently created B. cepacia strain panel
(Mahenthiralingam, Coenye, et al, 2000). Information on the taxonomy of the strains
was obtained from Dr. P. A. R. Vandamme, (Laboratorium voor Microbiologic,
Universiteit Gent, Belgium).
2.1.2. Chemicals and Media
Unless otherwise stated all the media were provided by Oxoid Ltd., Basingstoke,
Flampshire, England and all the chemicals by Sigma-Aldrich Company Ltd., Dorset,
England. All media were prepared in distilled water and sterilised by autoclaving at
121°C 15 psi for 15 min.
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Columbia agar base (CAB): 39g L"1
Iso-sensitest agar: 31.4g L"1
Nutrient broth and Yeast extract (NBYE): Nutrient broth No.2 plus 0.5% yeast
extract (Difco Laboratories, Detroit, Michigan, U.S.A.)
Nutrient agar buffered (NAB): Nutrient agar buffered with 0.45g/L KH2PO4 and
2.39g/L Na2HP04.12H20
Burkholderia cepacia medium (BCSM): ( MAST Diagnostics, Bootle, Merseyside)
32.5g L"1 were sterilised and cooled to approximately 60°C before adding one selactab
(MAST) per 100ml of agar. The final concentration of antibiotics was lOOpg ml"1 of
ticarcillin and 300 units ml"1 ofpolymyxin B.
Tryptone soya agar (TSA): 40g L"1
MacConkey Agar( without salt): 47g L"1
Pseudomonas agar F (Difco): 38g L"1 with 1% glycerol added prior to sterilisation
Minimal salts NH4CI 20g, NH4NO3 4g, Na2S04 anhydrous 8g, K2P04 anhydrous 12g,
KH2 PO4 4g, Mg SO4 7H20 0.4g, salts were dissolved in distilled waterin the order
indicated and the volume made up to 1000ml
Minimal agar (MA) made up by mixing: 300ml sterile bacteriological agar No 1
solution, 100ml minimal salts and 4ml 20% glucose solution
Phosphate buffered saline(PBS): one tablet dissolved in 100ml ofwater and sterilised.
Saline: 0.85% NaCl (w/v), sterilised.
Skimmed milk: Skimmed milk powder 10% (w/v) sterilised by autoclaving at 121°C 15
psi for 5 min.
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Table 2.1: Burkholderia cepacia complex isolates used in this thesis
Strain Source and Location Reference
B. cepacia
genomovar I
CEP 509 CF, Australia Mahenthiralingam et al, 2000
C1963 CF, Edinburgh, UK Maxwell, 2000
ATCC 17759 Soil, Trinidad Mahenthiralingam et al, 2000
ATCC 25416 Onion, USA Mahenthiralingam et al, 2000
J2535 Rotting bark, Edinburgh, UK Butler et al, 1995
J2540 Soil, Edinburgh, UK Vandamme et al, 1997
J2552 Soil, Edinburgh, UK Butler et al, 1995
LMG 17997 UTI, Sweden Mahenthiralingam et al, 2000
B. multivorans
CF-A1-1 CF epidemic, UK Mahenthiralingam et al, 2000
C1052 CF, Edinburgh, UK Maxwell, 2000
C1524 CF, Edinburgh, UK This thesis
C1572 CF, Manchester, UK This thesis
C1576 CF, epidemic Glasgow, UK Mahenthiralingam et al, 2000
C1652 CF, Cardiff, UK This thesis
C1670 CF, Glasgow, UK This thesis
C1857 CF, Dundee, UK This thesis
C1911 CF, Edinburgh, UK This thesis
C2775 CF, Aberdeen, UK Nzula et al, 2000
C5393 CF, Canada Mahenthiralingam et al, 2000
LMG 13010 CF, Belgium Mahenthiralingam et al, 2000
JTC CGD, USA Mahenthiralingam et al, 2000
CI 962 Pus from brain abscess, UK Elobson et al, 1995
Table 2.1. cont.
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Strain Source and Location Reference:
ATCC 17616 Soil, USA Mahenthiralingam et al, 2000
J2395 Hospital plant and soil, UK This thesis
J2866 Rhizosphere, Edinburgh, UK This thesis
J2867 Rhizosphere, Edinburgh, UK This thesis
J2868 Rhizosphere, USA This thesis
249-2 Laboratory, USA Mahenthiralingam et al, 2000
B. cepacia
genomovar III
BC7 CF epidemic, Canada Mahenthiralingam et al, 2000
CEP 511 CF epidemic, Australia Mahenthiralingam et al, 2000
C517 CF, Edinburgh, UK This thesis
C1335 CF, Edinburgh, UK This thesis
C1394 CF, epidemic, Manchester, UK Mahenthiralingam et al, 2000
C1632 CF, epidemic, Newcastle, UK Maxwell, 2000
C2374 CF, Edinburgh, UK This thesis
C5424 CF, epidemic, Canada Mahenthiralingam et al, 2000
C6433 CF, epidemic, Canada Mahenthiralingam et al, 2000
K56-2 CF, epidemic, Canada Mahenthiralingam et al, 2000
PC184 CF, epidemic, USA Mahenthiralingam et al, 2000
J415 CF, Edinburgh, UK Mahenthiralingam et al, 2000
715j CF, USA Abe, Nakazawa, 1996
J2315 CF, epidemic, Edinburgh, UK Mahenthiralingam et al, 2000
ATCC 17765 UTI, UK Mahenthiralingam et al, 2000
C1773 Blood culture, Papworth, UK Maxwell, 2000
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Table 2.1 cont.
Strain Source and Location Reference:
B. cepacia genomovar III
R2817 Rice rhizosphere, Philippines This thesis
R2827 Rice rhizosphere, Philippines This thesis
R8351 Wheat rhizosphere, Australia This thesis
R8571 Rice rhizosphere, Philippines This thesis
R8574 Rice rhizosphere, Philippines This thesis
R8580 Rice rhizosphere, Philippines This thesis
R8605 Rice hizosphere, Philippines This thesis
R9235 Rice rhizosphere, Philippines This thesis
R9239 Rice rhizosphere, Philippines This thesis
R9243 Rice rhizosphere, Philippines This thesis
R9335 Wheat rhizosphere, Australia This thesis
R9342 Wheat rhizosphere, Australia This thesis
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Table 2.1 cont.
Strain Source and Location Reference:
B. stabilis
LMG 14294 CF, Belgium Mahenthiralingam et al, 2000
C7322 CF, Canada Mahenthiralingam et al, 2000
LMG 18888 Blood, Belgium Mahenthiralingam et al, 2000
LMG 14086 Respirator, UK Mahenthiralingam et al, 2000
B. vietnamiensis
LMG 6988 (C2972) Blood, Sweden Vandamme et al, 1997
LMG 6999 (C2973) Neck abscess, Sweden Nzula et al, 2000
FC 441 CGD Mahenthiralingam et al, 2000
CI 704 CF, Edinburgh, UK This thesis
LMG16230 (C2977) CF, Belgium This thesis
LMG16234 (C2979) CF, Sweden This thesis
LMG 16232 CF, Sweden Mahenthiralingam et al, 2000
PC 259 CF, USA Mahenthiralingam et al, 2000
ATCC 53266 Corn roots, USA Nzula et al, 2000
ATCC 53267 Corn roots, USA Nzula et al, 2000
ATCC 29424 Soil, USA Nzula et al, 2000
LMG10823 (C2974) Soil, Indonesia This thesis
LMG10824 (C2975) Rice root, Indonesia This thesis
LMG10929 (C2976) Rice, Indonesia Gillis et al, 1995
AMMD* Pea rhizosphere, USA King, Parke, 1993
LMG 10929 Rice, Vietnam Mahenthiralingam et al, 2000
J1697 CDC, Atlanta This thesis
J1705 CDC, Atlanta This thesis
Indefinite
C1511 I-III-IV CF, Manchester, UK Maxwell, 2000
CI763 I-III-IV CF, Manchester, UK This thesis
C2008 I-III CF, Liverpool, UK This thesis
C2349 I-III CF, Glasgow, UK This thesis
ATCC 25608 Incision wound, USA This thesis
J2891 Cornfield, USA This thesis
C3039 Rice, Canada This thesis
C3041 Rice, Canada This thesis
ATCC 10856 Onion, USA This thesis
* now B. ambifaria (B. cepacia genomovar VII)
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Table 2.2. Other bacterial isolates used in this thesis
Strain Description
Pseudomonas aeruginosa
PAOl Non-CF clinical isolate, classic laboratory strain
NTCC 10662 Control strain for antibiotic sensitivity testing
Escherichia coli
HB101 Contains the plasmid pLofwith a Hg resistance
marker, commonly used for large-scale plasmid
production
JM 109 Commonly used strain that will support growth
of vectors carrying amber mutations.
Burkholderia gladioli
ATCC 10247 Isolated from Gladiolus, USA
2.1.3. Maintenance of bacteria
Bacteria were cultured on CAB overnight at 37°C and a bacterial suspension made in
skimmed milk was stored at -70°C.
2.1.4. Media for the isolation ofB. cepacia from the rhizosphere
Malka minimal media
Malka minimal media (Robert-Gero Poiret, et al, 1970) comprised the following
reagents dissolved in distilled water;
Solution A: Na2 HPO4, 73.4g L"1 and KH2PO4, 32.4g L"1 and 2-3 drops ofCHCI3 added,
pH 7.0.
Solution B: Mg2SC>4, 20.5g L"1 and 2-3 drops of CHCI3 added.
Solution C: 1M mono-sodium L-glutamate, fdter sterilised
Solution D: FeSCU 7H2O 1.83g L~'and one drop of concentrated HC1 added
Solution E: (NH4)2S04 50g L"1, filter sterilised
The sterile solutions were mixed by adding; 8ml solutions A, B, C, E, 0.4ml solution D,
2ml of sterile 50% glucose, 400ml sterile distilled water and 300pg ml"1 of filter
sterilised polymyxin B sulphate (Sigma). 10ml of the mixture was dispensed into sterile
universal tubes.
Arginine -glucose media
Arginine-glucose medium (Stewart, 1971) was prepared as follows;
The indicator mixture was made up by adding 0.03 g cresol red (BDH, Merk Ltd.,
Dorset, England) and 0.02g bromothymol blue (BDH) to 1ml of IN NaOH and 99ml of
distilled water and heating on a hot plate for 10 minutes to dissolve the dyes.
30ml of indicator mixture were added tol.Og Nutrient broth No 2, 0.5g L-arginine
(Oxoid), 5.0g Glucose (Sigma), 4.0g Agar No 3 and 459.9ml distilled water. The pH
was adjusted to 7.4 before the medium was sterilised, allowed to cool and 10ml
dispensed into sterile glass test tubes. Once the media had set on a slope it was stored at
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4°C for up to two weeks.
PCATmedium
PCAT medium (Burbage and Sasser, 1982) was prepared as follows:
0.2g MgSCL. 7H20 and 2g azelaic acid (ICN Biomedicals Ltd., Oxfordshire, England)
were added to 0.5L of distilled water was heated while stirring using a magnetic stirrer
in a large flask with until the later had dissolved. Once the solution had cooled the
following were added, 0.2g tryptamine ((ICN) dissolved in a large drop of ethanol), 4g
KH2PO4, 4g K2PO4, 0.02g yeast extract 15g agar Nol. The volume of the medium was
then made up to 1L with distilled water. The pH was adjusted to 5.7 before sterilisation.
A filter sterilised alcoholic solution of cycloheximide (Sigma) 200mg L"1 was added
before the plates were poured. The medium was kept at 4°C and used within 48h.
2.1.5. Buffers for pulsed field gel electrophoresis
SE buffer:
4.38g ofNaCl and 9.30g ofEDTA Na2 were dissolved in 900ml distilled water, the pH
adjusted to 7.5, and after the volume had been made up to 1L, the buffer was filter-
sterilised and stored at 4°C.
Lysis buffer:
1 g N-lauroylsarcorsine and 18.6g EDTA Na2 were added to 80ml distilled water and
approximately 10ml of 10M NaOH to dissolve the EDTA. After adjusting the pH to 9.5
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and the volume being made up to 100ml, the buffer was filter-sterilised and stored at
room temperature.
TE buffer:
1.21g Tris (hydroxymethyl)-aminomethane (Bio-Rad, Laboratories Ltd., Hertfordshire,
England) and 3.72g EDTA were dissolved in 900ml of distilled water. After adjusting
the pH to 7.5 and the volume being made up to one litre, the buffer was filter-sterilised
and stored at 4°C.
2.1.6. Media for the selection of transformed isolates
LB media for the selection ofE. coli JM109 cells transformed with pGEM containing
the dsb fragment was made up as follows:
3g ofAgar Nol and 4g of LB broth (Gibco BRL, Life Technologies Ltd., Paisley,
Scotland) were dissolved in 200ml distilled water and sterilised. When the agar had
cooled to approximately 60°C, filter-sterilised ampicillin was added to a concentration
of lOOmg L"1; then 40pL of IPTG (Promega UK, Southampton, England) was added
from a lg stock solution and 200pL of X-gal (Promega) was added from a 50mg ml"1
stock solution. After mixing thoroughly and gently, 20ml was poured into a sterile petri
dish and allowed to set.
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2.1.7.Media and reagents for cellular fatty acid analysis
Trypticase soy broth agar (TSBA) for growing aerobic bacteria for cellular fatty acid
analysis was prepared by combining the following reagents in a Duran bottle.
30g Trypticase soy broth (BBL Microbiology Systems, Becton Dickinson European HQ,
Erembodegem, Belgium), 15g Granulated agar (Difco) and 1L of distilled water.
The mixture was stirred to dissolve the reagents and autoclaved for 15 min at 121°C.
After cooling in a water bath to 60°C, the agar was dispensed aseptically into sterile
petri dishes, allowed to solidify and the plate kept at 4°C until required.
Reagents for fatty acid analysis were supplied by members of staff at the Laboritorium
voor Microbiologic, Universiteit Gent.
Saponification reagent: The saponification reagent consisted of the following;
45g NaOH (Merck Ltd., Dorset, England), 150ml Methanol and 150ml de-ionised water.
The NaOH pellets were added to water and methanol while stirring and the stirring
continued until the pellets had dissolved.
Methylation reagent: 325 ml 6.ON HC1 and 275ml Methanol (Merck)
The HC1 was added to the methanol while stirring.
Extraction Solvent: 200ml Hexane (Merck) and 200ml
Methyl-tertiary Butyl Ether, MTBE, (Merck). The MTBE was added to hexane while
stirring
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Base wash: 10.8g NaOH (Merck) and 900ml deionised distilled water. The NaOH
pellets were added to water while stirring and the stirring continued until the pellets had
dissolved.
2.2. METHODS
2.2.1. Isolation ofBurkholderia cepacia from the environment
B. cepacia was isolated from lOg of soil collected around the rhizosphere of plants
found in different locations within the United Kingdom.
2.2.1.1. Isolation of B. cepacia by antibiotic selection
B. cepacia was isolated by modification of the Butler method (Butler et al, 1995). lOg of
soil were suspended in 10ml ofMalka minimal media and incubated at 37°C for five and
12 days. lOOpl of each soil suspension was then spread on the surface ofBCSM agar
plates using a sterile glass spreader and the plates incubated at 30°C for 48h. Each
different colonial morphotype was picked and sub-cultured on CAB until pure cultures
were obtained. Suspensions of the pure cultures were made in 0.85% saline and then
inoculated, using a multi-point inoculator (A400 Multipoint inoculator, Denley,
Billinghurst, Surrey), onto CAB, which was incubated at 4, 37 and 41 °C. The same
cultures were also inoculated onto MacConkey agar and Pseudomonas agar F in order to
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identify and exclude lactose fermenting and fluorescent organisms respectively. The
remaining cultures were tested for oxidase production and those that gave positive
results were sub-cultured onto arginine-glucose medium. The results were read after 24,
48 and 120h incubation at 30°C. All isolates that gave a yellow slope with the bottom of
the tube remaining green and maintained this pattern even after five days incubation,
were presumptively identified as B. cepacia and were sub-cultured onto CAB. After
overnight incubation at 30°C, the isolates were identified using the API 20NE (bio
Meriex, Marcy l'Etoile, France ) according to the manufacturer's instructions.
2.2.1.2. Isolation of B. cepacia using PCAT medium
lOg of soil were suspended in 10ml in 0.85% saline and left at ambient temperature for
three hours. lOOpl of each soil suspension was spread on the surface PCAT medium
agar plates using a glass spreader and the plates incubated at 30°C for 48h. Each
different colony was picked and sub-cultured on CAB until pure cultures were obtained.
The pure cultures were subsequently treated as described for the pure cultures in 2.2.1.1.
2.2.2. Determination of MIC
The agar dilution method for MIC determination was used following guidelines outlined
in a guide to sensitivity testing, (British Society for Antimicobial Chemotherapy, 1991).
Antibiotics dissolved in the appropriate solutions were filter-sterilised before being
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added to cooled Iso-Sensitest agar. The antibiotic plates were stored overnight at 4°C
before use. Overnight cultures of test organisms were diluted and inoculated onto the
antibiotic plates using a multipoint inoculator, giving a final inoculum of 104 cfu for
each spot. The plates were incubated overnight at 37°C in air or in air with 5% CO2 as
appropriate. MIC was recorded as the lowest concentration of antimicrobial inhibiting
the visible growth of each test organism after overnight incubation. The tests were
repeated three times with P. aeruginosa NCTCC 10662 as the control organism.
2.2.3. Bacteriocin typing
Bacteriocin typing was carried out using previously described methods (Govan, Harris,
1985). Six producer and eight indicator B. cepacia isolates were grown in CAB plates
overnight at 30°C. Suspensions of each isolate to be tested and each producer strain,
also grown overnight in CAB plates, were made in 0.9 ml of 0.85% sterile saline and
mixed by vortexing before inoculating plates containing 10ml of tryptone soy agar using
a multi-point inoculator. The plates were incubated at 30°C for 5.5 h. Suspensions of
indicator and test strains were made in Wasserman tubes containing 2.5ml nutrient broth
and incubated at 30°C for 4h. After incubation, the plates inoculated with producer and
test strains were placed over filter paper soaked in chloroform for 15 min in a fume
hood. The plates were then exposed to air for a further 15 min. lOOpl ofbroth culture
containing indicator or test strains was mixed with 2.5ml of overlay agar, mixed and
poured over the plates inoculated with test strains or producer strains respectively. After
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the agar had set, the plates were incubated overnight at 30°C and results interpreted as
previously described (Govan and Harris, 1995). The overlay agar was made by adding
lg bacto-peptone and 0.3g agar to 100ml distilled water, sterilised and 2.5ml aliquots
dispensed in sterile Wasserman tubes and kept warm until required.
2.2.4. Pulsed-field gel electrophoresis
Overnight cultures of each isolate in NBYE were centrifuged at 3 200 x g for lOmin and
the pellet re-suspended in SE buffer. The inoculum was standardised to OD 590 of 1.5
and plugs of 1 % low melting agarose (Bio-Rad) were cast in a plug mould which had
previously been wiped in 70% ethanol.
Lysis ofplugs
The set plugs were transferred to sterile bijou bottles with 2ml of lysis buffer containing
0.05% Triton-X 100 before incubating overnight at 56°C in a water-bath. Lysis buffer
was replaced by three changes of an equal volume of TE buffer with incubation at 4°C
for 30min with each change.
Restriction ofDNA in agarose
Restriction ofDNA in agarose was carried out on a 2.5mm x 9mm portion in a sterile
Eppendorf tube. 90pl of sterile distilled water was mixed with lOpl lOx reaction buffer2
(Gibco BRL) and left at 4°C for 30min. The buffer was replaced with 90pl of sterile
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distilled water, 1 Ojj.1 lOx reaction buffer2, 2pl of lOrngmf1 bovine serum albumin, 2pl
0.1M dithiothriotol and 2pl Xbal (Gibco BRL), mixed and incubated overnight in a
water-bath at 37°C.
Separation ofDNA fragments
The enzyme mixture was replaced with TE buffer before being used. A 1% pulse field
agarose gel was prepared in 0.5 x Tris Borate EDTA (TBE) buffer, allowed to set and
the plugs loaded. The plugs were sealed using some molten agarose left over from the
gel. Pulsed-field gel electrophoresis was carried out in a CHEF-DRII tank
(Bio-Rad) using 2L of 0.5%TBE. The gel was run for 20 h at a constant temperature of
14°C and voltage of 200V, with pulse times of 2.9 to 35.4s and a ratio of 1.0.
Following electrophoresis, the gel was stained for 15min in lpgrnF1 solution of ethidium
bromide (Bio-Rad), destained twice using distilled water and shaking for 15min and the
bands viewed under a UV transilluminator. Photographs were taken using a polaroid
camera.
2.2.5. Production of extracellular enzymes
Overnight broth cultures ofB. cepacia isolates and P. aeruginosa PAOlin NBYE were
washed in saline, diluted to a concentration of 108 cfu ml*1 and then inoculated onto
appropriate substrates (see following sections). The plates were incubated at 37°C and
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observed for clearing of the media around the bacterial growth after 72hours.
Production ofCaseinase
Four different media were used for the detection of caseinase. These were made up by
mixing equal quantities of each sterile medium with 10ml of sterile skimmed milk
(Oxoid), 10% w/v. The basic media included: a 3% w/v solution of agar bacteriological
(Agar Nol), tryptone soya agar, tryptone soya agr with 5% peptone (w/v) (Difco) and
LB Broth (Gibco BRL) with 3% w/v solution of agar bacteriological (Agar Nol).
Production ofElastase
Elastase production was determined on media containing 2% (w/v) Agar No 1 which
was sterilised and allowed to cool before adding 1% Elastin-congo red (ICN), which had
been decontaminated by placing under a UV lamp for 15min. 20ml medium was
dispensed into sterile petri dishes and allowed to set at room temperature before use.
Elastase production was observed as a zone of clearing around the bacterial growth.
Production oflipase
Production of lipase was tested on CAB with 5% egg yolk emulsion added to the cool,
sterile agar. The plates were inoculated with a multipoint inoculator, incubated at 37°C
for 48h and examined for a pearly sheen around the bacterial growth.
Production ofcatalase
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Production of catalase was tested by placing one or two bacterial colonies on a drop of
hydrogen peroxide on top of a microscope slide and observing for the production of
effervescence within 20 seconds.
2.2.6. Pathogenicity of B. cepacia and B. gladioli on onions and potatoes.
Peeled white and red onions and washed baking potatoes, all of British origin, were
sliced into rings and placed into sterile petri dishes lined with Kimberly Clarke wipes
soaked in sterile distilled water. The rings were inoculated with 1ml of an overnight
culture ofB. cepacia J2315, AMMD or B. gladioli ATCC 10247 giving a final
concentration of 108 cfu and incubated at 30°C for five days. Controls were inoculated
with an equal volume of sterile distilled water before incubation for a similar period.
After five days the plates were examined for tissue maceration and discolouration.
2.2.7. Isolation and propagation of B. cepacia bacteriophages
Overnight NYBE cultures of 38 B. cepacia isolates were harvested at 3 200 x g for 30
min and the supernatants filtered using 0.2pm syringe filters (Gelman Sciences, Ann
Arbor, U.S.A.). The supernatants were screened for the presence of phage by spotting
onto bacterial lawns of the same panel of isolates, using a multipoint inoculator.
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A single phage plaque on an agar plate was removed by stabbing into the medium using
a sterile glass pipette. This was transferred to 1.5ml of phage buffer, centrifuged at
13 000 x g and the supernatant collected. Stock phage preparations were made by
fdtration as stated above.
High-titre phage preparations were made as follows: lOOpl of a phage preparation were
added to 2.5ml molten soft nutrient agar, previously seeded with lOOpl of an overnight
culture of the propagating strain. The mixture was then overlayed on CAB plates and
allowed to set. After 18 h at 37°C, overlays showing semi-confluent lysis were
transferred into 10 ml phage buffer (lOmM-Tris/HCl, pH 8.0,10mM MgCh)
(Matsumoto, Itoh, et al, 1986). The lysate was then vortexed, centrifuged at 3 200 x g
for 30 min and the supernatant fdtered. Phage titres were determined as plaque-forming
units (pfu ml"1) in soft agar overlays. Stock preparations were maintained at 4°C.
2.2.8. Isolation of antibiotic resistant bacterial mutants
Spontaneous bacterial mutants were isolated by spreading 100 pi of overnight broth
cultures ofB. cepacia (approximately 108cfu ml"1), on the surface of iso-sensitest agar
containing antibiotic at concentrations ranging from the basic MIC to 32 x the MIC.
After incubation at 37°C in air for 48h, mutational frequencies were calculated from
results obtained with the highest concentration of antibiotic on which resistant mutants
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were detected. The mutants were cultured again on the medium containing the same
concentration of antibiotic and maintained in skimmed milk at -70 0 C.
2.2.9. Host range of B. cepacia phages
o 1
Stock phage solutions, diluted in phage buffer to approximately 10 pfu ml were
spotted on to lawns ofB. cepacia and P. aeruginosa using a multipoint inoculator and
examined for lytic activity after 24 h at 37°C.
2.2.10. Extraction of phage DNA
Phage DNA was extracted using a previously described method (Matsumoto, Itoh, et al,
1986). Genome size of unrestricted DNA was estimated by PFGE (initial and final pulse
time of 5s and 20s, 170V at 14°C for 19h) incorporating a X ladder DNA PFGE standard
kit (New England Biolabs, Hitchin, Hertfordshire,UK).
2.2.11. Extraction of LPS
B. cepacia LPS was extracted using the aqueous phenol method ofWestphal and
Luderitz (1954) as modified by Hancock and Poxton (1988). Bacteria were grown for
48 hours in NBYE at 37°C in an orbital incubator (Gallenkamp, Loughborough, Leics)
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at 120 rpm. The cells were harvested by centrifugation at 10 000 x g for 15min and
washed twice in PBS. The pellet was incubated overnight at -70°C before being
lyophilised over 48 hours (Edward Modylo freeze dryer, Edwards High Vacuum Ltd.,
Surrey, UK). Dried cells were resuspended to 5% w/v in pyrogen-free water and then
placed in a 67°C water-bath in a fume cupboard. An equal volume of 90% phenol was
also heated to 67°C before being mixed with the cell suspension and holding at the same
temperature for 15 min with occasional mixing. The mixture was cooled in an ice bath
and then centrifuged at 10 000 x g for 15min at 4°C in sterile pyrogen-free glass tubes.
The upper aqueous layer containing the LPS was transferred to dialysis tubing and
dialysed overnight against running tap water and then for 4h with two changes of
pyrogen-free water. After ultracentrifugation at 100 000 x g for 3h at 4°C, the pellet was
resuspended in a minimal volume of pyrogen-free water using a syringe and needle and
then frozen and lyophilised as described above. The LPS was stored at -20°C.
2.2.12. Neutralisation of phage activity by LPS
The effect ofpre-incubation with LPS on phage activity was determined using a
modification of the method described by Govan (Govan, 1974). Phage preparation
(0.5ml), containing approximately 10 3 pfu ml _1 was mixed with 0.5 ml ofbacterial LPS
(20 mg ml"1 solution in distilled pyrogen-free water) and incubated at 37°C for 1 h.
Controls comprised phage and buffer without LPS. The experiment was repeated and
the results calculated as the means of three experiments.
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2.2.13. Transduction
Transduction experiments were carried out using the method described by Krishnapillai
(Krishnapillai, 1971). Phages NS1 and NS2 were propagated on the ceftazidime
resistant mutants of three B. cepacia strains with MICs of 8pg ml"1. Phage lysate
(0.5ml) was added to a PBS suspension of the sensitive B. cepacia parent strains ATCC
53265, ATCC 29424 and C2973 at a multiplicity of 1 and left for 20 min at 37°C to
allow phage adsorption. The cells were harvested at 3 200 x g for 30 min, resuspended
in TNM buffer (Tris 0.01M pH 7.4, NaCl 0.15M, MgS04 0.01M) (Krishnapillai, 1971)
and lOOpl spread on CAB containing ceftazidime at 8 ug ml"1. Transductants were
recovered after incubation at 37°C for 72h. Controls comprised recipient strains plus
TNM buffer alone.
2.2.14. Electron microscopy
Phage lysates were centrifuged at 3 200 x g to remove cell debris, and then at 100 000 x
g for lh. The phage pellet was resuspended in 1M ammonium acetate. After negative
staining with 2% (w/v) potassium phosphotungstate solution (pH 7.0), phage
morphology was observed with a transmission electron microscope (Hitachi type 12A
operating at 60 K).
2.2.15.Extraction of genomic DNA for dsb polymerase chain reaction (PCR)
Genomic DNA was extracted using standard methods (Sambrook, Fritsch, et al, 1998).
102
2.2.16. Amplification of the dsb gene by PCR
Amplification of the dsb gene was carried out using the following primers:
Forward primer (dsb+): d AACTCGAAACGGACGACGAC
Reverse primer(dsb'): d CCTTGAACATGCCAGGGAAC
All amplifications were carried out in a 50pl volume containing lOpl of reaction buffer
(Promega UK, Southampton, England ), 5 pi of a template DNA sample, 4U of Taq
DNA polymerase (Promega), 0.13 mM each 2'-deoxynucleoside 5'-triphosphate
(Promega), 0.5pM each nucleotide primer and 2.5pl dimethyl sulfoxide (DMSO). The
reactions were performed on a DNA thermal cycler (Gene E, Techne, Cambridge, UK)
for 35 cycles, each cycle consisting of lmin 10s at 94°C for denaturation, 1 min at 62°C
for annealing and lmin 30s at 72°C for polymerisation.
10 % gel loading buffer, containing 0.05% bromophenol blue, 0.05% xylene cyanol and
25% glycerol, was added to the PCR products and 20 pi loaded to a gel. A lOObp ladder
(New England Biolabs, Beverley, MA, U.S.A.) was used to estimate the size of the PCR
product. Gel electrophoresis was carried out on a 1.5% agarose gel in 0.5 x TBE buffer
at 50V for 3h. A band of 750bp was presumed to be the dsb PCR product. Purity and
concentration of the PCR product was determined using optical density measurements
(An absorbance of 1 at 260nm is equivalent to 50pgmf') (Sambrook, Fritsch, et al,
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1998).
Sequencing of the dsb fragment was performed at the Department of Haematology, The
Edinburgh Royal Infirmary with the same primers as those used for PCR.
Ligation ofPCR product and cloning vector
pGEM (Promega) was chosen as the cloning vector. In order to determine the amount of
insert DNA required for the vector, the following formula was used:
ng of insert = ns ofvector x kb size of insert x vector: insert ratio
kb size ofvector
where; the vector: insert ratio is 3:1
size of insert is 742bp = 0.72kb
size of vector is 3000bp = 3kb
Ligations were set up as shown in Table 2.3 and left at 4°C overnight.
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Table 2.3. Ligation of product and PCR product reaction mixes
Product Reaction Positive control Back control
10 x ligase buffer lpL lpL lpL
pGEM lpL lpL lpL
PCR product lpL none none
Control insert DNA none 2pL none
T4 DNA ligase lpL lpL lpL
Sterile water 6pL 5pL 7pL
2.2.17. Transforming E. coli cells
50pL of competent E. coli JM109 cells was dispensed into three sterile Eppendorf tubes
and 2pL of ligation mix added with a control ofjust E. coli cells. After leaving the cells
undisturbed on ice for 30 min, the cells were heat shocked by being placed in a 42°C
waterbath for 50s and immediately placed on ice for 5min. 950pL of SOB (Sambrook,
Fritsch, et al, 1998) was added to each tube and mixed gently before the tubes were
incubated at 37°C with gently shaking at lOOrpm for 1,5h. Serial tenfold dilutions of the
culture were made in sterile 0.85% saline and lOOpL spread on LB selection agar plates
with lOOmgL"1 ampicillin, IPTG (Promega) and X-gal (Promega) and incubated
overnight at 37°C.
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Plates were removed from the incubator and kept at 4°C to aid clearer differentiation
between colonies. Single colonies that were less intensely blue than the others were
transferred into a sterile Wasserman tube containing 1.5 ml of SOB with 1 OOmgL"1
ampicillin and incubated with vigorous shaking. Mini preparations of plasmid DNA
were made from 1ml of each culture using standard methods (Sambrook, Fritsch, et al,
1998) and 0.5ml of each culture was reserved.
A restriction mix for each plasmid extraction was set up to remove the dsb fragment
from pGEM using the restriction enzyme Eco RI (Promega) according to the
manufacturer's instructions.
The restricted DNA was separated by electrophoresis on a 1.5% agarose gel in 0.5 x
TBE at 60v for approximately 3h. The gel was stained and examined for a band of
742bp. When such a band was detected, the reserved 0.5ml of SOB culture was streaked
onto LB agar plates containing 1 OOmgL"1 ampicillin. Plasmid mini preparations were
made, digested and separated by agarose gel electrophoresis as already described.
Large-scale preparation ofplasmid DNA was carried out using standard methods
(Sambrook, Fritsch, et al, 1998). 500ml of sterile LB with 1 OOmgL"1 ampicillin was
inoculated with the isolate harbouring the 742bp band and incubated with shaking at
37°C. The plasmid DNA was purified by precipitation with polyethylene glycol as
outlined by (Sambrook, Fritsch, et al, 1998).
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The purified plasmid DNA was restricted with EcoRI and separated by agarose gel
electrophoresis as already described.
E. coli HB101 containing the plasmid pLofHg was recovered from storage in glycerol at
-70°C, streaked onto CAB plates and incubated overnight at 37°C. Large-scale
preparation of plasmid DNA was carried out as already described and restricted with Sfil
(New England Biolabs) according to the manufacturer's instructions.
This digest was incubated at 50°C for 2h leaving a 3' overhang. The restricted DNA was
separated on a 0.8% gel in 0.5x TBE at 70v for 2h. The gel was stained in ethidium
bromide and a band of about 4kb was excised.
2.2.18. Recovering DNA from agarose gel
The excised band was placed into a sterile 0.5ml PCR tube with a hole at the bottom
made with a hypodermic needle. The PCR tube had 80pL of glass beads (Sigma,
diameter 212-300 microns) and was held inside a sterile Eppendorf tube. The two tubes
were left overnight at -20°C and centrifuged at 13 000 x g for 30min. Ethanol
precipitation of the DNA in the liquid that collected at the bottom of the Eppendorf tube
was carried out using standard methods (Sambrook, Fritsch, et al, 1998).
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2.2.19. Creation of blunt ends.
Blunt ends were created in pSNl using the enzyme Bbsl (New England Biolabs), as
indicated by the manufacturer. Incubation for 2h at 37°C resulted in a 5 overhang,
lpl of T4 DNA polymerase and 0.5pL dNTP mix (lOOpM of each dNTP) was added to
the restriction mix. This was incubated at 37°C for 5min and the reaction stopped by
adding 2pL of sterile 0.5M EDTA.
A reaction mix for pLofwas set up by placing 2 pL plasmid DNA (with 3 overhangs
resulting from digestion with Sfil) to a strelile PCR tube. lpL of T4 DNA polymerase
(Promega), 0.5pL dNTP mix (lOOpM of each dNTP) and 46.5pl buffer E (Promega)
was added. The mixture was incubated at 37°C for 5min and the reaction stopped by
adding 2pL of sterile 0.5M EDTA.
The DNA was purified by two phenol / chloroform extractions followed by ethanol
precipitations.
2.2.20. Ligating blunt ends
A ligation mix consisting of blunted pSNl DNA, pLofHg DNA and ligase buffer
(Promega) was set up. This was mixed gently and heated at 45°C for five minutes,
cooled on ice for two minutes before adding 2pL T4 DNA ligase (Promega), mixing and
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incubating at 16°C for 72h.
2.2.21. Transformation ofB. cepacia J2315 by electroporation
B. cepacia J2315 was grown in 100ml of LB at 37°C in an orbital incubator to an optical
density of 0.6 at X 595. The cells were centrifuged at 3 200 x g for ten minutes and the
pellet was re-suspended in sterile ice-cold 10% glycerol in half the original volume of
the media. The process was repeated five times using ice-cold apparatus and solutions
each time.
Precipitated DNA from the ligation of pSNl and pLofwas added to 50pL of cells and
electroporation carried out on a (Equibo, Easyjetplus) electroporator using the following
parameters;
Voltage: 250V, capacity: 25 uF, resistance: 201Q.
The cells were immediately added to 1ml of cold LB and left to stand on ice for 15min
before being incubated at 37°C with gently shaking (100 rpm) for two hours. Ten-fold
dilutions were made and lOOpL was spread on the surface ofBCSM containing 18mgL"'
ofHgCL- The plates were incubated at 37°C for 72h.
Genomic DNA was extracted and stored at -20°C. After staining in ethidium bromide, a
band of about 3kb was excised and the DNA recovered.
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2.2.22. Natural transformation of the B. cepacia complex
Natural transformation of the B. cepacia complex was carried out using modifications of
a previously described method (Juni, 1974). B. cepacia J2315 transformed with pLof
containing the mercury resistance gene was cultured on BCSM plates with 18mgL_1
mercury chloride. Crude DNA for transformation was prepared by suspending two
loopfuls of the transformed B. cepacia J2315 in 0.5ml sterile lysing solution (0.05%
SDS in 0.15M NaCl and 0.015M trisodium citrate). The suspension was heated at 70°C
for lh, cooled to room temperature and stored at -20°C until required.
A grid of squares was marked on the bottom of a CAB plate and each square labeled to
correspond with the recipient B. cepacia strains in which the dsb gene had been
identified. A small amount of cell paste from each strain, cultured in either CAB or
minimal agar was placed on the corresponding square. A loopful of the crude DNA
extract was mixed with the cell paste and spread over an area of approximately 5-8mm.
The loop was sterilised between different strain to avoid cross-contamination. A loopful
of crude DNA alone was also spread to verify sterility. An equal amount of cell paste
was spread on a different CAB plate without the crude DNA extract to serve as a
negative control and the plates were incubated overnight at 30°C.
After overnight incubation, the DNA extract was checked for sterility. A small amount
of cell paste was removed from each square of the test and control plates and streaked
uniformly on a sector of BCSM plates with 18mgL_1 mercury chloride after which the
110
plates were incubated at 30°C for 48h. The assay was repeated three times each, with
the recipient strains propagated on both CAB and minimal agar.
2.2.23. Isolation of Plasmids
Overnight cultures of B. cepacia in NBYE were centrifuged at 3200 x g for 10 min and
the pellet washed in 5ml lOmM Tris pH 8.0. After centrifugation under the same
conditions, the pellet was dispensed in 5.4 ml TE buffer pH 8.0 and 0.21ml of lOmg ml"1
lysozyme (Sigma) in TE buffer was added and the bottles incubated in a water-bath at
37°C for lh. 0.3ml of 20% SDS, pre-incubated at 55°C, was added and the mixture
incubated for 15min in a 55°C water-bath. After incubation, the contents were vortexed
at high speed for up to two minutes in order to shear the DNA. The solution was
denatured by adding 0.2 ml of freshly made 3N NaOH and left for ten minutes at room
temperature with occasional mixing. 0.5ml of 2M Tris pH 7.0 was added, the
preparation mixed and 1,5ml of 5M NaCl added. The mixture was then treated with an
8ml of salt-saturated phenol (Sigma), centrifuged at 13 000 x g and the top aqueous
phase removed and treated with an equal volume of choroform: isoamyl alcohol (24:1).
After centrifugation, the top phase was again removed and placed into sterile universal
bottles. To the top phase was added 6ml of chloroform. The top phase was again
removed, 12ml of ethanol added and the tubes placed at -70°C for lh. The contents
were then centrifuged at 3 200 x g for 30 min. The top phase of the ethanol was
removed leaving approximately 1.5ml containing the pellet. This was transferred to an
ill
Ependorff tube, centrifuged at 13 000 x g for 10 min and after removing the supernatant,
the pellet was re-suspended in 150pl TE buffer pH 8.0.
2.2.24.Cellular fatty acid analysis
Inoculatingplates and harvesting
TSA plates were inoculated from a pure bacterial culture, rotating the plate 90° and
sterilising the loop between each of the four quadrants as illustrated in Fig 2.1.
Fig 2.1 Inoculating ofTSBA plate for cellular fatty acid analysis.
After incubating at 28°C for 24 hours, the cells were harvested from the overlap of the
second and third quadrant by scraping the surface of the culture medium using a sterile
loop. The cells in this area are in late log phase and yield the most stable fatty acid
compositions. The harvested cells were wiped onto the bottom of a clean, dry 13mm x
100mm screw cap culture tube.
Saponification
1 .Oml of the saponification reagent was added to each tube in the batch and a control
tube with no cells in it. The tubes were tightly sealed with a clean teflon-lined screw
cap, vortexed for 5-10s and placed in boiling water. After 5 minutes the tubes were
removed from the boiling water, vortexed for 5-10 s and returned to the boiling water.
After 30 minutes of saponification, the tubes were cooled in water at room temperature.
(The saponification reagent is a strong methanolic base and when combined with heat, it
kills and lyses the cells and their fatty acids are cleaved from the cell lipids and
converted to their sodium salts).
Methylation
Methylation converts the sodium salts of fatty acids to fatty acid methyl esters, which
increases the volatility of the fatty acids for the gas chromatography (GC) analysis.
When the tubes had cooled to room temperature, 2.0 ml of the methylation reagent was
added to each tube. The tubes were heated at 80°C in a water bath for lOmin and cooled
to room temperature before extraction of the fatty acid methyl esters could be carried
out.
Extraction
During this step, the fatty acid methyl esters are extracted from the acidic aqueous phase
and transferred to an organic phase with a liquid-liquid extraction procedure. This was
carried out by adding 1.25ml of the extraction solvent to each tube and tightly sealing it
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before placing it on a shaking machine (Janke & Kunkel HS250) for 10 min at 75 rev
min"1. The lower, aqueous phase was removed and discarded using a clean Pasteur
pipette from each sample.
Base wash
A mild base solution is required to remove the free fatty acids and residual reagents from
the organic extract. It is essential to remove the residual reagents as they damage the
chromatographic system. 3.0 ml of the base wash was added to each tube and the tubes
placed on a shaking machine for 5 min. Whenever necessary, a few drops of saturated
NaCl / water solution were added and the tubes rotated gently, while being held
vertically, between the palms and left to settle for a few minutes to aid in breaking the
emulsion. Using a clean Pasteur pipette for each sample, the upper, organic phase was
removed from each bottle and transferred to a labeled, clean GC sample bottle. A cap
was immediately placed on the bottle to prevent evaporation. The caps were then
crimped onto the sample bottles and loaded onto the automatic sampler behind the
calibration mix.
Calibration was carried out by a member of staff at the Laboratorium voor
Microbiologic, Universiteit Gent, after loading the injector turret with a fresh bottle of
hexane/MTBE wash solvent and two empty waste bottles.
Details of bottles loaded into the sample tray were entered into the computer's sample
table and the computer prompted to analyse the samples.
A detailed description of the GC equipment is given in the Appendix.
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2.2.25. Preparation ofwhole-cell bacterial protein extracts
A loopful of bacteria grown for 48h at 28°C in nutrient agar buffered (NAB) was
transferred to a sterile Eppendorf tube and washed by resuspending in 900pL NaPBS
buffer followed by centrifugation at 1000 rpm for 5 min on a bench centrifuge
(Eppendorf centrifuge 5417C). The supernatant was discarded and 900pL sample
treatment buffer (STB) followed by lOOpL 20% SDS added to the pellet. After mixing
thoroughly, the mixture was heated at 95°C in a dry bath for 10 minutes (Thermolyne,
Type 16 500 Dri bath). The tubes were cooled on ice and the suspension treated with
ultrason at an output of 50W (Labsonic 2000, needle probe tip 127mm long 4mm
diameter) for 15s in order to break down DNA and polysaccharides. The suspension
was then centrifuged at 10 OOOrpm for 8 min and the supernatant, containing the protein
extract poured into a sterile Eppendorf tube. The extract was stored at -20°C until
required.
2.2.26. SDS-PAGE analysis of whole-cell bacterial protein extracts
Separation gel
A 12% separation gel, 1.5mm thick was prepared using stock solutions shown in the
Appendix.
The gel was made up by mixing the following constituents in a flask with a stirrer:
10ml separating gel buffer, 16.0ml monomer solution, 0.4ml of 10% SDS and 13.4ml
double distilled water. The mixture was warmed to 25°C for about 5min before adding
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20.0pl TEMED and 0.14ml of 10% freshly opened and made up (NH4)2S2C>8.
After mixing thoroughly, the mixture was poured between the assembled glass plates in
casting stand, to a height of about 12.5cm from the base. The gel was overlaid with 2ml
ofwater saturated isobutanol to maintain an anaerobic condition and to obtain a flat
surface and then submerged in a water bath at 25°C for two hours. After polymerisation,
the water-saturated isobutanol was discarded and the gel surface rinsed twice with
distilled water and twice with double distilled water. The gel was overlaid with 1.6ml of
1/4 diluted separating gel buffer containing 0.1% SDS and left to polymerise overnight
at 19°C. The overlaying % diluted separating gel buffer was discarded, the gel surface
rinsed twice in double distilled water and any excess liquid drained.
Stacking gel
A 5% stacking gel, 1.5mm thick was prepared using stock solutions, shown in the
Appendix.
A stacking gel was made up by mixing the following constituents in a 50ml Erlenmeyer
flask with a stirrer: 2.5ml stacking gel buffer, 1.7ml monomer solution, 0.1ml of 10%
SDS and 5.7ml double distilled water. The mixture was warmed at 25°C in a water bath
for about 5min before adding 1 2.5jlx1 TEMED and 0.05ml of 10% freshly opened and
made up (NH4)2S208. After mixing thoroughly, the stacking gel solution was poured on
top of the polymerised separating gel, a 1.5mm teflon comb inserted between the plates
and the gel left to polymerise for at least an hour.
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Sample application and electrophoresis ofSDS-solubilisedproteins
Four slots of the reference strain Psychrobacter immobilis LMG 1125 were loaded in
each gel and one slot with a low molecular weight marker (see Appendix). The final
volume in each slot was adjusted to 10pl with tracking dye (see Appendix).
Once loaded the upper buffer reservoir was attached on top of the plates which were
then removed from the casting stand and immersed into the lower buffer reservoir
containing running buffer (see Appendix). The running buffer was used for a maximum
of three times. Freshly prepared upper tank buffer was poured into the upper chamber
and the gel run at a constant current of 6.0mA overnight until the tracking dye reached a
level of about 9.5cm from the top of the separating gel.
Gelfixing, staining and destaining
The proteins were fixed and denatured in fresh 3% Tricarboxylic acid (TCA) solution
with gentle shaking for 15min. The fixing solution was discarded and staining was
carried out for 1 hour in fresh Serva R blue staining solution (see appendix), with gentle
shaking at room temperature. After the proteins were stained, the staining solution was
discarded and fresh destaining solution added to the gel and left on a gently shaking
machine for 20 min. The step was repeated three times before the gel was ready for
drying.
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Gel drying gel andphotography
Uncoated cellulose acetate sheets (type 325 P23 UCB) were prepared for gel drying by
soaking in a water bath at about 40°C. The gel apparatus was placed on the gel drier
(Hoeffer Scientific Instruments, drygel jr model SE540) in the following order from top
to bottom;
filter paper
uncoated cellulose acetate sheet,
gel
uncoated cellulose acetate sheet
filter paper and
permeable plastic sheet of dryer.
The gel was dried under vacuum for 2hours. Gels were photographed in the department
and photographic positive prints standardised.
Processing ofdried ofgels
The dried gels were scanned using a LKB Bromma 2202 Ultroscan Laser Densitometer
and the software used was Gel Compar, Comparative Analysis of Electrophoresis
Patterns, Version 2.0, Data Capture Program 1992. The data was re-scaled using Gel
Compar, Comparative Analysis ofElectrophoresis Patterns Version 2.0, Data Input and
Conversion Program, 1992. The spectra were then converted to protein bands using Gel
Compar Normalisation SDS-PAGE 3.1 and the bands aligned to the reference strain
Psychrobacter immobilis LMG 1125 pattern in the database. The data was then
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analysed using Gel Compar, Comparative Analysis of Electrophoresis Patterns, Version
4.2, 1992-1997, and compared to the laboratory's SDS-PAGE data base.
2.2.27. PCR for the identification of B. cepacia
Alkaline lysis extraction ofDNA
DNA used in PCR for the taxonomic identification of bacterial isolates was extracted by
alkaline lysis. 20pl of lysis buffer was added to lor 2 bacterial colonies in a sterile
Eppendorf tube and heated on a heating block forl5min at 95°C. The heated suspension
was centrifuged briefly before adding 180pl of double distilled water. After
centrifugation at 13 000 rpm on a bench centrifuge for 5min, the suspension was stored
at -20°C.
PCR for the identification ofthe B. cepacia complex
PCR for the identification of rhizosphere isolates was carried out using template DNA
extracted by alkaline lysis. All PCR reagents were purchased from Qiagen Inc. Canada.
All amplifications were carried out in a 25pi volume containing 5pi Qiagen solution Q,
1 U Taq DNA polymerase, 2pl template DNA, 15pl of each primer and 250pM of each
deoxynucleoside triphosphate. The reactions were performed on a DNA thermal cycler.
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Analysis ofthel6S rDNA genes
Primer pairs UNI2 and UNI5 (universal 16S rDNA primers) (Mahenthiralingam,
Bischof, et al, 2000), were used to amplify a 1020bp fragment. The PCR reaction was
initiated with denaturation at 94°C for 2 min, followed by 30 cycles each consisting of
30s at 94°C for denaturation, 45s at 60°C for annealing and 60s at 72°C for
polymerisation. This was followed by a final polymerisation step at 72°C for 10 min. In
order to produce discriminatory restriction fragment length polymorphisms (RFLPs) the
PCR product was restricted with Ddel (New England Biolabs) as indicated by the
manufacturer. The product was separated on a 2% agarose gel in 1 x TBE at 70V.
Analysis ofrecA
Genomovar-specific recA primers (Mahenthiralingam, Bischof, et al, 2000), were used
for the identification of the B. cepacia genomovars I and III.
BCRG11 and BCRG12 (B. cepacia genomovar I) (Mahenthiralingam, Bischof, et al,
2000) were used to amplify a 492bp product. Amplification conditions were the same as
those for 16S rDNA, with annealing being carried out at 62°C.
BCRG3A1 and BCRG3A2 (B. cepacia genomovar III-A), BCRG3B1 and BCRGB2 (.B.
cepacia genomovar III-B) (Mahenthiralingam, Bischof, et al, 2000) were used to
amplify 378 and 781 bp products respectively. Amplification conditions were the same
as those for 16S rDNA, with annealing at 62°C.
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2.2.28. Amplification of epidemic strain markers
Two markers of epidemic B. cepacia strains, cblA (Sun, Jiang, et al, 1995) and BCESM
( Mahenthiralingam, Simpson, et al, 1997) were amplified using previously reported
primers and cycling conditions.
121
CHAPTER 3
The Burkholderia cepacia complex
Pseudomonas cepacia was originally described at the agent of 'soft rot', a bacterial rot
that occurs in damaged onion bulbs (Burkholder, 1950). Advances in taxonomy led to
the creation of the genus Burkholderia in 1992, with Burkholderia (Pseudomonas)
cepacia as the type strain (Yabuuchi, Kosako, et al, 1992). More recent taxonomic
studies involving integrated genotypic and phenotypic analysis of a large collection of
Burkholderia strains revealed that B. cepacia is not a single species but rather, consists
of at least seven distinct genomic species, called genomovars a term introduced to
denote phenotypically similar but genotypically distinct groups of strains (Ursing,
Rossello-Mora, et al, 1995). Initially there were no distinguishing phenotypic
characteristics between the Burkholderia genomovars but phenotypic characteristics
peculiar to genomovars II, IV and V were subsequently identified. This led to these
groups being renamed B. multivorans, B. stabilis and B. vietnamiensis, respectively
(Vandamme, Holmes, et al, 1997). The remaining B. cepacia genomovars, together
with the renamed species, now constitute the B. cepacia complex. In recent years, this
group of organisms has gained considerable interest as opportunistic pathogens,
biopesticides and bioremediation agents.
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3.1. Colonial morphology and pigmentation
The colonial morphotypes ofmembers of the B. cepacia complex vary considerably in
size and shape but the majority are circular with smooth edges and range from less than
1mm to 4mm in diameter. Although most strains are non-pigmented, and do not
produce exopolysaccharide on CAB, a variety of pigments are produced across the
B. cepacia complex, as depicted in Fig 3.1. C1963, a CF isolate, is the only strain
studied in this thesis that produces exopolysaccharide on CAB. However, some strains
are able to produce exopolysaccharide when cultured on the richer S medium (Richau,
Leitao, et al, 2000) and incubated for longer periods (see section 3.2). A few strains,
such as the well-characterised epidemic genomovar III strain J2315, have a dry colonial
appearance and produce a brown melanin-like pigment when grown on CAB at 37°C. A
few strains produce a yellow pigment and the environmental B. cepacia genomovar I
strain J2535, was found to produce a red/magenta pigment when grown in CAB at 30°C.
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Fig 3.1 .a. B. cepacia J2315 showing moderate production ofbrown melanin-like
pigment and dry colonies when grown on CAB at 37°C for 24 h.
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Fig 3.1 .b. B. cepacia CI963 and J2535 (both genomovar I) showing mucoidy and red
pigmentation, respectively when grown on CAB at 30°C for 24 h.
125
Fig. 3.I.e. B. cepacia ATCC 25416 (genomovar I) and strain AMMD
(.B. vietnamiensis) illustrating yellow pigmentation and non-pigmentation respectively
after growth on CAB at 37°C for 24 h.
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3.2. Exopolysaccharide production in the B. cepacia complex
In this thesis most B. cepacia strains did not produce exopolysaccaride after growth on
CAB. However, when the same strains were grown on S medium (Richau, Leitao, et al,
2000), more strains were found to produce exopolysaccharide. The strains studied
consisted of three B. cepacia genomovar I, 13 B. multivorans, 26 B. cepacia genomovar
III, 12 B. vietnamiensis\ with 29 of the strains isolated from clinical specimens and 25
from the environment. Fig 3.2 illustrates the production of exopolysaccharide by
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Gen I, B. cepacia genomovar I; Bm, B. multivorans', Gen III, B. cepacia genomovar III; Bv, B.
vietnamiensis', Clin, clinical strains; Env, environmental strains.
Fig. 3.2. Distribution of exopolysaccharide production on S medium by clinical and
environmental isolates of the B. cepacia complex
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3.3. Phenotypic and genotypic typing of B. cepacia complex isolates
3.3.1. Bacteriocin typing
Bacteriocin typing was used to investigate the heterogeneity of isolates belonging to the
B. cepacia complex. The technique employed was previously described by Govan and
Harris (1985). The distribution of cepaciacin types found in a collection of 45 clinical
and environmental strains of the B. cepacia complex is shown in Table 3.1.
Table 3.1. Distribution of cepaciacin types of 45 clinical and environmental strains of
the B. cepacia complex.
Cepaciacin
type











3.3.2. Pulsed-field gel electrophoresis (PFGE)
The phenotypic heterogeneity in bacteriocin production and sensitivity demonstrated by
bacteriocin typing was confirmed when genotypic fingerprinting of the same collection
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of B. cepacia complex isolates was performed by PFGE. Taken together, the results
of bacteriocin typing and PFGE confirmed that the B. cepacia isolates included in
this study were distinct strains i.e. non-clonal
8 9
Fig 3.3.a) PFGE profiles of environmental and clinical isolates of the B. cepacia
complex. Lanes 1 to 10, J1705, CI704, ATCC 53266, ATCC 53267, ATCC 29424,
C2972, C2973, C2974, C2975, C2976, respectively
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Fig 3.3.b) PFGE profiles of environmental and clinical isolates of the B. cepacia
complex. Lanes 1 to 10, CI052, CI572, CI652, CI857, C1911, C2775, 715j, ATCC
17616, J2502, AMMD, respectively.
Fig 3.3.c) PFGE profiles of environmental and clinical isolates of the B. cepacia
complex. Lanes 1 to 10, C517, CI335, C1511, CI524, CI670, CI773, C2349,
C2374, J1697, C3041, respectively.
130
Fig 3.3.d) PFGE profiles of environmental and clinical isolates of the B. cepacia




3.4.1. Colonial morphology and pigmentation
Diversity between and within the genomovars is one of the distinguishing features of the
B. cepacia complex. In this study, differences in colony morphology and pigment
production were observed between strains in the same genomovar. Although strains
ATCC 25416, CI963 and J2535, all belong to B. cepacia genomovar I they have distinct
appearances on CAB medium. Strain CI963 is non-pigmented and mucoid on CAB
medium whereas strain ATCC 25416 produces a yellow pigment, and J2535 produces a
red/margenta pigment on CAB. Very few isolates were found to produce a mucoid
colonial phenotype. Mucoidy of strain CI 963 on CAB medium was found to be
temperature dependent, with copious amounts of exopolysaccharide produced at 30°C
and very little, if any, at 37°C.
The optimum growth temperature of the B. cepacia complex isolates examined was
found to be 30-37°C with a maximum of 41°C and most strains grew well at 37°C.
However, strain J2535 was found to be non-culturable when a frozen sample was
thawed and incubated at 37°C. This critical dependence on temperature, although not
common, could lead to failure to culture from frozen stocks of other members of the
B. cepacia complex. Interestingly, a similar phenomenon has been found in some
B. cepacia strains when stocks are incubated at 37°C after storage at 4°C (Pitt and
Govan 1993).
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3.4.2. Production of exopolyssacharide by the B. cepacia complex
The role of exopolysaccharide production in increasing the pathogenicity of invading
organisms has been reviewed by (Costeron, Cheng, et al. 1987). These authours suggest
that the exopolysaccharide allows bacteria to survive, grow and the colonies to persist
within a protective matrix which acts as a barrier to reduce the penetration of antibiotics
and protects the bacteria from the host's defence mechanisms, in particular, engulfment
by phagocytes. The role ofmucoidy is strikingly demonstrated in the case of
P. aeruginosa infection of CF lungs. The P. aeruginosa strains infecting CF patients are
non-mucoid and with persistence, become highly mucoid due to the production of the
exopolysaccharide, alginate (Koch and Hoiby, 1993). In the patients, this transformation
to a mucoid colonial morphotype coincides with chronic infection and the inability to
eradicate the pathogen by antibiotic therapy (Govan and Deretic, 1996).
Mucoid B. cepacia isolates are considered to be extremely rare in both environmental
and clinical isolates (Govan and Deretic, 1996). However, in this study, when cultured
on S medium, the majority strains (75%) of the B. cepacia complex produced
exopolysaccharide compared to only one isolate when the strains were cultured on CAB.
Similar results with S medium have recently been reported, (Richau, Leitao, et al, 2000).
In this study, Richau and colleagues found that 70% of the isolates cultured on S
medium produced exopolysaccharide. Interestingly, mucoidy on S medium requires
incubation at 30°C, the same temperature at which the B. cepacia genomovar I strain
CI963 is mucoid on CAB. Maximal exopolysaccharide production in B. cepacia has
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been reported to occur in media containing 2% (w/v) glucose and 0.4 M NaCl and
grown at 35°C (Allison and Glodsbrough, 1994). Thus, exopolysaccharide production
by B. cepacia depends not only on the composition of the growth medium but also on
the incubation temperature.
Unlike the case ofmucoid P. aeruginosa, the exopolysaccharide produced by the B.
cepacia complex is not alginate but a heteropolysaccharide composed of glucose,
mannose, rhamnose, glucuronic acid and galactose (Allison and Glodsbrough, 1994).
However, this polysaccharide, like alginate, restricts the diffusion of different antibiotics
and can interact with host and other bacterial polymers to form a heterodisperse
polysaccharide gel (Allison, 1992).
In this study, B. cepacia genomovar I was the only genomovar examined with a greater
proportion of non-mucoid (67%) to mucoid strains (33%). However, the relatively small
number of strains examined in this genomovar could influence these proportions.
Interestingly, a much larger proportion of environmental isolates (90%) were mucoid
compared to clinical isolates (59%). This result would appear to contrast with the
predomonance ofmucoid P. aeruginosa in clinical isolates from CF patients. It should
be noted, however, that the experimental conditions used did not mimic conditions in the
CF lung. The correlation between production of exopolysaccharide and medium
osmolarity (Allison and Glodsbrough, 1994) is comparable to the high concentrations of
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Na+ and CI" ions in the CF lung. Presently, it is not known whether B. cepacia
exopolysaccharide assists in the organisms' proliferation and persistence in the lung.
3.4.3. Phenotypic and genotypic typing of B. cepacia complex isolates
The use of bacteriocin typing to characterise members of the B. cepacia complex was
found to be restricted; 22% of the isolates investigated could not be classified. Of the
typable isolates, 24% belonged to the same cepaciacin type S22/P0, this type also
included strains from different genomovars and those of clinical as well as
environmental origin. PFGE proved to be a more discriminating technique than
bacteriocin typing. PFGE revealed distinct profiles for each of the forty-five isolates
and confirmed a lack of clonality between isolates included in this study. A minor
caveat is that PFGE profiles for the strains J2552 and J2891 could not be generated
despite the use of different methods and various restriction enzymes. This phenomenon
has been encountered in a minority ofB. cepacia strains and is thought to be due to the
production of DNAses by these organisms (Dr. C. J. Doherty, personal communication).
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CHAPTER 4
Resistance of the B. cepacia complex to antibiotics
4.1. Antibiotic susceptibility of the B. cepacia complex
The sensitivity of the B. cepacia complex to various antibiotics was determined by the
agar dilution method following standard guidelines (British Society for Antimicrobial
Chemotherapy, 1991). P. aeruginosa NTCC 10662 was used as the reference strain;
there is currently no antibiotic sensitivity reference strain for the B. cepacia complex.
Although inherent resistance to multiple antibiotics is often reported to be one of the
typical characteristics of the B. cepacia complex, the data summarised in Tables 4.1 and
4.2 shows that resistance is not uniform across the group. In this study, clinical strains
tended to be more resistant to antibiotics, probably because of previous exposures to the
same antimicrobial drugs. Surprisingly, the inhibitory effect of chloramphenicol was
dependent on genomovar status; for example, B. vietnamiensis strains were more
sensitive to ceftazidime and chloramphenicol than strains from other genomovars,
regardless of their source. Ciprofloxacin was found to be the most effective inhibitory
agent and all strains examined were resistant to polymyxin and tetracycline
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Table 4.1a MICs (mg/L) of different antibiotics against B. cepacia genomovar I and
B. multivorans (genomovar II)
Strain Genv Ceft Chlo Cipr Tob Pol Tet Tri
ATCC17759 I 4 8 0.12 32 >128 64 4
ATCC25416 I 4 16 4 64 >128 64 2
LMG17997 I 2 8 2 16 >128 64 2
CEP 509 I 8 16 4 128 >128 >128 4
CI 963 I 2 16 1 64 >128 >128 64
J2535 I 1 8 1 16 >128 64 4
J2540 I 0.12 4 0.25 8 >128 >128 0.5
J2552 I 2 16 1 16 >128 2 0.5
ATCC17616 II 4 8 0.5 32 >128 8 2
LMG13010 II 2 32 2 16 >128 8 2
CF-A1-1 II 4 16 4 64 >128 16 4
CI 962 II 0.5 8 2 128 >128 8 2
C5393 II 8 128 4 32 >128 16 32
C1576 II >128 32 8 >128 >128 16 4
C1572 II 8 32 4 >128 >128 64 4
C1857 II 0.5 16 2 >128 >128 16 2
C1911 II 2 16 2 64 >128 8 2
C2775 II 8 16 16 16 >128 16 2
C1632 II 8 32 2 >128 >128 128 8
JTC II 4 16 2 64 >128 4 2
249-2 II 2 8 0.12 16 >128 2 0.5
Breakpoint 2 8 4 1 4 1 2
NTCC 10662 1 128 0.12 1 1 16 32
Genv, genomovar; Ceft, ceftazidime; Chlo, chloramphenicol; Cipr, ciprofloxacin;
Tob, tobramycin; Pol, polymyxin; Tet, tetracycline; Tri, trimethoprim.
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Table 4.1b MICs (mg/L) of different antibiotics against clinical and environmental
strains ofB. cepacia genomovar III
Strain Genv Ceft Chlo Cipr Tob Pol Tet Tri
ATCC17765 III 4 16 2 64 >128 32 2
BC7 III 2 16 0.12 8 >128 128 0.25
CEP 511 III 2 16 32 128 >128 64 32
C1394 III 1 16 2 >128 >128 >128 64
C5424 III 2 8 0.12 8 >128 128 0.25
C6433 III 2 16 32 32 >128 >128 32
C517 III 0.5 64 2 32 >128 32 64
C1335 III 0.5 64 2 128 >128 32 64
C1773 III 1 16 >128 128 >128 128 2
C2374 III 8 16 >128 64 >128 64 32
J2315 III 8 16 4 >128 >128 128 64
J415 III 4 64 2 64 >128 >128 4
K56-2 III 4 16 4 128 >128 32 32
PC 184 III 0.12 4 16 8 >128 64 0.5
R2817 III 2 4 0.25 4 >128 32 1
R2827 III 4 16 0.25 16 >128 64 16
R8351 III 1 8 0.25 8 >128 32 1
R8571 III 4 4 0.25 8 >128 64
R8574 III 4 8 0.25 16 >128 64 1
R8580 III 4 8 0.25 16 >128 64 1
R8605 III 4 16 0.25 16 >128 64 1
R9235 III 32 32 0.25 16 >128 64 16
R9239 III 2 8 0.25 8 >128 64 1
R9243 III 2 8 0.25 8 >128 64 4
R9235 III 2 8 0.25 16 >128 64 1
R9342 III 2 8 0.25 16 >128 128 2
Breakpoint 2 8 4 1 4 1 2
NTCC10662 1 128 0.12 1 1 16 32
Genv, genomovar; Ceft, ceftazidime; Chlo, chloramphenicol; Cipr, ciprofloxacin; Tob,
tobramycin; Pol, polymyxin; Tet, tetracycline; Tri, trimethoprim; 'R', environmental isolates.
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Table 4.1c MICs (mg/L) of different antibiotics against B. stabilis (genomovar IV) and
B. vietnamiensis (genomovar V)
Strain Gen Ceft Chi Cipr Tob Pol Tet Tri
C7322 IV 2 16 4 64 >128 >128 32
LMG18888 IV 2 16 0.12 8 >128 64 0.25
LMG14294 IV 8 4 64 8 >128 64 32
LMG14086 IV 8 16 0.12 8 >128 64 2
LMG10929 V 2 4 0.12 16 >128 2 32
LMG16232 V 2 8 1 16 >128 8 4
ATCC53266 V 1 8 0.5 32 >128 64 1
ATCC53277 V 2 8 1 16 >128 32 2
CI 704 V 1 8 1 32 >128 8 2
C2972 V 4 32 2 32 >128 16 8
C2973 V 0.5 8 0.5 1 >128 2 1
C2974 V 0.5 8 0.5 16 >128 4 2
C2975 V 1 8 0.5 16 >128 4 2
C2977 V 0.5 8 0.5 0.5 >128 1 2
C2979 V 2 8 1 32 >128 4 32
FC 441 V 2 8 0.12 16 >128 4 2
J1697 V 1 16 0.5 4 >128 4 1
J1705 V 0.5 8 0.5 2 >128 2 2
AMMD V 0.5 8 0.25 16 >128 64 0.5
PC 259 V 2 8 0.12 16 >128 8 32
Breakpoint - 2 8 4 1 4 1 2
NTCC10662 - 1 128 0.12 1 1 16 32
Gen, genomovar; Ceft, ceftazidime; Chlo, chloramphenicol; Cipr, ciprofloxacin;
Tob, tobramycin; Pol, polymyxin; Tet, tetracycline; Tri, trimethoprim.
139
Table 4.2.a. Susceptibility ofB. cepacia genomovar I and B. multivorans (genomovar II)
to different antibiotics
Strain Genv Ceft Chlo Cipr Tob Tet Tri
ATCC17759 I R S S R R R
ATCC25416 I R R S R R S
LMG17997 I S S s R R s
CEP 509 I R R s R R R
CI 963 I S R s R R R
J2535 I S S s R R R
J2540 I s S s R R S
J2552 I s R s R R S
ATCC17616 II R S s R R S
LMG13010 II s R s R R s
CF-A1-1 II R R s R R R
CI 962 II S S s R R S
C5393 II R R s R R R
C1576 II R R R R R R
C1572 II R R s R R R
C1857 II S R s R R S
C1911 II S R s R R s
C2775 II R R R R R s
C1632 II R R s R R R
JTC II R R s R R s
249-2 II S S s R R s
NTCC 10662 - S R s S R R
Genv, genomovar; Ceft, ceftazidime; Chlo, chloramphenicol; Cipr, ciprofloxacin;
Tob, tobramycin; Pol, polymyxin; Tet, tetracycline; Tri, trimethoprim; S, sensitive; R,
resistant.
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Table 4.2.b. Susceptibility of clinical and environmental strains ofB. cepacia
genomovar III to different antibiotics against
Strain Genv Ceft Chlo Cipr Tob Tet Tri
ATCC17765 III R R S R R S
BC7 III S R S R R S
CEP 511 III S R R R R R
CI 394 III s R S R R R
C5424 III s S s R R S
C6433 III s R R R R R
C517 III s R S R R R
C1335 III s R s R R R
C1773 III s R R R R S
C2374 III R R R R R R
J2315 III R R S R R R
J415 III R R s R R R
K56-2 III R R s R R R
PC 184 III S S R R R S
R2817 III S S s R R S
R2827 III R R s R R R
R8351 III S S s R R S
R8571 III R S s R R R
R8574 III R S s R R S
R8580 III R s s R R S
R8605 III R R s R R s
R9235 III R R s R R R
R9239 III S S s R R s
R9243 III S s s R R R
R9335 III s s s R R S
R9342 III s s s R R s
NTCC10662 - s R s S R R
Genv, genomovar; Ceft, ceftazidime; Chlo, chloramphenicol; Cipr, ciprofloxacin;
Tob, tobramycin; Pol, polymyxin; Tet, tetracycline; Tri, trimethoprim; S, sensitive; R,
resistant.
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Table 4.2.c. Susceptibility of B. stabilis (genomovar IV) and
B. vietnamiensis (genomovar V) to different antibiotics
Strain Genv Ceft Chlo Cipr Tob Tet Tri
C7322 IV s R S R R R
LMG18888 IV s R s R R S
LMG14294 IV R S R R R R
LMG14086 IV R R S R R S
LMG10929 V S S s R R R
LMG16232 V s S s R R R
ATCC53266 V s s s R R S
ATCC53277 V s s s R R S
CI 704 V R s s R R S
C2972 V R R s R R R
C2973 V S s s S R S
C2974 V s s s R R S
C2975 V s s s R R s
C2976 V s s s R R s
C2977 V s s s S S s
C2979 V s s s R R R
FC 441 V s s s R R S
J1697 V s R s R R s
J1705 V s s s R R s
AMMD V s s s R R s
PC 259 V s s s R R R
NTCC10662 - s R s S R R
Genv, genomovar; Ceft, ceftazidime; Chlo, chloramphenicol; Cipr, ciprofloxacin;
Tob, tobramycin; Pol, polymyxin; Tet, tetracycline; Tri, trimethoprim; S, sensitive; R,
resistant.
4.2. Effect of carbon dioxide on the susceptibility of the B. cepacia complex to
different antibiotics
Alteration of growth conditions, particularly incubation in a microaerophilic atmosphere
has been reported to alter bacterial sensitivities to antibiotics. The MICs of antibiotics
for representative study strains were determined by the agar dilution method in the
presence of air and 5% CO2 and the results are shown on Table 4.3. In this study,
incubation in 5% CO2 was found to have no effect to B. cepacia's sensitivity to selected
antibiotics.
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C1963 2 2 8 8 1 2 64 64 16 16
J2535 1 1 1 1 1 1 4 2 8 16
J2552 2 4 2 4 1 2 0.5 1 16 16
C1572 8 16 64 >128 4 8 4 4 32 8
C1576 >128 >128 128 >128 8 8 4 4 32 32
C1857 0.5 1 8 16 2 4 2 2 16 16
C1911 2 1 2 8 2 2 2 2 16 8
C2775 8 8 8 8 16 8 2 4 4 4
J2395 2 2 8 16 8 2 4 4 8 16
C517 0.5 0.5 8 8 2 8 64 64 64 64
C1335 0.5 1 8 8 2 8 64 64 64 64
CI 394 1 1 8 8 2 4 64 64 16 16
C1773 1 4 16 8 >128 >128 2 4 16 16
C2374 8 8 >128 >128 >128 >128 32 64 16 8
J2315 4 8 128 >128 4 8 32 64 16 16
CI 704 1 1 16 16 1 2 2 4 8 8
J1697 1 1 2 2 0.5 0.5 1 4 16 16
J1705 0.5 1 1 2 0.5 1 2 4 8 8
J2742 0.5 1 2 2 0.25 1 0.5 1 8 8
NCTC
10662
1 1 2 2 0.12 1 32 64 128 128
Ceft, ceftazidime; Cefp, cefpirome; Cipr, ciprofloxacin; Tri, trimethoprim;
Chlo, chloramphenicol.
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4.3. Antibiotic-resistant mutants of the B. cepacia complex
One of the major difficulties in managing B. cepacia infections is that once effective
antibiotics have been identified, further antibiotic resistance often develops during
therapy. A series of experiments were performed to determine the rate of acquisition of
resistance to different antibiotics. B. cepacia complex strains repeatedly cultured in
increasing amounts of ceftazidime, ciprofloxacin and chloramphenicol, were considered
to be antibiotic-resistant mutants if the MIC increased at least six-fold. Using this
method, resistant mutants were selected against ceftazidime and ciprofloxacin but not
against chloramphenicol. A total of four B. cepacia genomovar I, nine B. multivorans
(genomovar II), seven B. cepacia genomovar III and 14 B. vietnamiensis (genomovar V)
were tested.
Table 4.4. Selection of antibiotic resistant mutants of the B. cepacia complex
Genomovar % mutants selected against
ceftazidime ciprofloxacin chloramphenicol
I 50 75 0
II 56 44 0
III 29 0 0
V 36 86 0
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4.3.1. Antibiotic susceptibility of antibiotic-resistant mutants
B. cepacia strains that develop further resistance during therapy may show cross-
resistance between classes of unrelated antimicrobial compounds. In order to determine
the degree of cross-resistance to different classes of antibiotics the sensitivity of
ceftazidime-resistant mutants, obtained in the previous section, to ampicillin, cefpirome,
ciproflaxacin and chloramphenicol was determined using the agar dilution method. The
sensitivity of ciproflocaxin-resistant mutants to ofloxacin, grepafloxacin, ceftazidime
and chloramphenicol was also determined. Table 4.5 shows that the ceftazidime-
resistant mutants only showed resistance to other p-lactam antibiotics and not to
unrelated antibiotics.
Table 4.5. Antibiotic susceptibility (MICs, mg/L) of ceftazidime-resistant mutants
Strain Ceft Amp Cefp Cipr Chlo
ATCC 29424 1 4 1 0.5 8
ATCC 29424b 8 128 1 0.25 8
ATCC 53266 1 64 4 0.25 8
ATCC 53266b 16 128 64 0.25 8
ATCC53267 2 8 1 0.5 8
ATCC53267b 16 16 8 0.5 4
C2973 0.5 16 4 0.25 16
C2973b 8 0.12 0.5 0.25 8
C517 0.5 16 4 2 64
C517b 3 32 8 2 64
C1911 2 64 2 2 16
C191lb 16 128 16 1 16
J2540 0.12 0.5 2 0.25 4
J2540b 6 16 8 0.25 4
J2742 0.5 16 0.5 0.12 8
J2742b 8 128 64 0.12 8
'b', ceftazidime-resistant mutant; Ceft, ceftazidime; Amp, ampicillin;
Cefp, cefpirome; Cipr, ciprofloxacin,; Chlo, chloramphenicol.
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Table 4.6 shows that, like the ceftazidime-resistant mutants, the ciprofloxacin-resistant
mutants in this study had additional resistance to other quinolones and not to unrelated
classes of antimicrobial agents.
Table 4.6. Antibiotic susceptibility (MICs, mg/L) of ciprofloxacin-resistant mutants
Strain Cipr Oflo Ceft Grep Chlo
CEP509 4 16 8 4 32
CEP509c 32 32 16 16 128
ATCC 17616 0.5 2 4 1 32
ATCC 17616c 8 128 8 64 64
LMG 18888 0.12 8 2 4 32
LMG 18888c 2 64 4 8 32
LMG 14086 0.12 2 8 0.5 32
LMG 14086c 8 16 8 1 32
PC 259 0.12 8 2 8 64
PC 259c 8 16 2 16 64
C2973 0.5 16 0.5 4 64
C2973c 16 16 1 16 128
J1705 0.5 32 0.5 2 8
J1705c 8 64 1 2 8
J2742 0.25 4 0.5 1 8
J2742c 2 8 0.5 2 16
'c', ciprofloxacin-resistant mutant; Cipr, ciprofloxacin; Oflo, ofloxacin,;
Ceft, ceftazidime; Grep, grepafloxacin; Chlo, chloramphenicol.
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4.4. Discussion
4.4.1. Antibiotic susceptibility of the B. cepacia complex
Inherent resistance to different classes of antibiotics is one of the characteristics of the B.
cepacia complex. In this study, the antibiotics used for susceptibility- testing were
chosen to represent the major classes of antibiotics, as well as agents that are routinely
used for the treatment of infections caused by pseudomonads. Polymyxins are cationic
polypeptides and although five classes have been identified, polymyxins A, B, C, D and
E only polymyxin B and E are available for clinical use; polymyxins A,C, and D are
considered too toxic for human use. Polymyxin E is commonly called colistin and has a
similar antibacterial spectrum to polymyxin B. In general, the polymyxins are active
against Gram-negative bacteria such as P. aeruginosa and H. influenzae, but have little
or no activity against Gram-positive organisms. The mode of action ofpolymyxins is
bactericidal through interference with the structure and function of their outer
cytoplasmic membranes.
Although colomycin (colistin) is effectively used for the treatment of P. aeruginosa and
other Gram-negative bacilli infections (Littewood, Koch, et al, 2000), Table 4.1 shows
that all study strains belonging to the B. cepacia complex are resistant to polymyxin B.
(Preliminary tests indicated that similar sensitivities were obtained for both colistin and
polymyxin B, hence the latter was subsequently used in this study). These results are
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similar to those obtained by Fass and Barnishan (1980), who found all the B. cepacia
strains to have colistin MICs of greater than 64 mg/L. It should be noted, however, that
the 1980 study could not take account of the genomovar status of the B. cepacia strains
examined. Resistance to polymyxin appears to be inherent in all members of the B.
cepacia complex and accounts for its value as the selective agent in Burkholderia
cepacia medium, including the highly effective medium produced by Mast Diagnostics
which 300u/ml ofpolymyxin B.
Tobramycin is an aminoglycoside, a group of basic compounds containing amino sugars
and an amino cyclitol structure. Tobramycin is one of the first-line antibiotics used in
the treatment ofP. aeruginosa infections as well as infections caused by other
Gram-negative bacilli. Like other aminoglycosides, tobramycin acts by suppressing
bacterial growth through the inhibition of protein synthesis. Aminoglycosides bind to
the 30S subunit of bacterial ribosomes leading to misreading ofmRNA codons as well
as detachment of ribosomes from the mRNA. Out of the 68 strains tested in this study,
only 2 (3%) were sensitive to tobramycin. Interestingly, both of the sensitive strains
were B. vietnamiensis. The remaining 66 strains were resistant to tobramycin although
the level of resistance was varied and generally less than that exhibited towards
polymyxin. For the study strains, tobramycin MICs ranged from 0.5->128 mg/L and 38
(56%) had MICs of less than 32 mg/L. This wide range ofMICs is similar to that
obtained by Rajyaguru and Muszynski (1997), namely, 0.06->32 mg/L. However, this
data differs slightly from previously described results (Fass and Barnishan, 1980) in
which a MIC range of 32 ->64 mg/L, when only 10 strains were examined.
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Cationic antibiotics such as polymyxins and aminoglycosides are absorbed by
Gram-negative bacteria through a self-promoted uptake that disrupts the organism's
outer membrane structure (Rajyaguru and Muszynski, 1997). Cationic antibiotics bind
to anionic sites at the bacterial surface and alter the permeability of the outer membrane.
It has been shown that members of the B. cepacia complex are inherently resistant to
polymyxins and aminoglycosides in part because these compounds can not permeabilize
the organisms' outer membranes (Moore and Hancock, 1986). It has also been
suggested that the inability of cationic antibiotics to permeabilise the B. cepacia
complex outer membrane is due to the bacteria having an LPS composition, structure or
function that is different from that of other Gram-negative organisms (Rajyaguru and
Muszynski, 1997). Evidence for this hypothesis includes the fact that the B. cepacia
complex contains much lower levels of anions, such as phosphates, compared to other
Gram-negative bacteria (Cox and Wilkinson, 1991). Lower level of anions would lead
to a lowered affinity of the LPS for cationic antibiotics.
Since first isolated in 1944, several tetracycline compounds have been identified. All
tetracyclines have a similar molecular structure, consisting of four benzene rings and
also exhibit a similar spectrum of antibacterial activity. Tetracyclines are active against
most Gram-positive bacteria and some Gram-negatives; the latter includes H. influenzae
and Bordetella pertussis. Tetracyclines are another group of antibiotics that inhibit
bacterial protein synthesis though binding to the 30S ribosomal. The use of tetracyclines
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in clinical practice has gradually decreased owing to the prevalence of resistance and the
development ofmore effective alternative antibiotics. In this study, all but one of the B.
cepacia complex strains showed resistance to tetracycline; the exception was C2977, a
B. vietnamiensis strain that was also sensitive to all the antibiotics except polymyxin B.
In the case of tetracycline, a wide range ofMICs, 1-128 mg/L, covering both
susceptibility and resistance to the antibiotic was observed. This data differs from
previously reported results in which all the B. cepacia strains were resistant to
tetracyline, with MIC ranges of 8->64 mg/L (Fass and Barnishan, 1980) and 16-512
mg/L (Pitt, Kaufmann, et al, 1996). It should be noted, however, that the MIC range
obtained in this study, which includes sensitivity to tetracycline, is due to a single
sensitive strain.
Similar to the aminoglycosides and polymyxins, tetracyclines have a relatively small
molecular weight and are hydrophilic and cationic. In the case of the B. cepacia
complex, resistance to tetracycline could be partly due to the inability of the antibiotic to
insert into and permeabilise the bacterial outer membrane. Plasmid-encoded resistance
to tetracycline is also widespread.
Chloramphenicol was the first broad spectrum antibiotic to be discovered and is also a
potent inhibitor ofbacterial protein synthesis. In this study, the MICs of the strains
studied ranged from 4-64 mg/L and 50% of the strains were resistant to
chloramphenicol. Interestingly, in the early 80s, chloramphenicol was reported to be
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one of the few antibiotics exhibiting activity against'B. cepacia' (Isles, Maclusky, et al,
1984). In recent years its use has declined. Resistance to chloramphenicol is frequently
due to the production of the enzyme chloramphenicol acetyltransferase (CAT) that
acetylates and inactivates the drug. In B. cepacia complex decreased permeability is
thought to be the mechanism of resistance as no production ofCAT or ribosomal
resistance was detected in a high level resistance strain (Burns, Hedin, et al, 1989). This
mechanism of resistance has been described in other Gram-negative bacteria.
Trimethoprim interrupts bacterial purine synthesis by interfering with the enzyme
dihydrofolic acid reductase (DHFR), an essential enzyme in DNA synthesis. Since
trimethoprim acts on the same metabolic pathway as sulphonamides, combination of
these two drugs as trimethoprim-sulfamethoxazole results in synergy. Trimethoprim
MICs observed in this study ranged from 0.25-64 mg/L and thus the B. cepacia strains
tested in this study were more sensitive than those studied by Pitt and co-workers
(1996), who recorded a MIC range of 2-512 mg/L. Historically, trimethoprim-
sulfamethoxazole and chloramphenicol were considered to be the most effective
antibiotics for the treatment ofB. cepacia infections (Isles, Maclusky, et al, 1984) even
though they have rather limited antimicrobial activity. Newer, more effective antibiotics
have now surpassed them both.
Ciprofloxacin is a quinolone and like other quinolones inhibits bacterial DNA synthesis
by targeting bacterial topoisomerases or gyrases. The target for ciprofloxacin is the A
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subunit ofDNA gyrase. In this study, most strains tested (88%) were sensitive to
ciprofloxacin although the range ofMICs observed, 0.12-64 mg/L, was very wide. This
wide MIC range is similar to previously reported results (Lewin, Doherty, et al, 1993),
who reported a range of < 0.06-128mg/L.
Ceftazidime is a third generation cephalosporin and inhibits bacterial cell growth.
Although the majority of strains tested in this study (62%) were sensitive to ceftazidime,
the proportion was much less than that observed for ciprofloxacin. Ceftazidime is
currently very effective in treating B. cepacia infections (Blumer, Stern, et al, 1985, Lu,
Chang, et al, 1997), despite resistance to p-lactams being common and well
documented. In most bacterial pathogens, increased resistance to P- lactams occurs
through decreased permeability or the production of |3-lactamases. It has been reported
that B. cepacia complex strains produce a unique and highly inducible p- lactamase,
PenA, an enzyme that is associated with a metabolic pathway enabling some B. cepacia
to use penicillin G as a sole source of carbon and energy (Beckman and Lessie 1979,
Prince, Wood et. al, 1988). To my knowledge, no other bacterial pathogens have been
shown to have the ability to metabolise an antibiotic in this way.
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4.4.2. Antibiotic susceptibility of different genomovars within the B. cepacia
complex
In this study, all B. cepacia complex strains were shown to be resistant to polymyxin B;
in contrast, sensitivity of all the strains studied to a single antibiotic was not detected.
\
Interestingly, susceptibility of a collection of recently identified environmental isolates
ofB. cepacia genomovar III to ceftazidime and trimethoprim did not differ significantly
to that of the clinical strains belonging to genomovar III. However, the environmental
isolates of genomovar III proved to be more sensitive to ciprofloxacin and
chloramphenicol than the clinial strains, X2=5.3, DF=1, 0.05 >p > 0.02 and A"2=9.8,
DF=1, 0.01> p > 0.001, respectively. To date, B. cepacia genomovar III strains have
been isolated most frequently from CF patients and, in some cases, are associated with a
rapid decline and a fulminant, necrotising pneumonia that is often referred to as the
'cepacia syndrome'. The similarity in susceptibility of clinical and environmental
isolates of genomovar III to trimethoprim, a previously routinely used antibiotic, and
ceftazidime that is currently one of the few antibiotics effective against the B. cepacia
complex is remarkable. Clinical isolates are typically thought to be more resistant to
antibiotics used in clinical practice than environmental isolates because ofprevious
exposures to the drugs.
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Susceptibility ofB. cepacia complex strains to choramphenicol was also dependent on
the genomovar status, X2=15.3, DF=4, 0.01>p>0.001 and the 17 B. vietnamiensis strains
tested were found to be more sensitive to chloramphenicol than strains belonging to
other genomovars, X2=14.8, DF=1, p < 0.001. The increased susceptibility of
B. vietnamiensis strains to chloramphenicol might be explained by a subtle difference in
binding of chloramphenicol to the 70S ribosomes of this genomovar. This could be due
to differences in the binding sites or other factors associated with the binding of the
antibiotic. The amino acid sequences of target sites of representative strains from the
different genomovars would have to be compared to ascertain this. Interestingly,
B. vietnamiensis strains, ofboth clinical and environmental origin, were also more
sensitive to ceftazidime than strains from genomovars I-IV, X2=6.13, DF=1,
0.01>p>0.001.
4.4.3. Effect of carbon dioxide on antibiotic sensitivity
The MICs of representative B. cepacia strains in air and carbon dioxide were determined
for the B-lactams ceftazidime and cefpirome. In addition, trimethoprim, ciprofloxacin
and chloramphenicol were also tested. Increased resistance to B-lactams in carbon
dioxide, when observed, was not more than a two-fold increase in MIC and much less
than indicated previously (Corkill, Deveney, et al, 1994). Similarly, this study found
that incubation ofB. cepacia strains in 5% CO2 had no effect on their susceptibilities to
trimethoprim, ciprofloxacin or chloramphenicol. In the present study, the increases in
MIC in the presence of carbon dioxide were erratic and not related to the genomovar
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status or clinical or environmental source. Corkill et al (1994) reported that inhibition of
B. cepacia by B-lactam antibiotics decreased in an atmosphere of air with 5% CO2
compared to air alone, and this reduced susceptibility was attributed to increased
expression of B-lactamase activity in a CO2 -enriched atmosphere.
In the present study, carbon dioxide was found to have no effect on the susceptibility of
P. aeruginosa to B-lactams, confirming previous observations (Corkill, Deveney, et al,
1994). However, incubation in 5% CO2 led to an eight-fold increase in P. aeruginosa's
MIC in ciprofloxacin; this antibiotic was not tested by Corkill and co-workers. The
decreased susceptibility ofP. aeruginosa to ciprofloxacin after incubation in carbon
dioxide contrasts with Traub and Leonhard (1995) who found,with the exception of
aminoglycosides, no appreciable alteration ofMICs ofmost antimicrobial drugs for
different bacterial pathogens, including P. aeruginosa, after incubation in 3% and 5%
C02.
4.4.4. Sensitivities of the antibiotic-resistant mutants
B. cepacia complex strains are inherently resistant to different classes of antibiotics. In
addition, once effective antibiotics have been identified, further antibiotic resistance
often develops during therapy. Ideally, biopesticide strains should be sensitive to the
antibiotics used in clinical practice and not have the potential for becoming resistant.
B. vietnamiensis strains are favoured for biopesticide use because of their low incidence
of isolation from CF patients. This study found B. vietnamiensis strains more sensitive to
ceftazidime and chloramphenicol than strains from other genomovars. Sensitivity to
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antibiotics used in clinical practice would seem to imply that B. vietnamiensis strains are
safe for large-scale commercial application since if acquired by CF patients, they could
be eradicated by antibiotic treatment. Strains that are naturally sensitive to antibiotics
could acquire resistance by mutation or horizontal transfer of resistance genes. This
study was carried out to determine the incidence ofmutation conferring resistance to
antibiotics in the B. cepacia complex.
Ceftazidime and ciprofloxacin resistant mutants were generated in strains from
B. cepacia genomovar I, B. mulivorans, B. cepacia genomova III and B. vietnamiensis.
Mutants were detected from frequencies of 10"6 to as low as 10"10. Similar quinolone
7 Q
and (3-lactam resistant mutational frequencies of 10" to 10" were reported previously
(Sanders, Sanders, et al, 1984). Interestingly, in contrast to other antibiotics, no
chloramphenicol-resistant mutants (i.e. with a six-fold increase in MIC) were generated.
B. vietnamiensis isolates showed the greatest increases ofMICs for ceftazidime and
ciprofloxacin. Thus, although B. vietnamiensis strains were shown to be more sensitive
to ceftazidime than strains from the other genomovars, they also showed the greatest
potential for mutations to high resistance. If acquired by CF patients and other
immuno-compromised individuals, therefore, B. vietnamiensis infections could be
difficult to eradicate owing to the organisms' mutations to high resistance to the
antibiotics used in clinical practice.
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Some of the ceftazidime-resistant mutants had increased MIC for the other 13-lactam
antibiotics, cefpirome and ampicillin, but no corresponding increases were observed for
ciprofloxacin and chloramphenicol. Similarly, the ciprofloxacin resistant mutants also
had increased resistance to other quinolones ofloxacin and grepafloxacin but no
increased resistance to chloramphenicol or ceftazidime. Hence, it appeared that the
resistance generated in B. cepacia only affected antibiotics belonging to the same class,
possibly implying that the antibiotics binding sites were altered rather than porin-
associated decreased permeability, which would have resulted in cross-resistance
involving unrelated antibiotics.
The use of antibiotics is often linked to the selection of resistant mutants since the
antibiotics increase the frequency of genetic variation, resulting in resistance. Strong
mutator genes promote genetic diversity which is probably the driving force in the
evolution of antibiotic resistance under antibiotic pressure (Taddei, May, et al, 1997).
Pathogenic bacteria are associated with a high frequency of strains with enhanced rates
ofmutations, i.e. hypermutable strains (LeClerc, Li, et al, 1996). Isolates ofE. coli and
Salmonella enterica implicated in food-related outbreaks were found to contain a higher
incidence of hypermutable strains, compared to non-pathogenic strains (LeClerc, Li, et
al, 1996).
Recent studies suggest that the adaptation ofbacteria to a heterogeneous and changing
environment such as the CF lungs, that are progressively deteriorating, constantly
exposed to different antibiotics and the host's immunity, promotes the selection of
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hypermutable strains (Oliver, Canton, et al, 2000). P. aeruginosa strains isolated from
CF patients, unlike those obtained from patients with acute infections, have a high
frequency ofmutator strains (Oliver, Canton, et al, 2000). Interestingly, the same
authors found the high mutator P. aeruginosa strains to be at least twice as resistant to
several antibiotics as the non-mutator isolates. It is believed that the high proportion of
mutator P. aeruginosa isolates from CF patients suggests that rapid adaptation is
required by bacterial populations to survive in the lungs of these patients.
Thus, according to these recent theories, since the B. cepacia complex consists of
emerging pathogens, and in the CF lungs, they inhabit a heterogeneous, changing
environment, it is possible that this group of organisms contains a high incidence of
hypermutable strains. High mutator P. aeruginosa isolates from CF patients had
mutation frequencies of xl0~6 (Oliver, Canton, et al, 2000). In the present study, some
B. cepacia strains had resistant mutant frequencies to ceftazidime and ciprofloxacin of
xlO"6, which, according to Oliver and co-workers, indicates hypermutable strains.
This study provides preliminary data that, like the other major CF pathogen
P. aeruginosa, B. cepacia complex strains could have a high frequency of strains with
enhanced rates ofmutations. A more detailed study on B. cepacia's mutation rates
would have to be carried out to ascertain this. There is also a need to determine whether
or not B. cepacia's high resistance to several antibiotics is associated with
hypermutation, as in P. aeruginosa.
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In conclusion, although certain members of the B. cepacia complex such as
B. vietnamiensis and the environmental isolates of genomovar III are more sensitive to
antibiotics, when these strains were challenged with antibiotics routinely used in the
treatment of CF patients, they showed increased resistance that was more marked than
that observed for the less sensitive strains. Thus strains cannot be regarded as posing a
lower risk of causing difficult-to-clear infections, since they all have the potential to
become resistant to antibiotics. Since the B. cepacia complex comprises emerging
pathogens in the changeable environment of CF lungs, it is expected that these
organisms have a high incidence of hypermutable strains, which in some organisms, are
associated with increased levels of resistance to antibiotics. To my knowledge, this is the
first 'proper' examination of antibiotic susceptibilities of the B. cepacia complex as
opposed to B. cepacia. Flowever the data on B. stabilis (B. cepacia genomovar IV)




The B. cepacia complex: virulence factors & epidemic
markers
As described in some detail in the introduction, although B. cepacia was originally
described as a phytophathogen, it has now emerged as a life-threatening opportunistic
pathogen in immuno-compromised humans. Ironically, members of the B. cepacia
complex have also raised considerable biotechnological interest as candidate
biopesticides and bioremediators. The issue of human hazards posed by B. cepacia has
become increasingly contentious. It has been argued that since the majority of candidate
biopesticides were originally isolated from natural environments they present a
relatively low risk to humans. Similarly agricultural microbiologists and
biotechnologists have argued that clinical isolates ofB. cepacia are distinctive from
environmental B. cepacia and, for example, lack phytopathogenicity (Bevivino,
Tabacchioni et al, 1994).
Members of the B. cepacia complex have been recognised as important pathogens in
patients with cystic fibrosis since the early 1980s. Treatment of CF patients colonised
with B. cepacia is complicated not only by the organism's intrinsic resistance to
commonly used antipseudomonal antibiotics but also by its ability to spread from
patient-to-patient, both in hospitals and through social contact. The prognosis for CF
patients harbouring B. cepacia is variable, ranging from asymptomatic carriage through
161
a gradual decline to a rapid, fatal necrotising pneumonia that is sometimes accompanied
by septicaemia (Isles, Maclusky, et al, 1984). The nature of the virulence factors and
host/ pathogen interactions that contribute to the pathogenicity of the B. cepacia
complex remain largely unkown. Several putative virulence factors have been proposed,
some ofwhich will be investigated in this section.
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5.1. Phytopathogenicity of the B. cepacia complex and B. gladioli
In order to determine whether or not there are differences in the phytopathogenicity of
clinical and biopesticide B. cepacia strains, the pathogenicity of an epidemic CF strain,
B. cepacia J2315, a candidate biopesticide strain B. vietnamiensis AMMD and a
B. gladioli ATCC 10247 was investigated on British white and red onions, and baking
potatoes. In this study, phytopathogenicity was found to be dependent on the host plant
tested.
Fig 5.1.a) Phytopathogenicity of the B. cepacia complex (J2315, AMMD) and
B. gladioli (ATCC 10247) on white onions.
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AMMD
Fig 5. l.b) Phytopathogenicity of the B. cepacia complex (J2315, AMMD) and
B. gladioli (ATCC 10247) on red onions
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5.1.c) Phytopathogenicity of the B. cepacia complex (J2315, AMMD) and B. gladioli
(ATCC 10247) on potatoes.
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5.2. Putative virulence factors and epidemic markers of the B. cepacia complex
Several putative virulence markers have been identified in the B. cepacia complex. In
addition, two epidemic strain markers cblA, encoding a major adhesin, cable pilus and
the genomic marker, BCESM {Burk.hold.eria cepacia epidemic strain marker) have also
been associated with some epidemic strains. Most previous studies of epidemic markers
were performed prior to or during the taxonomic re-organisation of the B. cepacia
complex. In this study, the distribution of elastase, lipase, melanin, catalase and the
regulatory dsb gene, together with cblA and BCESM was investigated in 71 isolates
representing the major sub-populations which comprise the B. cepacia complex. These
isolates included the 30 strains that make up the B. cepacia strain panel. The results are
summarised in Table 5.1 and Fig 5.2. Overall, the distribution of putative virulence and
epidemic markers varied considerably both in incidence across the whole B. cepacia
complex and within genomovars. The significance of these results is discussed
separately in section 5.3.
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Table 5.1 .Putative virulence factors of the B. cepacia complex
Strain Ela Lipa dsb Prot Cat Mela BCESM cblA
B. cepacia
genomovar I
ATCC 17759 - + - + - - - -
ATCC 25416 - + + + - - - -
LMG 17997 - + - + - + - -
CEP 509 - + - - - + - -
CI 963 - + - + - - - -
J2535 - + + + - - - -
J2540 - + - + - - - +
J2552 - + - + - - NT NT
B. multivorans
ATCC 17616 - - - + - - - -
LMG 13010 - + - - + - - -
CF-A1-1 - + - - + - - -
C1596 - + - + + - NT NT
C1572 + - - - + - NT NT
C1576 - - - + + - - -
C1652 - - - - + - - -
C1857 - + - + + - - -
C1911 - - - + + - - -
C2775 - + - + + - - -
C5393 - + - - + + - -
CI 962 - + - - + - - -
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Ela, elastase; Lipa, lipase; Prot, protease; Mela, melanin; BCESM, Burkholderia cepacia epidemic strain
marker; cbl A, cable pilus type A; NT, not tested; +, present; absent.
Table 5.1. cont.
Strain Ela Lipa dsb Prot Cat Mela BCESM cbl A
JTC + - + + - - -
J2395 + - + + - - -
J2866 + - - + - - -
J2867 + - - + - - -
J2868 + - - + - - -
249-2 - - - - - - -
B. cepacia
genomovar III
ATCC 17765 - - - - - + -
BC7 + + - + + + +
C517 - - - + - - -
C1335 - - + - - - -
C1394 - + + - - - +
CI 632 - - + + - - -
C2374 + - + - - NT NT
C5424 + + + + + + +
C6433 + - + + - + -
CI 773 + - - + - NT NT
K56-2 + + + - - + +
PC 184 + + + + - + -
715j + + + - - NT NT
J2315 + + + + + + +
CEP 511 + + + + + + -
Ela, elastase; Lipa, lipase; Prot, protease; Mela, melanin; BCESM, Burkholderia cepacia epidemic strain
marker; cbl A, cable pilus type A; NT, not tested; +, present; absent.
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Table 5.1 cont.
Strain Ela Lipa dsb Prot Cat Mela BCESM cblA
B. cepacia
genomovar III
R2817 + NT - - -
R2827 - NT - - -
R8351 NT NT - - -
R8571 - NT - - -
R8574 - NT - - -
R8580 - NT - - -
R8605 + NT - - -
R9235 - NT - - -
R9239 + - NT - - -
R9243 + - NT - - -
R9338 NT NT - - -
R9342 NT NT - - -
C3039 + + - + - -
C3041 + + + + -
Indefinite
C1511 I-III-IV - + NT + NT NT
C2008 I-III + NT + NT NT
C2349 I-III + NT + NT NT
Ela, elastase; Lipa, lipase; Prot, protease; Mela, melanin; BCESM, Burkholderia cepacia epidemic strain




Strain Ela Lipa dsb Prot Cat Mela BCESM cbl A
B. stabilis
LMG 18888 + + - - -
LMG 14086 + + - - -
LMG 14294 + + - - -
C7322 + - - - -
B. vietnamiensis
ATCC 53266 + + - - -
ATCC 53267 + + + - -
ATCC 29424 + + - -
LMG 16232 + + - - -
LMG 10929 + - - - -
C2972 - - - - -
C2973 + + - - -
CI 704 - + - - -
C2977 + - - - -
C2979 + + - - -
C2974 + - - - -
C2975 + + - - -
C2976 + - - - -
FC 441 + - - - -
PC 259 + - - - -
AMMD + + - - -
J1697 + + - NT NT
J1705 + + - NT NT
Ela, elastase; Lipa, lipase; Prot, protease; Mela, melanin; BCESM, Burkholderia cepacia epidemic strain
marker; cbl A, cable pilus type A; NT, not tested; +, present; -, absent.
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1 2 3 4 5 6 7 8 9 10 Tl 12 13 1415 16 17 18 19 20
Fig 5.2.a) Distribution of the dsb gene in the B. cepacia complex strain panel
Lanes 1 to 20, CEP 511, PC 184, C6433, C5424, K56-2, BC7, 249-2, ATCC 17616,
JTC, CF-A1-1, LMG 13010, C5393, C1962,, C1576, ATCC 17759, ATCC 25416,
LMG 17997, CEP 509, pSNl, 100 bp ladder, respectively.
3 10111213
Fig 5.2.b) Distribution of the dsb gene in the B. cepacia complex strain panel
Lanes 1-13, LMG 16232, LMG 10929, FC 441, PC 259, LMG 10486, LMG 18888,




5.3.1. Phytopathogenicity of the B. cepacia complex
Investigation of phytopathogenicity with members of the B. cepacia complex was
informative and suggested differences to some currently held opinions. For example,
these preliminary studies showed that the clinical B. cepacia strain J2315 and the
rhizosphere strain B. vietnamiensis AMMD both caused maceration ofBritish white
onions; furthermore, there was no difference in the extent or nature of the maceration.
This result contrasts with previous reports, (Gonzalez and Vidaver, 1979), in which B.
cepacia strains isolated from plants or the rhizosphere had greater plant pathogenicity
than strains of clinical origin. An explanation for this discrepancy could lie in the type
of onion used and the low number of strains examined.
In British red onions, strain AMMD caused a slimy soft rot, similar to the type of rotting
observed on the white onion, whereas the clinical strain J2315 failed to cause any
rotting. This onion-specific difference in phytopathogenicity is interesting and suggests
that the pathogenicity of the B. cepacia complex for onions may be dependent on the
variety of onion used, as well as on the individual strains examined. This dependence of
B. cepacia complex strains' pathogenicity on the variety of onion tested was recently
reported by Sfalanga and co-workers (1999); who found that the B. cepacia complex
strain NCPPB5782 caused complete maceration of the cv. Bianca agostana onion slices
but had no effect on the cv. Dorata di Parma slices.
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B. gladioli is taxonomically closely related to the B. cepacia complex and routinely used
identification methods such as the API 20NE are unable to distinguish between these
two groups of organisms. Inoculation of both types of onions with a strain of
B. gladioli resulted in the accumulation of a slimy layer on the surface of the onion
slices and not the typical soft rot caused by B. cepacia. It is possible that B. gladioli
does not cause soft rot on onions although more studies would have to be carried out to
verify this observation.
Since the B. cepacia complex could be used as a biopesticide on a wide variety of plants,
pathogenicity on potatoes was also tested. B. gladioli caused a complete softening of the
potato slice, B. cepacia J2315 caused less rotting and B. vietnamiensis AMMD caused
no rotting of the potato slice. When the phytopathogenicity of the B. cepacia complex
was assessed on potato slices therefore, the representative clinical strain was more
pathogenic than the environmental isolate from the rhizosphere. This result again
confirms that phytopathogenicity was not restricted to environmental isolate tested and
that the property was possessed by a well-documented clinical strain.
In conclusion, phytopathogenicity of the B. cepacia complex may not be restricted to the
origin of the strain, whether clinical or rhizosphere, but rather, be dependent on the host
plant and the individual strain of the B. cepacia complex, regardless of its origin.
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5.3.2. Production of proteases by the B. cepacia complex
In this study, a minority (6%) of the B. cepacia complex strains studied produced
proteolytic activity which degraded elastin and the strains producing elastase included
both environmental and clinical isolates. This low prevalence together with the
comprehensive collection investigated could explain why a previous study on B. cepacia
isolates from CF patients reported that none of the isolates studied could degrade elastin
(McKevitt, Woods, et al, 1984). Elastin forms the major constituent of elastic tissue
fibres and these include the walls of the alveoli of the lungs. Results from this and
previous studies indicate that elastase production is not a widespread property within the
B. cepacia complex and is probably not one of the virulence factors responsible for CF
lung disease.
In this study, most strains of the B. cepacia complex (57%) produced protease as
assessed by their ability to digest skimmed milk. Significantly, the proteolytic strains
were ofboth clinical and environmental origin and spanned all five genomovars studied.
This widespread distribution contrasts markedly with (Bevivino Tabacchioni, et al,
1994), who reported that only clinical strains produced protease. However,in the
Bevivino et al study, only four strains were included and azoalbumin was used as the
substrate and not skimmed milk. A similar study that also used skimmed milk as a
substrate reported that the majority of strains studied could degrade casein (McKevitt,
Woods, et al, 1984). However, this study found that the ability to detect casein
degradation varied with the medium used. Few strains were able to degrade casein in all
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four media used. Thus, estimates of protease production need to be assessed carefully
and may be underestimated if an unsuitable medium is used for the assay. A striking
result from the proteolytic assays performed during this thesis was that none of the
recently identified rhizosphere B. cepacia genomovar III strains showed the ability to
degrade casein. This is an interesting result and needs to be investigated in more detail.
In an attempt to probe protease production further, the presence of the dsb gene, whose
product is required for the formation ofB. cepacia's metalloprotease (Abe and
Nakazawa, 1996), was investigated. The dsb gene was detected by PCR in 11 (17%) of
the 65 strains studied and of those strains possessing the gene, eight (73%) belonged to
B. cepacia genomovar III. All the genomovar III strains were isolated from CF patients.
Interestingly, no less than seven of the eight genomovar III strains with the dsb gene
have caused epidemics in different CF communities. It should be noted however that
three isolates J2315, BC7 and K56-2 are clonally related representatives of the epidemic
ET12 lineage, isolated from different geographical regions (Mahenthiralingam, Coenye,
et al, 2000). No information was available on the epidemic potential of the remaining
B. cepacia strain 715j. Interestingly, the dsb gene was not detected in strain CI632, a B.
cepacia genomovar III isolate that caused an epidemic in Newcastle, UK (Simpson,
Finlay et al, 1994). These results could mean that either the observed association is
purely coincidental or that the dsb gene is unstable and CI632 has subsequently lost its
copy.
Two other strains with the dsb gene, J2535 and ATCC 25416 belong to B. cepacia
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genomovar I and were isolated from rotting bark and onion, respectively (Butler,
Doherty, et al, 1995; Mahenthiralingam, Coenye, et al, 2000). The remaining strain,
C3041, was one of three candidate biopesticide strains that were subsequently
withdrawn because they were perceived to be of a human risk owing to possession of
'virulence' characteristic including the BCESM, or because they were found to belong to
genomovar III.
Although the role ofproteases in the pathogenicity of the B. cepacia complex has not
been unequivocally established, intratracheal instillation of a purified metalloprotease
produced by the B. cepacia genomovar III strain 715j into rat lungs, produces
bronchopneumonia (McKevitt, Bajaksouzian, et al, 1989). In conclusion, as far as the
virulence potential ofproteases in the B. cepacia complex is concerned, the jury is still
out.
5.3.3. Lipase production in the B. cepacia complex
In this study, production of lipase was found to be common within the B. cepacia
complex and these results are similar to previous observations (McKevitt, Woods, et al,
1984; Gessner and Mortensen, 1990). The egg yolk plate assay is commonly used for
the detection of lecithinase, an enzyme which catalyzes the hydrolysis of lecithin
(phosphatidylcholine) resulting in the liberation of phosphorous and choline as well as
the precipitation of fat, which gives rise to the reaction's characteristic opalescence
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(Esselmannm and Liu, 1961). Lecithin is a phospholipid found in the membranes of
animal cells.
Egg yolk is a complex substrate consisting of a mixture of compounds and a more direct
measurement of lecithinase activity would be to use a single substrate such as
/?-nitrophenylphosphorylcholine. Previous research has shown that B. cepacia strains
producing a typical egg yolk reaction may not produce lecithinase activity on
/>-nitrophenylphosphorylcholine (Lonon, Woods, et al, 1988), indicating that the lipase
activity on egg yolk agar could be due to an enzyme other than lecithinase. Despite
these sometimes misleading results, egg yolk agar is still routinely used for the detection
of lecithinase in other organisms such as Clostridium perfringens. Egg yolk agar has the
advantages ofbeing cheap and readily available.
Earlier studies found all lecithinase producing B. cepacia strains to be haemolytic
(Esselmann and Liu, 1961) but more recent studies have found no direct correlation
between the amount of lecithinase and beta haemolytic activity (Nakazawa, Yamada, et
al, 1987; Vasil, Krieg, et al, 1990). However, all haemolytic strains have been shown to
produce lecithinase (Nakazawa, Yamada, et al, 1987; Vasil, Krieg, et al, 1990).
A possible role ofB. cepacia lipase as a virulence factor was provided by the
demonstration that rat pulmonary alveolar macrophages have a reduced capacity for
phagocytosis when incubated with B. cepacia lipase (Straus, Lonon, et al, 1992). These
researchers found that B. cepacia lipase acted on and changed the surface of
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macrophages and led to a reduction in their ability to internalise the organism. Thus
B. cepacia lipase could allow the organism to evade the immune system by avoiding
phagocytosis by macrophages.
5.3.4. LPS and virulence of the B. cepacia complex
Although this study did not include examination of the LPS chemotypes of the
B. cepacia complex, LPS is a well known virulence factor due to its potent immuno-
stimulatory effects on macrophages, granulocytes and B-lymphocytes (Rietschel,
Kirikae, et al, 1993). Several studies indicate that B. cepacia LPS contributes to the
organisms' pathogenesis in CF lung disease and suggest an explanation for the 'cepacia
syndrome', its unique association with B. cepacia colonisation and absence from
patients colonised with other pathogens. Most strains of the B. cepacia complex express
smooth LPS, although some genomovar III strains can also express rough LPS (Evans,
Poxton, et al, 1999) but virulence is not related to LPS chemotype.
Various strains ofB. cepacia produce an extracellular toxic complex (ETC) composed of
carbohydrate, LPS and protein, which is lethal to mice and produces extensive lung
damage in rats (Straus, Lonon, et al, 1989). The most toxic ETC preparations are those
with the highest concentration of LPS, and purified LPS has the same toxicity on mice
as the complex, an indication that the LPS portion of the ETC probably confers toxicity
to the complex.
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More evidence for the toxicity ofB. cepacia LPS was provided by (Shaw, Poxton, et al,
1995), who demonstrated that B. cepacia LPS is not only endotoxic but can also induce
high levels of tumour necrosis factor (TNF). Interestingly, this study found that B.
cepacia LPS induced approximatley nine times as much TNF compared to P.
aeruginosa LPS. This indicates that although P. aeruginosa is the leading CF pathogen
affecting up to 90% of patients, B. cepacia has a greater potential to cause and sustain
immune-mediated damage in the lung. The same researchers also found that
environmental isolates ofB. cepacia had a high capacity to stimulate TNF, although at
much lower levels than clinical isolates. LPS preparations from both clinical and
environmental strains of the B. cepacia complex were at least four times more endotoxic
than preparations from P. aeruginosa strains. Stimulation of TNF by B. cepacia LPS
was recently confirmed by Zughaier and co-workers (Zughaier, Ryley, et al, 1999b),
who also found B. cepacia LPS to have greater inducing activity than LPS from P.
aeruginosa and even S. maltophilia.
Involvement ofB. cepacia LPS in the immune system was further demonstrated when it
was shown to increase CD1 lb, a component of the complement receptor CR3 which is
expressed on the surfaces ofmacrophages and is involved in various neutrophil activities
including activation (Hughes, Stewart, et al, 1997). LPS from both clinical and
environmental B. cepacia induced a marked increase in CD1 lb expression whereas LPS
from P. aeruginosa had very little effect (Hughes, Stewart, et al, 1997). Similarly, LPS
from B. cepacia was able to prime intracellular production of H2O2 in neutrophils to
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greater levels than fori5, aeruginosa. A significant observation was that LPS
preparations of the environmental B. cepacia genomovar I strain J2552 primed neurophil
respiratory burst activity to the greatest degree.
Two groups of researchers have proposed a hypothesis for the involvement ofB. cepacia
LPS in the 'cepacia syndrome'. Hughes et al (1997) and Zughaier et al (1999b) have
suggested that B. cepacia LPS-mediated stimulation of neutrophils and macrophages
may be greater in certain individuals, thus increasing the rate of inflammatory damage
and sometimes permitting the systemic spread ofB. cepacia and thus resulting in the
'cepacia syndrome'. The greater immuno-stimulatory effect ofB. cepacia LPS
compared to that of other CF pathogens (Shaw, Poxton, et al, 1995 ; Hughes, Stewart, et
al, 1997; Zughaier, Ryley, et al, 1999b; Hutchinson, Bonell, et al, 2000) could also
explain the exclusive observance of 'cepacia syndrome' in patients colonised with
B. cepacia.
5.3.5.Catalase and melanin production in the B. cepacia complex
Catalases are widely distributed in nature and perform diversified functions. Arguably,
the most beneficial catalase for humans is the catalase-peroxidase encoded by the katG
gene ofMycobacteria tuberculosis (Heym, Zhang, et al, 1993). The catalase-peroxidase
ofM. tuberculosis mediates the organism's susceptibility to isoniazid, one of the most
effective agents in the treatment of tuberculosis (Zhang, Heym, et al 1992). Mutation of
the katG gene leads to resistance to isoniazid.
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Most bacterial species produce catalases that confer obvious advantages to themselves
rather than to humans. In this study ofmembers of the B. cepacia complex, catalase
production was only observed in clinical strains and not in environmental ones. These
potentially important results are consistent with a previous report (Gessner and
Mortensen, 1990) that found significant differences in the production of catalase by
B. cepacia isolates from CF patients compared to environmental and non-CF controls.
Stimulated neutrophils and macrophages reduce molecular oxygen to highly reactive and
toxic oxygen species that include the superoxide O2" and hydrogen peroxide H2O2. The
superoxide is unstable and reacts to form hydrogen peroxide (Hassett and Cohen, 1989).
Catalases convert hydrogen peroxide to harmless water and molecular oxygen and can
thus play an important role in bacterial virulence by combating the respiratory burst of
human phagocytes. The environmental B. cepacia genomovar I strain J2552, shown in
this study not to produce catalase, is efficiently killed by hydrogen peroxide (Smith,
Green, et al, 1999). In contrast B. cepacia J2315 which produces catalase is resistant to
killing by hydrogen peroxide alone (Smith, Green, et al, 1999). Thus, strain J2315 is
resistant to killing by hydrogen peroxide because the catalase it produces converts
hydrogen peroxide to harmless water and molecular oxygen. In contrast, the
environmental isolate J2552 is rapidly killed by hydrogen peroxide since it lacks the
catalase required to inactive it.
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Owing to their nature as stable free radicals, melanins from various sources typically
demonstrate potent scavenger activity against O2" (Sichel, Corsaro, et al, 1991). More
recently, melanin from the epidemic B. cepacia ET12 lineage has been shown to act as
an efficient scavenger of superoxide radicals produced during the respiratory burst of
monocytes (Zughaier, Ryley, et al, 1999a). These researchers suggest that melanin-
producing strains ofB. cepacia derive protection from its free-radical scavenging
properties, which could aid the colonisation and transmission of these strains.
An interesting and potentially important result from this survey ofB. cepacia isolates
was that melanin-producing strains were of clinical origin a result which mirrors that
found with catalase production. Furthermore, most strains that produced melanin also
produced catalase. Interestingly, two of the three clinical genomovar I strains, which
produced no catalase, produced melanin and thus still exhibit an antioxidant mechanism.
In conclusion, whilst B. cepacia LPS is a potent immuno-stimulant, the organisms could
remain protected from the reactive oxygen species of the respiratory burst by the
antioxidant enzyme catalase and by the scavenging properties ofmelanin. While
continual shedding of LPS activates phagocytes and induces a potent inflammatory
response, protection ofB. cepacia from the host's defense system contributes to the
organism's persistence in the CF lung.
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5.3.6. Distribution of genes encoding putative transmissibility factors in the
B. cepacia complex
The ability of some B. cepacia isolates to cause cross-infection among CF patients is
now well known and documented (LiPuma, Dasen, et al, 1990; Govan, Brown, et al,
1993), and CF patients colonised with B. cepacia are routinely treated separately from
non-colonised patients in order to minimise the risk of cross-infection. Since B. cepacia
can also be transmitted by social contact (Govan, Brown, et al, 1993; Pegues, Carson, et
al, 1994; Cazzola, Amalfitano, et al, 1996), colonised and noncolonised patients are
advised to avoid social contacts and comply with other draconian segregation policies.
To date, three genetic markers have been described in strains responsible for patient-to-
patient spread. The first of these markers to be described was the cbl A gene, encoding
giant cable pili that bind to CF mucin and airway epithelial cells (Sajjan, Corey, et al,
1992; Sajjan and Forstner, 1992; Sajjan and Forstner, 1993; Sajjan, Sun, et al, 1995;
Sun, Jiang, et al, 1995). Two other markers, a hybrid of two insertion sequences, the
IS402-IS1356 element (Tyler, Rozee, et al, 1996) and a 1.4kb fragment designated the
B. cepacia epidemic strain marker (BCESM) (Mahenthiralingam, Simpson, et al, 1997),
have also been associated with epidemic strains but no known function.
Distribution of the cblA and BCESM markers was investigated in this study. Four of the
eight B. cepacia genomovar III epidemic isolates possessed both markers, two had only
the BCESM and one had only the cbl A marker. CI 632, the Newcastle, UK, epidemic
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strain possessed neither of these two markers. Notably, this was also the only epidemic
B. cepacia genomovar III strain in which the dsb gene, encoding a protease assembly
protein, was not detected. The BCESM marker was also detected in strain ATCC
17765, a B. cepacia genomovar III strain that caused a urinary tract infection in a UK
non-CF patient.
Neither cblA nor BCESM markers was detected in CI576, a B. multivorans strain
responsible for a large epidemic in Glasgow. Absence of the BCESM from epidemic
strains has been reported previously (Mahenthiralingam, Simpson, et al, 1997) and it
was suggested that this region may be subject to some instability. Of interest from an
ecological and evolution view, the cbl A marker was also detected in J2540, a B. cepacia
genomovar I strain isolated from soil.
Taken together, these results suggest that genetic markers are useful in the identification
ofpotentially epidemic strains but should be used with caution since no presently known
factor can be used to unequivocally designate a strain as either epidemic or non-
epidemic. A recent report (Clode, Kaufmann, et al, 2000) suggests that only patients
colonised with strains in which epidemic markers are identified by PCR should be
segregated from other CF patients. In view of current knowledge such a
recommendation and practice could prove presumptuous and indeed dangerous, since
strains such the Glasgow epidemic strain, C1576 (Whiteford, Wilkinson, et al, 1995;
Mahenthiralingham, Coenye, et al, 2000) possess none of the known epidemic markers.
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CHAPTER 6
B. cepacia genomovar III: Origins
Although all reported genomovars of the B. cepacia complex have been isolated from
CF patients (Vandamme, Holmes, et al, 1997), the majority of these isolates, and most
epidemic strains, are associated with B. cepacia genomovar III and B. multivorans
(Vandamme, Holmes, et al, 1997; Mahenthiralingam, Coenye, et al, 2000;
Mahenthiralingam, Bischof, et al, 2000). The high prevalence ofB. cepacia genomovar
III isolates in clinical material and their association with life-threatening and epidemic
spread, has led to this genomovar being considered an unacceptable risk to humans and
thus strains of this genomovar are excluded from consideration as candidate
biopesticides.
One of the puzzling aspects of genomovar III is that despite being isolated with the
greatest frequency from CF patients, until recently, there were no reports of its isolation
from the environment. Several theories were put forward to explain this anomaly. One
theory was that CF patients are initially colonised by other B. cepacia genomovars
strains which evolve in vivo into B. cepacia genomovar III strains. However, the
evolutionary distances between the different B. cepacia genomovars obtained from
taxonomic studies indicate that such evolutionary transformation is highly unlikely (Dr.
P. Vandamme, personal communication). Another possibility is that the lack of isolation
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ofB. cepacia genomovar III from the environment is due to the use of unsuitable
selection culture conditions. For example, isolation methods used by medical
microbiologists commonly use antibiotic selection (Butler, Doherty , et al, 1995) which
could suppress the growth of some soil organisms. Another possible reason for lack of
genomovar III isolation from environmental sites is that the environmental sites
surveyed might not include the natural habitats of these organisms. For these reasons,
during this study an attempt was made to isolate B. cepacia from the rhizosphere of
plant species using several cultivation methods.
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6.1. Isolation of B. cepacia from the rhizosphere
In preliminary experiments, forty-five rhizosphere sites were examined for B. cepacia.
In addition, five pond sediments were also examined because of a previous publication
concerning B. cepacia in such environments (Wise, Shimkets, et al, 1995). The selection
media used were PCAT medium (Burbage and Sasser,1982) and Malka minimal
medium (Robert-Gero, Poiret, et al, 1970; Butler, Doherty, et al, 1995) which contains
300u/ml polymyxin B. Oxidase positive, non-fluorescent, non-lactose fermenters were
screened on arginine-glucose medium (Stewart, 1971; Butler, Doherty, et al, 1995) and
presumptively identified as 'B. cepaciaFurther identification was performed using the
API 20 NE system. From these studies, 21 'B. cepacia' isolates from eleven different
sites were obtained and these are indicated in Table 6.1. Only one lB. cepacia' isolate
was cultured from pond sediment.
Table6.1: B. cepacia complex isolates cultured from pond sediment and the rhizosphere,
identified using the API 20NE test











pPond sediment isolate; MMP, minimal media with polymyxin; a,D'c Identical PFGE profiles.
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6.2. Taxonomic identification ofB. cepacia isolates
Modern bacterial classification is based on a polyphasic taxonomic approach that utilises
phenotypic tests such as whole-cell protein and fatty acid analysis, as well as genotypic
tests. This study used a polyphasic taxonomic approach for the identification of the
environmental isolates presumptively identified as members of the B. cepacia complex.
6.2.1. Identification of isolates using fatty acid analysis
Although bacteria alter the fatty acid composition of their lipids to maintain membrane
fluidity, in constant growth conditions the qualitative and quantitative analysis of fatty
acid composition is a useful tool for the classification and identification of organisms.
Thus, fatty acid composition was used as the preliminary step for the classification of the
environmental isolates. Although most environmental isolates presumptively identified
by API 20NE as B. cepacia, were confirmed by fatty acid analysis, Table 6.2 shows that
some discrepancies between these two methods were observed in a minority of the
strains.
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Table 6.2: Identification of environmental isolates based on cellular fatty acid analysis
Isolate Identification Probability
J2859 Sphingobacterium 0.770
J2925 Pseudomonas putida 0.793
J2927 B. cepacia 0.626
J2928 B. cepacia 0.669
J2939 B. glathei 0.527
J2940 B. cepacia 0.315
J2941 B. cepacia 0.361
J2942 B. cepacia 0.662
J2943 B. cepacia 0.655
J2944 B. cepacia 0.616
J2945 B. cepacia 0.477
J2946 B. cepacia 0.581
J2947 B. cepacia 0.664
J2948 B. cepacia 0.735
J2949 B. cepacia 0.584
J2950 NT NT
J2951 B. cepacia 0.553
J2952 Salmonella 0.167
J2953 Salmonella 0.418
J2954 B. glathei 0.313
J2955 B. glathei 0.552
NT not tested. The probability was determined by computer; which compared the fatty
acid composition of the test isolate to that of bacterial standards stored in the database.
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6.2.2. Identification of isolates using SDS-PAGE
In the next stage of polyphasic identification, whole-cell bacterial protein extracts
were prepared and used to classify the environmenal isolates. Standard growth
conditions were used to enable comparisons between organisms, as the composition
of whole-cell proteins also varies with growth conditions. Fig 6.1 shows that a few
isolates had identical SDS-PAGE profiles.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Fig.6.1.a). SDS-PAGE Profiles: Lanes 1 to 18; Marker, reference strain LMG 1125,
J2948, J2927, J2928, J2943, LMG 1125, J2950, J2942, J2944, J2951, LMG 1125,
J2949, J2942, J2941, J2940, LMG 1125, Marker, respectively.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Fig.6.1.b). SDS-PAGE Profiles: Lanes 1 to 19; Marker, reference strain LMG1125,
E26, E27, LMG1125, J2955, J2954, LMG1125, J2953, J2939, J2925, J2945,
LMG1125, J2952, J2859, J2946, J2940, LMG1125, LMG19447.
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The SDS-PAGE profiles obtained for the environmental isolates were compared to
standard Burkholderia SDS-PAGE profiles both manually and using a computer
programme as detailed in the appendix. Table 6.3 shows that the isolates identified by
fatty acid analysis as belonging to genera other than Burkholderia, were also excluded
from the B. cepacia complex by SDS-PAGE. The remaining 17 isolates were confirmed
as B. cepacia by SDS-PAGE and also allocated to genomovar I-III-IV, and B.
multivorans (previously known as genomovar II) and to a group similar to the newly
described Burkholderia species B. graminis (Viallard, Poirier, et al, 1998; Kahng,
Kukor, et al 2000).
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J2927 B. cepacia genomovar I-III-IV
J2928 B. cepacia genomovar I-III-IV
J2939 B. graminis-like
J2940 B. graminis-like
J2941 B. cepacia genomovar I-III-IV
J2942 B. multivorans
J2943 B. multivorans
J2944 B. cepacia genomovar I-III-IV
J2945 B. cepacia genomovar I-III-IV
J2946 B. cepacia genomovar I-III-IV
J2947 B. multivorans
J2948 B. multivorans
J2949 B. cepacia genomovar I-III-IV
J2950 B. cepacia genomovar I-III-IV






6.2.3. Identification of isolates using 16S rDNA
The genotype of an organism is stable in all environments and identification based
on parts of the genome is increasingly being employed in taxonomic studies. In this
study, the 16S rDNA gene of the environment isolates was examined and the results
are shown in Fig 6.2 and Table 6.4.
Fig 6.2. 16S rDNA Lanes 1 to 14; marker, negative control, positive control, J2948,
J2927, J2928, J2943, J2950, J2942, J2944, J2951, J2949, J2947, J2941, respectively.
Lanes 15 to 28; marker, J2940, J2940, J2946, J2859, J2952, J2945, E26, E27, J2925,
J2939, J2953, J2954, J2955, respectively.
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The rhizosphere isolates' 16S rDNA amplified by PCR was restricted with Ddel and
restriction fragment length polymorphism (RFLP) analysis revealed sequence
polymorphisms that could identify B. multivorans and strains not belonging to the
B. cepacia complex. However, B. cepacia genomovars I, III, IV {B. stabilis) could not
be separated.
Table 6.4. Identification of rhizosphere isolates based on the RFLP of the 16S rDNA














































B. cepacia genomovar I, III, IV
B. cepacia genomovar I, III, IV
B. multivorans
B. cepacia genomovar I, III, IV
B. multivorans
B. cepacia genomovar I, III, IV
B. cepacia genomovar I, III, IV
B. cepacia genomovar I, III, IV
B. multivorans
B. cepacia genomovar I, III, IV
Not B. cepacia complex
Not B. cepacia complex
B. cepacia genomovar I, III, IV
Not B. cepacia complex
Not B. cepacia complex
B. cepacia genomovar I, III, IV
Not B. cepacia complex
Not B. cepacia complex
Not B. cepacia complex
Not B. cepacia complex
Not B. cepacia complex
Lanes 22 & 23 were B. multivorans CF isolates
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6.2.4. Genomovars I and III recA-specific PCR
In the next stage ofpolyphasic taxonomic analysis, the environmental isolates identified
by 16S rRNA analysis as B. cepacia genomovars I, III and IV were examined using rec
A specific PCR (Mahenthiralingham, Bischof, et al, 2000) for B. cepacia genomovars I,
III a and III b. All were found to be negative.
6.2.5. Further analysis of rhizosphere isolates
The negative genomovar I and III recA-specific PCR results prompted a DNA-DNA
hybridisation investigation of all Burkholderia sp isolates and the following results were
obtained:
i) J2942, J2943, J2947 and J2948 were identified as B. multivorans (genomovar II).
ii) J2927, J2928, J2941, J2944, J2945, J2946, J2949, J2950 and J2951 were found
to represent yet another genomovar within the B. cepacia complex; B. cepacia
genomovar VIII
iii) J2940 was identified as B. graminis
iv) Three isolates, J2939, J2954 and J2955 were found to represent a novel



















13 B. cepacia complex
4 B. graminis-like (non B. cepacia complex)
4 non Burkholderia




In this study, a survey of 50 sites yielded 21 B. cepacia isolates (42%) when
identification was performed by the API 20NE system. More isolates (38%) were
identified on minimum media with 300 u/ml polymyxin (MMP), than on the PCAT
medium (14%) and the majority of isolates (48%) were identified using both media.
Fatty acid and whole-cell protein analysis revealed that all the isolates identified on
PCAT medium (J2925, J2952, J2953) and one identified on the MMP medium (J2859)
did not belong to the genus Burkholderia. Isolates J2925 (Pseudomonas fluorescens),
J2952 and J2953 (both Salmonella as identified by whole-cell fatty acid analysis) were
initially identified as B. cepacia on the API 20NE, with good identification scores ;
namely, at 99.9%, 95% and 99.9% discrimination levels, respectively. When API 20NE
test was repeated, isolate J2925 was identified as P. fluorescens, however; J2952 and
J2953 were identified as B. cepacia at 66.3% and 95% discrimination levels,
respectively. In addition, the API 20NE identified all four B. graminis-like organisms
as B. cepacia.
The API 20NE system is one of several commercial systems that are routinely used in
diagnostic laboratories for the identification ofB. cepacia from CF specimens and
identification at 95% discrimination level is normally considered acceptable
identification. Disturbingly, this study confirms previous reports indicating that
commercial identification systems are unreliable for the identification of the B. cepacia
complex (Kiska, Kerr, et al, 1996; van Pelt, Verduin, et al, 1999; Shelley, Spilker, et al,
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2000). Furthermore, most commercial identification systems cannot distinguish
B. gladioli from B. cepacia (Kiska, Kerr, et al, 1996; van Pelt, Verduin, et al, 1999;
Shelley, Spilker, et al, 2000). Despite being flawed, the API 20NE test is still
considered to be the best commercial system for the identification of B. cepacia
currently available (van Pelt, Verduin, et al, 1999). At present, the use ofDNA-based
methods are considered necessary for reliable final identification ofmembers of the
B. cepacia complex (van Pelt, Verduin, et al, 1999; Shelley, Spilker, et al, 2000). Since
culture of the B. cepacia complex from CF patients has profound medical, social and
psychological implications, it is imperative that these organisms are identified
accurately.
In this study, the PCAT medium failed to provide the high degree of selectivity for B.
cepacia reported previously (Nacamulli, Bevivino, et al, 1997). Further selection tests
were required for the identification ofB. cepacia in addition to growth on both PCAT
and malka mimimal medium. Isolation of the B. cepacia complex from the environment
using these two methods was extremely laborious and time-consuming, making these
methods impractical for large-scale application. In this thesis, several months were
spent isolating only 13 'true' B. cepacia complex isolates from the environment. More
practical methods of isolation urgently need to be developed before accurate assessments
of the background levels of the B. cepacia complex in the natural environment can be
made.
In this study, the isolation rate of confirmed B. cepacia 13 (26%) is marginally higher
than the figure of 21% previously reported by (Butler, Doherty, et al, 1995) using
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similar methods. Reports on the natural abundance of B. cepacia in various
environments range from very low, 1% (Mortensen, Fisher, et al, 1995) and 4%
(Mortensen, Fisher, et al, 1995) to reasonably frequent, 213 isolates from 11 different
sites of backwater stream sediment (Wise, Shimkets, et al, 1995). The wide variation in
isolation rates of'B. cepacia' from the environment is could be due to the different
habitats sampled and to errors caused by simple phenotypic identification systems which
are less accurate than the polyphasic system used in the present study.
Although CB. cepacia' has been recovered form a variety of habitats, recent evidence
suggests that a greater proportion of viable bacteria can be cultured from the rhizosphere
and rhizoplane than from the bulk soil (Troxler, Zala, et al, 1997). The different
sampling techniques used in previous studies range from molecular techniques (Wise,
Shimkets, et al, 1995) to growth on a range of selective media (Hagedorn, Gould, et al,
1987; Nijhuis, Maat, et al, 1993; Butler, Doherty, et al, 1995; Nacamulli, Bevivino, et
al, 1997), and could be a major factor accounting for the discrepancies in isolation rates.
Finally, physical properties of the soil such as the pH, water content and chemical
composition could result in different rates of colonisation by iB. cepaciaand thus
influence the rates of isolation.
Whole-cell fatty acid and protein analysis are used extensively and effectively in the
taxonomic classification and identification of bacteria (Vancanneyt, Witt, et al, 1996;
Vandamme, Holmes, et al, 1997; Vandamme, Mahenthiralingam et al, 2000). In this
study, whole-cell fatty acid analysis was found to be effective only in identifying the
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genus Burkholderia but was unreliable in differentiating between the different species.
However, it was still found to be useful for excluding organisms that were not related to
'B. cepaciaThis study confirmed that although SDS-PAGE is a phenotypic
mechanism of taxonomic classification, the results of SDS-PAGE correlated well with
16S rDNA classification. In conclusion, polyphasic taxonomy is necessary for reliable
identification ofmembers of the B. cepacia complex and should now be included in
taxonomic research.
As has been indicated previously, B. cepacia genomovar III and B. multivorans are
recovered most frequently from CF patients and, are most commonly associated with
epidemic spread and poor clinical prognosis (Vandamme, Holmes, et al, 1997;
Mahenthiralingam, Coenye, et al, 2000; Mahenthiralingam, Bischof, et al, 2000;
Shelley, Spilker, et al, 2000). The need for further studies on the clinical relevance of
the different genomovars is well recognised (Vandamme, Holes, et al, 1997;
http://www.epa.gov, 12 July 2000; Mahenthiralingam, Bischof, et al 2000). Information
from such studies could be useful in predicting the clinical outcome from particular
isolates. Furthermore, since most biopesticide strains being considered for commercial
applications are B. cepacia genomovar I or B. vietnamiensis, information on the risks
associated with different genomovars would be useful in determining the risks
associated with the use of B. cepacia complex isolates as biopesticides.
In this study, 53% of the Burkholderia sp isolates obtained from the rhizosphere were
found to belong to a new genomovar within the B. cepacia complex; genomovar VIII.
200
No comparisons could be made with previous studies on the isolation rates of
'5. cepacia' from the rhizosphere since earlier studies were performed prior to the
knowledge of the complex taxonomy of the B. cepacia complex. Interestingly, although
very few environmental B. multivorans isolates have been described, this study found
that four, (24%) of all Burkholderia sp isolated from the rhizosphere belonged to this
species. Interestingly, three isolates were found to represent a novel Burkholderia
species. The results from this study illustrate the complexity of the taxonomy of the B.
cepacia complex and the detailed identification ofBurkholderia isolates now possible
through use of the polyphasic taxonomic approach. Identification methods used prior to
the polyphasic taxonomic approach would have identified all the isolates obtained in this
study, simply as 'B. cepacia.' Thus, a comparison of environmental 'B. cepacia'
isolates should take into account the identification methods used.
Although no B. cepacia genomovar III isolates were obtained from the rhizosphere in
this study, isolation ofB. cepacia genomovar III from the rhizosphere in France,
Phillipines and Italy has recently been reported (Govan, Balendreau, et al, 2000; Dr. P.
Vandamme, personal communication). This new data implies that some of the
B. cepacia genomovar III isolates recovered from CF patients could have been acquired
from the natural environment. Interestingly, B. cepacia genomovar III and
B. vietnamiensis have also been demonstrated recently as agents of sub-clinical mastitis
in sheep (Berriatua, Ziluaga, et al, 2001). This report represents the first description of
natural B. cepacia infection in domestic animals and a possible mode of transmission of
the organism to susceptible human hosts. It is interesting to note that in the Berriatua et
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al study, B. cepacia genomovar III strains (isolated with a high frequency from CF
patients and associated with epidemic spread) and B. vietnamiensis (often associated
with candidate biopesticide strains), were both responsible for the mastitis in sheep.
Thus, the two groups ofB. cepacia complex members that could be considered most
dangerous and least dangerous, were both responsible for infection in veterinary
medicine. This report casts serious doubts on the consideration of some B. cepacia
complex members as less dangerous than others and hence safe for large-scale
commercial application as biopesticides.
Knowledge of the true level of B. cepacia in the environment is one of the factors that
the United States Environmental Protection Agency considered as essential for adequate
evaluation of B. cepacia as a biopesticide (http://www.epa.gov, 12 June 2000). This
information is required to determine the influence of introduced biopesticide strains on
the natural B. cepacia population and to assess the risks, if any, posed by these
biopesticides to susceptible humans, in comparison with the risks associated with
naturally occurring background levels ofB. cepacia. The recently detected
environmental B. cepacia genomovar III isolates can now be included in such studies,
leading to a more robust and comprehensive assessment of the relationship between




The B. cepacia complex genome and genetic exchange
The B. cepacia complex exhibits contrasting characteristics that have led to it being
referred to as both humanity's friend and foe (Govan, Balendreau, et al, 2000).
Typically, members of the complex have the ability to metabolise a wide variety of
compounds and can even use the antibiotic, penicillin G as a sole carbon and energy
source (Beckman and Lessie, 1979). This ability to degrade complex compounds has
generated commercial interest in these bacteria as bioremediation agents for
environmental degradation of recalcitrant xenobiotic compounds,including herbicides
and defoliants such as agent orange (Grant, 1979; Kilbane, Charteijee, et al, 1982,
Danganan, Ye, et al, 1994). Historically, members of the B. cepacia complex were best
known as phytopathogens causing 'soft rot' in damaged onion bulbs (Burkholder, 1950).
In recent years, the B. cepacia complex has emerged as important life-threatening
opportunistic human pathogens in immuno-compromised hosts, in particular, in patients
with cystic fibrosis and chronic granulomatous disease. It has been suggested that this
adaptability of the B. cepacia complex is due the organisms' large, complex genome
(Holmes, Govan et al, 1998; Govan and Vandamme, 1998; Mahenthiralingam, Coenye,
et al, 2000).
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The B. cepacia complex genome consists of three large circular replicons that have
numerous insertion sequence elements and rRNA genes, as well as a large plasmid of
about 200kb, making its total genome between 6.8 and 8.1 Mb (Cheng and Lessie, 1994,
Rodley, Romling, et al, 1995). It has been suggested that partitioning of the genome is
advantageous because it allows members of the B. cepacia complex to replicate rapidly
despite their large genome size (Stouthammer and Kooijman, 1993).
It is estimated that B. cepacia complex isolates have approximately twelve different
transposable elements in their genome (Gaffney and Lessie, 1987); the insertion
sequences present in the plasmid are also duplicated in the chromosomes. The different
transposable elements and insertion sequences mediate genomic re-arrangements
(Gaffney and Lessie, 1987) and activate the expression of poorly expressed genes
through both insertions and deletions (Scordilis, Ree, et al, 1987); this would enable the
B. cepacia complex to make use of genetic material which otherwise would not be
expressed. Transposable elements, therefore, contribute significantly to the genomic
plasticity of the B. cepacia complex and possibly played an important role in the
evolution of novel catabolic functions such as the ability to degrade recalcitrant organic
compounds and penicillin G.
Interestingly, the insertion sequences themselves are probably of foreign origin, as
suggested by relatively low guanosine plus cytosine (G+C) content compared to that of
B. cepacia complex DNA (Ferrante and Lessie, 1991; Byrne and Lessie, 1994). This
implies that at some point in their evolution, members of the B. cepacia complex
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successfully sequestered and incorporated foreign DNA into their genome. Insertion
sequencies not only impart unusual metabolic abilities but also transmissibility to the
B. cepacia complex in the context ofhuman pulmonary infection. A hybrid of two
insertion sequencies IS 402-IS1356 is one of the three markers associated with the
epidemic spread ofB. cepacia complex strains within the CF community (Tyler, Rozee,
et al, 1996).
Thus, the B. cepacia complex presents important and diverse challenges. These
inherently antibiotic-resistant organisms, with a complex and highly plastic genome,
cause life-threatening infections in susceptible humans but ironically are also highly
efficient and cost-effective biopesticides and bioremediation agents. Bulk release of
B. cepacia complex biopesticides into the environment could potentially facilitate
horizontal gene transfer with soil microorganisms and/or members of the B. cepacia
complex of clinical interest. The three most common methods of bacterial gene transfer
are; transduction, which is facilitated by bacteriophages; conjugation through direct cell
contact and transformation, mediated by uptake of naked DNA from the organism's
environment. This thesis assessed the potential for transduction, conjugation and
transformation to facilitate horizontal genetic exchange across different subgroups of the
B. cepacia complex, including clinical, environmental and candidate biopesticide strains.
Bacteriophages whose host spectrum spanned all subgroups of the B. cepacia complex
were isolated and natural transformation was demonstrated.
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7.1. Bacteriophages of the B. cepacia complex
Some of the studies on the bacteriophages of the B. cepacia complex which form part of
this thesis have recently been published (Nzula, Vandamme, et al, 2000). In summary,
38 strains ofB. cepacia from clinical and environmental sources were tested for
lysogeny by employing the same B. cepacia strains as indicator strains. Two strains,
ATCC 29424 (genomovar V) and ATCC 17616 (genomovar II), proved to be lysogenic,
providing the phages, named NS1 and NS2 respectively.
7.1.1. Virological characteristics and morphology of the phages NS1 and NS2
Plaques ofNS1 and NS2 on host cell lawns were found to be about 1mm in diameter,
and either clear or turbid depending on the host strain. Neither phage was inactivated by
treatment with chloroform. Electron microscopy showed NS1 and NS2 to resemble T-




The potential for NS1 and NS2 to act as agents of transduction was examined by
propagating the bacteriophages on ceftazidime-resistant mutants of the B. cepacia
complex strains ATCC 53266, ATCC 53267 and C2973; phage lysates were then used
to infect the sensitive parent strains. Ceftazidime resistance was transduced at a
o z
frequency ranging from 1.0x10" to 7.0 x 10" per infected cell depending on the phage
and recipient strain; these frequencies compared to spontaneous mutation frequencies
which varied from undetectable to 6.8 x 10"11. Similar results were obtained in three
replicate experiments.
7.1.3 Lytic spectrum of phages NS1 and NS2 against B. cepacia and P. aeruginosa.
Table 7.1 outlines B. cepacia strains sensitive to one or more phages; these strains
include environmental and clinical isolates of the B. cepacia strain panel
(Mahenthiralingam, Coenye, et al, 2000) and representatives of the species and
genomovars of the B. cepacia complex (Vandamme, Holmes, et al, 1997). When
combined, the host range ofNS1 and NS2 included B. multivorans and B. vietnamiensis,
as well as genomovars I and III. Interestingly, J2540 was the only genomovar I strain
among 18 strains tested that was sensitive to NS1 or NS2. Neither phage lysed any of
the four B. stabilis strains tested. Only a few representatives of this group were
available for investigation and these results are inconclusive, however, as the genome of
this organism is highly conserved and shows little diversity based on PFGE analyses
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(Vandamme, Mahenthiralingam, et al, 2000), it is possible that resistance to NS1 and
NS2 may be a characteristic ofB. stabilis. Ofparticular interest, each of the seven
genomovar III clones in the B. cepacia strain panel, including the intercontinental
epidemic lineage ET12, showed sensitivity to one or more of the phages. However,
none of the recently isolated environmental B. cepacia genomovar III strains were
sensitive to NS1 and NS2. Several biopesticide candidate strains were also found to be
sensitive to NS1 and NS2; these included ATCC 53266 and ATCC 53267.
Table 7.1 Isolates of the B. cepacia complex sensitive to NS1 and NS2
Isolate Genomovar NS1 NS2
J2540 I + +
C2775 II + +
J2315 III - +
ATCC 17765 III - +
CI 394 III - +
J415 III - +
BC7 III - +
K56-2 III - +
C6433 III - +
PC 184 III + +
CEP511 III + +
LMG 18836 V - +
ATCC 53266 V + +
ATCC 53267 V + +
ATCC 29424 V - +
C2973 V + +
LMG 16232 V + +
+, sensitive; resistant
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To determine if the host range ofB. cepacia phages extended to other pseudomonads, 42
strains ofP. aeruginosa, (14 environmental and 28 CF isolates), were examined for
sensitivity to NS1 and NS2. Eight P. aeruginosa isolates (19%) were lysed by at least
one of the phages, five by both phages (12%), one (2%) by NS1 and two (5%) by NS2
(Table 7.2). Unfortunately, the well-characterised laboratory strain PAOl, was
insensitive to both phages.
Table 7.2. Isolates ofP. aeruginosa sensitive to NS1 and NS2
Isolate Source NS1 NS2
A13 CF sputum + -
A14 CF sputum - +
A18 CF sputum + +
A20 CF sputum + +
A21 CF sputum + +
A31 CF sputum - +
J1376 Environment + +
J1476 Soil + +
+, sensitive; resistant
Sensitivity ofP. aeruginosa to B. cepacia phages prompted an investigation of the
corresponding sensitivity ofB. cepacia isolates to P. aeruginosa phages. Of 38 strains
ofB. cepacia investigated, three strains one each of genomovars I, III and V were found
to be sensitive to four well-characterised P. aeruginosa phages. These included the
virulent phage E79, and the transducing phages B3, F116L and G101 (Holloway,
Krishnapillai, et al, 1975).
210
7.1.4. Effect of LPS on phage activity
Sensitivity of the B. cepacia strains to NS1 and NS2 did not appear to correlate with
previously reported rough or smooth LPS chemotypes (Simpson, Finlay, et al, 1994;
Evans, Poxton, et al, 1999). However, experiments obtained during this thesis suggested
that LPS receptors were responsible for sensitivity ofB. cepacia to both phages.
Table 7.3 shows the effect ofpre-incubating NS1 and NS2 with LPS before infecting
sensitive strains. Depending on the phage and host strain, titres of plaque-forming units
decreased by between 33 and 98% compared to controls which had been pre-incubated
with buffer.
Table 7.3 Effect of LPS on phage activity
Strain Phage Number of Plaque forming
units per ml
Control Phage and LPS Decrease (%)
ATCC 29424 NS2 3620 870 76
C2973 NS1 640 430 33
C2973 NS2 270 130 52
ATCC 53267 NS1 5290 120 98
ATCC 53267 NS2 2050 90 96
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7.2. B. cepacia complex plasmids
This study examined 29 B. cepacia complex strains and found that 26 (90%) harboured a
small plasmid of about 23kb that could be detected by agarose gel electrophoresis.
Larger plasmids were detected by PFGE; nine of the ten strains in which large plasmids
were detected, contained a plasmid of 194 kb. The B. cepacia genomovar III strain CEP
511 contained a larger plasmid of about 242 kb (Fig 7.3).
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Fig 7.2.(a) Plasmids of the B. cepacia complex detected by agarose gel electrophoresis
Lanes 1 to 19, X Hind III marker, lkb ladder, J2315, CEP 511, CI576, C5393,
K56-2, AMMD, 249-2, PC 184, ATCC15416, FC441, LMG 10929, C1962, ATCC
17759, J415, JTC, C5424, CI394, respectively.
Fig 7.2.(b) Plasmids of the B. cepacia complex detected by agarose gel electrophoresis
Lanesl to 13 XHindUl marker, lkb ladder, LMG 14086, CF-A1-1, LMG 18888,




Fig 7.3 Plasmids of the B. cepacia complex detected by PFGE
Lanes 1 to 15, X ladder PFG marker, CEP511, C1576, C5393, LMG 14086,
CF-A1-1, 249-2, PC 184, ATCC 25416, FC411, CI962, JTC, J415, J2315, X ladder
PFG marker, respectively.
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7.3. Natural transformation of the B. cepacia complex
Ten recipient B. cepacia complex strains in which the dsb gene had been detected, were
propagated on CAB. The recipient strains were transformed with DNA from a
recombinant B. cepacia J2315 strain generated in this thesis, which harboured a mercury
resistance marker ligated to its dsb gene. Transformed cells were able to grow in BCSM
with 18 ml/L ofmercury whereas the non-DNA-treated controls could not.
When the recipient strains were propagated on minimal agar before treatment with the
crude DNA extract, more strains became transformable (Table 7.4). Most of the
B. cepacia genomovar III strains studied could undergo natural transformation.
Interestingly, the former candidate biopesticide C3041, and the B. cepacia genomovar I
strain J2535, could also be transformed naturally with DNA extracted from the highly
transmissible CF strain J2315.
Transformation could not be investigated in B. cepacia genomovar III strains 715j and
CEP 511, and the B. cepacia genomovar I strain ATCC 25416 since they were found to
be inherently resistant to mercury at concentrations of 18 mg L"1. With most strains it
was necessary to increase competence for transformation by previous growth in MA.
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Table 7.4. Natural transformation of the B. cepacia complex
Growth medium Transformed strains
Columbia agar base CI394
Minimal agar C1394, J2535, C3041, BC7, K56-2,
C5424
7.4. Discussion
7.4.1 Bacteriophages of the B. cepacia complex
A literature search found only two previous reported studies on B. cepacia phages. NS1
and NS2 appear to be morphologically similar to the T-even phages, with hexagonal
heads and contractile tails. Similar characteristics were described previously (Cihlar,
Lessie, et al, 1978; Matsumoto, Itoh, et al, 1986) for the transducing phages CP1 and
CP75, respectively. The molecular mass ofNS1 and NS2 phage genomes was
approximately 48kb, which is reasonably close to the molecular size of 52 kb reported
for CP75. Unfortunately, phages CP1 and CP75 were unavailable for comparative
studies.
The shared host spectrum of phages NS1 and NS2 between B. cepacia and
P. aeruginosa is particularly interesting and potentially important. P. aeruginosa and
B. cepacia share environmental habitats and often co-colonise airways of CF patients at
high bacterial density (10 9 cfu ml _1). Different strains of each pathogen may also co-
colonise the same patient. Phages such as NS1 and NS2, together with the classic
P. aeruginosa transducing phages F116L, G101 and B3, would have the potential and
opportunity to mediate transfer of virulence and resistance factors in vivo between
clinical isolates of two major opportunistic pathogens and environmental isolates of the
B. cepacia complex, including isolates that might be candidate biopesticide strains.
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Acquisition of virulence factors mediated by transduction has been reported in Vibrio
cholerae (Parker, Richardson, et al, 1970) and Streptococcus pyogenes (Kapur, Nelson,
et al, 1992). In V. cholerae, it has been suggested that transduction contributes to the
evolution of epidemic strains (Mooi and Bik, 1997). Although most transduction studies
are carried out on auxotrophic mutants, the transduction frequencies of 1.0 x 10" to 7.0
x 10"6 obtained in this thesis are similar to previously published frequencies of
transduction in different bacteria and phages (Krishnapillai, 1971; Matsumoto, Ito, et al,
1986\ Weiss, Capage, et al, 1994; Toth, Mulholland, et al, 1997).
Previous evidence for the assimilation of foreign DNA by B. cepacia has drawn on the
significantly lower G + C content of insertion sequences when compared with native
DNA (Lessie, Hendrickson, et al, 1996). It has also been reported that insertion
sequences found in B. cepacia J2315, a representative of the genomovar III and
epidemic lineage ET12, are identical to those found in Burkholderia pseudomallei
(Mack and Titball, 1998). B. pseudomallei is the highly virulent agent of the tropical
disease melioidosis and shares environmental habitats with B. cepacia and
P. aeruginosa. Of equal, if not more significance, there are also recent reports ofCF
patients co-colonised with B. pseudomallei and B. cepacia following holidays in South
East Asia. These developments are important and suggest that further studies should be
performed:
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1.to determine if the host range ofNS1, NS2 and the P. aeruginosa transducing phages
extends to B. pseudomallei, and to the closely related and highly virulent equine and
human pathogen, Burkholderia mallei.
2. to determine whether B. cepacia and P. aeruginosa transducing phages can mediate
transduction of genes associated with virulence and epidemic markers between different
subpopulations of the B. cepacia complex and between members of the complex and
other 'pseudomonads'.
The activity ofNS1 and NS2 is inhibited by LPS, suggesting that LPS is a binding site
for both phages. An LPS receptor would explain the sensitivity ofP. aeruginosa to
B. cepacia phages since Western blotting and absorption studies have indicated cross-
reactivity in antibodies to the core LPS of both species (Nelson, Butler, et al, 1993). An
NS2 receptor located within core LPS is also supported by previous analyses of
B. cepacia LPS chemotypes which showed that most clinical genomovar III isolates
express only core LPS (Evans, Poxton, et al, 1999) and our observation in this study that
the majority of clinical genomovar III isolates were sensitive to NS2. The LPS
chemotypes of the recently identified environmental B. cepacia genomovar III isolates
have still to be determined. However, the resistance of these environmental isolates to
NS2 could indicate that the LPS from environmental B. cepacia genomovar III isolates
differ from that of the clinical isolates belonging to the same genomovar. Further
studies are required to compare the LPS chemotypes of clinical and environmental
B. cepacia genomovar III isolates.
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An exhaustive literature search indicates that this is probably the first report of B.
cepacia transducing phages whose host spectrum spans environmental and clinical
isolates, several subpopulations within the B. cepacia complex and candidate
biopesticide strains. It is also the first report of the sensitivity ofB. cepacia isolates to
well-characterised transducing phages of P. aeruginosa. Given the present difficulties in
genetic manipulation ofmultiresistant strains ofB. cepacia, transducing phages could
provide a useful mechanism to study horizontal gene transfer in B. cepacia and other
pseudomonads. Further studies of the bacterial receptors for NS1 and NS2 could also
clarify the relationships of the LPS chemotypes ofB. cepacia and P. aeruginosa.
7.4.2. B. cepacia plasmids
Plasmids have been found in many genera of soil bacteria and conjugative plasmids have
been described as an important means of gene transfer in the environment (Reanney,
Gowland, et al, 1983). In this study, most of the B. cepacia strains examined were
found to harbour a plasmid of about 23kb. This common occurrence ofplasmids in
B. cepacia has been demonstrated previously (Gonzalez and Vidver, 1979), although no
phenotypic function was assigned to any of these plasmids. Furthermore, these studies
were performed prior to the knowledge of the complex taxonomy ofwhat at the time
was described as 'P. cepaciaThe large plasmid of 194kb detected in this thesis is
probably the same as the 200kb plasmid reported previously as a constituent of the
B. cepacia genome (Cheng and Lessie, 1994; Rodley, Romling, et al, 1995). Plasmids
conferring resistance to drugs such as tetracycline, ampicillin (Williams, Yeggy, et al,
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1979) and streptomycin (Hirai, Iyobe, et al, 1982), have been isolated from B. cepacia
strains. The streptomycin resistance B. cepacia plasmid Rms 425 can be transferred by
conjugation between isogenic strains ofP. aeruginosa and ofE. coli (Hirai, Iyobe, et al,
1982). The conjugative transfer ofplasmids between B. cepacia and P. aeruginosa is
important as these organisms share environmental habitats and both colonise airways of
CF patients.
Not only can B. cepacia DNA be transferred to P. aeruginosa, but B. cepacia can also
accept DNA by conjugative transfer from P. aeruginosa and transfer it to other
B. cepacia strains (Lennon and DeCicco, 1991). In addition, B. cepacia can harbour
broad-host-range plasmids that can be transferred by conjugation to P. putida as well as
E. coli and other enterobacteria (Sabate, Villanueva, et al, 1994).
Conjugation is the only mechanisms of genetic exchange that has thus far been
demonstrated to occur in B. cepacia in the natural environment. Conjugation of
B. cepacia strains in the rhizosphere of barley and radish has been shown to occur within
24 hours of inoculation (Walter, Porteous, et al, 1991). The number of transconjugates
in the rhizosphere peaks at about two days after planting and then start to decline
(Walter, Porteous, et al, 1991). Thus, B. cepacia appears to be able to exchange genes
by conjugation ifpresent in high densities in the soil. Experiments on the use of
B. cepacia complex strains as biopesticides indicate that there is a high density of
organisms in the soil immediately after inoculation, before the levels start to decline and
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stabilise (King and Parke, 1993). Thus, gene transfer through conjugation could be
expected to occur during this 'time frame' of high bacterial density in the soil.
7.4.3 Natural transformation of the B. cepacia complex
While relatively few studies have demonstrated gene exchange in soil, transformation
could occur if the DNA released from dead cells was able to transform competent
recipients. Most soils contain DNAse; and thus DNA released from bacteria would not
be expected to survive intact for long. However, it is possible in some ecosystems that
naked DNA might be protected from degradative nucleases by adsorption to particulate
material such as clay (Lorenz and Wackernagel, 1987).
In P. stutzeri and related Pseudomonas species (Carlson, Pierson, et al, 1983), natural
transformation by homologous chromosomal DNA has been demonstrated to occur
readily on plates. Carlson and co-workers found only double-stranded linear DNA to be
effective, with plasmid DNA and single-stranded DNA unsuitable for transformation of
P. stutzeri. A later study found that not only could P. stutzeri be transformed by plasmid
and extracellular DNA but transformation could occur in a non-sterile soil (Sikorski,
Graupner, et al, 1998). Thus, P. stutzeri appears to be able to exchange DNA by
transformation in its natural habitat. Interestingly, B. cepacia plasmid DNA can not
only transform other B. cepacia strains but it can also transform E. coli and other
enterobacteria, as well as the major CF pathogen and soil inhabitant P. aeruginosa
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(Hirai, Iyobe, et al, 1982; Sabate, Villanueva, et al, 1994). Thus, genetic exchange
through natural transformation with plasmid DNA could potentially occur between
different B. cepacia complex strains as well as between the B. cepacia complex and
P. aeruginosa.
Linear double-stranded DNA was used in this thesis to demonstrate natural
transformation of the B. cepacia complex. Interestingly, this study found that
competence of the B. cepacia complex increased with nutrient deprivation, as the
majority of strains were only transformed when propagated on minimal agar. Similar
results were reported by Carlson and co-workers (1983), who found that the competence
of P. stutzeri increased with nutrient deprivation. Ofmajor importance in this thesis,
DNA from the highly transmissible B. cepacia genomovar III strain, J2315, was
successfully used to transform other B. cepacia complex strains, including a biopesticide
candidate. This observation suggests that transformation could occur in the
environment, resulting in the exchange ofDNA between clinical and biopesticide
strains. Biopesticides strains could be present in very large quantities in the
environment if granted licenses for commercial application.
Available evidence from in vitro experiments indicates that some exchange through
transformation can occur between B. cepacia complex strains and between members of
the complex and other genera. While laboratory experiments do not automatically
translate to events in the natural environment, demonstration of natural competence in
the B. cepacia complex indicates a potential for transformation in conducive conditions
in natural environments.
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In conclusion, exchange of genes between different B. cepacia complex strains and
between the B. cepacia complex and other genera has been demonstrated in vitro
through transformation, transduction and conjugation. In addition, genetic exchange by
conjugation is known to occur in the rhizosphere, the natural habitat of the B. cepacia
complex. It seems highly likely that large-scale bulk applications of the B. cepacia
complex to the environment would encourage horizontal gene transfer not only between
different B. cepacia complex strains but also with other soil flora such as P. putida and
the major CF pathogen and soil organism, P. aeruginosa. At the moment, the risk of
such events to CF patients is not known and more studies are urgently required to
facilitate informed decision-making on the large-scale biotechnological applications of
the B. cepacia complex. The exchange of genetic material through natural
transformation between the well-characterised, epidemic B. cepacia genomovar III strain
J2315, and a candidate biopesticide strain demonstrated in this thesis; as well as the
isolation of transducing phages whose host spectrum spans clinical, environmental and
candidate biopesticide B. cepacia complex strains, provides new and potentially
important evidence of the transfer of virulence and resistance factors between




In the last twenty years, members of the B. cepacia complex have emerged as life-
threatening pathogens of immuno-compromised patients that occasionally infect healthy
individuals. Ironically, due their potent antifungal and extraordinary metabolic
properties, these bacteria also have considerable potential for commercial exploitation as
agricultural biopesticides and remediators of contaminated soils. In these roles, the B.
cepacia complex would provide an efficient, cost-effective and environmentally-friendly
replacement of conventional pesticides and reduce the need for nitrogenous fertilisers by
up to 20%. In an attempt to resolve these conflicting roles, and possibly provide 'safe'
biological-based commercial agents, attempts have been made to identify differences
between clinical and environmental isolates of the B. cepacia complex.
At present, the virulence factors of the B. cepacia complex remain ill-defined and not
well understood. Intrinsic resistance to several classes of antibiotics is characteristic of
the B. cepacia complex. For example, all B. cepacia complex strains are resistant to
colistin (colomycin), a polymyxin antibiotic that has been effectively used for many
years in the treatment of infections caused by P. aeruginosa and other Gram-negative
bacilli (Littlewood, Koch, et al, 2000). Although resistance to colomyxin is universal
for all B. cepacia complex strains, resistance to some antibiotics appears to be
genomovar-dependent. This could be encouraging for the use of the B. cepacia complex
as biopesticides, since strains for large-scale commercial application could be chosen
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from genomovars that are sensitive to antibiotics. However, from the seven antibiotics
studied in this thesis, genomovar-dependent sensitivity was only observed for
chloramphenicol, which is no longer routinely used for the treatment ofB. cepacia
complex infections and is associated with toxicity to the bone marrow.
In the studies performed for this thesis, B. vietnamiensis (genomovar V) strains appeared
more sensitive to chloramphenicol and ceftazidime than strains from the other
genomovars. It has often been argued that B. vietnamiensis poses a minor threat to CF
patients since the numbers isolated from the respiratory tracts of patients are relatively
low and strains in this genomovar have not, so far, been associated with acute
exacerbations and 'cepacia syndrome'. Thus, B. vietnamiensis strains have been
regarded as ideal candidates for use as biopesticides. Sensitivity to ceftazidime, one of
the few currently effective antibiotics for the treatment ofB. cepacia complex infections,
could provide an argument for the commercial application ofB. vietnamiensis strains as
biopesticides. However, B. vietnamiensis strains were not significantly sensitive to
ciprofloxacin, the other routinely used antibiotic. Furthermore, sensitive strains were
found to mutate readily to resist high levels of ceftazidime and ciprofloxacin. In
conclusion, the sensitivity ofB. vietnamiensis to antibiotics does not provide a sound
argument for their bulk distribution into the environment.
The widespread belief that only environmental, and not clinical isolates, possess
phytopathogens is potentially misleading. Both clinical and environmental strains can
be pathogenic for plants depending on the plant host tested. Thus, phytopathogenicity is
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not dictated by the origin of strains but rather, might be dependent on the individual
strain concerned. Accumulating evidence suggests that there are no inherent differences
between clinical and environmental strains that determine the phytopathogenie potential
ofmembers of the B. cepacia complex.
Although the mechanisms ofpathogenicity involved in B. cepacia complex infections
are unclear, several putative virulence factors have been described. Production of
elastase would be advantageous for a respiratory pathogen since elastin forms the major
constituent of elastic tissue fibres such as the walls of the alveoli of the lungs. However,
only a minority of B. cepacia complex strains, of both clinical and environmental origin,
produce elastase, making it an unlikely contributor to the organism's role in lung
disease. Most environmental, clinical and candidate biopesticide strains produce
protease. Interestingly, strains representing several sub-groups within the B. cepacia
complex were found to harbour the dsb gene whose product is required for the
disulphide bonds ofB. cepacia's metalloprotease PSCP. PSCP produces
bronchopneumonia in rats, thus all sub-groups of the B. cepacia complex could
potentially produce bronchpneumonia in suitable hosts.
The association of certain B. cepacia complex isolates with epidemic spread is now well
recognised and three genetic markers associated with enhanced transmissibility have
been identified. These 'epidemic markers', (cable pili, BCESM and IS402-IS1356) have
not only been detected in clinical strains but also in strains isolated from the
environment and candidate biopesticide strains. Of greater significance is the lack of
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detection of any of these markers in B. multivorans strains that are known to have
caused epidemics (Whiteford, Wilkinson, et al, 1995; Mahenthiralingam, Coenye, et al,
2000). Thus, at present, although identification of currently known epidemic markers is
useful and informative, their presence does not unequivocally identify all members of
the B. cepacia complex with enhanced transmissibility.
With the exception of the enzyme catalase and the pigment melanin that were produced
only by clinical strains, most putative virulence factors of the B. cepacia complex were
found in this thesis to be also produced by candidate biopesticide strains and
environmental isolates. Thus, clinical, environmental and candidate biopesticide strains
within the B. cepacia complex could be pathogenic to susceptible human hosts.
Until recently, the high isolation rate ofB. cepacia genomovar III isolates from the
respiratory tracts of CF patients, contrasted with their apparent absence from the natural
environments, presented an interesting and important enigma. However, reports of
B. cepacia genomovar III environmental isolates have recently started to emerge and
renewed the 'biopesticide' argument of agricultural microbiologists that there is no
danger in adding it to the environment when it is already present naturally. It could be
also argued that sub-populations of the B. cepacia complex that are naturally maintained
at high, stable numbers in the environment and have minimal clinical effects, would be
most suitable for commercial exploitation. Such a sub-population is yet to be identified.
The incidence of each of the B. cepacia genomovars in the environment and the clinical
outcome of patients colonised by them, needs to be assessed in order to determine the
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effects of introducing large quantities of the B. cepacia complex to the environment. In
conclusion, current evidence indicates that the classification ofB. cepacia complex
strains as clinical or environmental is superficial and bears no correlation to a strain's
potential pathogenicity to either humans or plants.
Undoubtedly, strains of the complex could prove to be effective and ecologically-
friendly biopesticides. Furthermore, their ability to degrade an array of recalcitrant
xenobiotic or toxic compounds suggests that they would also make ideal bioremediation
agents. One of the major obstructions to the biotechnological applications of the
B. cepacia complex is the lack of knowledge regarding the fate of these agents once
introduced into the environment. Factors such as bacterial persistence in the
environment, reproduction and mutation rate, and rate of gene transfer to other soil
organisms need to be studied and understood before sound and unequivocable
judgements can be made.
Genetic exchange between different B. cepacia complex strains and between the
complex and other genera has been demonstrated through the three major mechanisms
of transduction, transformation and conjugation. B. cepacia complex transducing
bacteriophages identified during this thesis and whose host spectrum spans
environmental, clinical and candidate biopesticide strains will be useful to investigate
gene transfer between these host groups. B. cepacia complex phages whose host
spectrum also includes P. aeruginosa (and possibly other pseudomonads) could facilitate
the exchange of genes between these two soil organisms and co-colonisers of the
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airways of CF patients. Furthermore, large-scale bulk applications ofB. cepacia to the
environment could provide the necessary high densities of organisms to facilitate the
exchange of genes between different B. cepacia complex strains and between the
B. cepacia complex and other soil organisms such as P. aeruginosa.
B. cepacia complex strains that are not pathogenic to humans, are incapable of
transferring their genes or acquiring foreign ones and have minimal effect on soil
microflora would be ideal for large-scale commercial exploitation. Such strains have yet
to be identified. Although there are some animal models of CF available and they have
proved useful (Dorin, Dickinson, et al, 1992; Dorin, Stevenson, et al, 1994; Davidson,
Dorin, et al, 1995; Speert, Steen, et al, 1999), they are not reliable enough to provide the
unequivocal evidence of'safe biopesticides'. At present, the introduction of bulk
quantities of the B. cepacia complex to the environment poses an unacceptable threat to
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1.1. The Microbial Identification System (MIS) Chromatographic unitfor cellularfatty
acid analysis.
The MIS chromatographic unit consists of a Hewlett-Packard 5890A Gas
Chromatograph (with flame ionising detector (FID)), a 3396A Integrator and a 7673A
Automatic Sampler (with injector, controller and tray).
The column used with the MIS is a 25mm x 0.2 mm methyl phenyl silicone fused silica
capillary column (HP 19091-102).
The MIS operates at a 100:1 split ratio i.e. 1/100 of the sample enters the capillary
column while the rest is vented out the split vent.
1.1.1. Gas flows
Supply gas Flows (approximate)
Air 400ml min"1
Hydrogen 30ml min"1 (FID)
55 ml min"1 (split vent)
5ml min"1 (Septum purge), carrier gas
Nitrogen (auxilliary gas) 30ml min"1
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1.2. MIS computer system
1.2.1. Computer system connected to the chromatographic unit
Hewlett-Packard Series 310 workstation with 1 megabyte RAM
40 megabytes 9153 C disk drive with 8.89cm flexible disk drive
Monochrome moniter
This unit has the following responsibilities:
Data acquisition from the chromatographic unit






5°C min"1 from 170°C to 270°C
30°C min"1 from 270°C to 310°C
2 min at 310°C
3 min at 170°C
1.2.2. Second computer unit
The second computer unit consists of the following:
IBM-compatible 864DX PC with 4 megabytes RAM
130 megabytes hard disk with 8.89 and 13.34 floppy drives
SVGA colour monitor
This unit has the following responsibilities:









Made up to 1.0L with double distilled water. pH 7.3 and stored at 4°C
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2.2. Tris-HCl buffers
The pH together with the conductivity were adjusted with a standardised 1.72M HC1
solution, titrated against NaOH IN .




H20 up to 100ml
pH 6.8 and stored at -20°C
0.75g Tris, 50ml of double distilled water and 3.27 ml 1.72N HC1 gives a pH of 6.80.
After adding 5ml C2H6OS and 5g sucrose and adjusting the volume to 100ml, the
solution has a conductivity of 3.87mS at 23°C.
b). Separation gel buffer
Tris 18.15g
H20 up to 100ml
pH 8.8 and stored at 4°C
Mixing 18.15g Tris, 50ml double distilled water, 24.2ml 1.72N HC1 and adjusting the
volume to 100ml gives the solution a pH of 8.78 and a conductivity of 16.7mS at 23°C.
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c). Stacking gel buffer
Tris 6g
H20 up to 100ml
pH 6.8 and stored at 4°C
Mixing 6g Tris, 50ml double distilled water, 27.8ml 1.72N HC1 and adjusting the
volume to 100ml gives the solution a pH of 6.82 and a conductivity of 25.8mS at 24°C.
2.3. Tris-glycine buffers




H20 up to 4L
pH 8.59 and stored at room temperature
The conductivity is 624pS at 19°C.




H20 up to 500ml
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Bis acrylamide (BDH) 0.8g
H20 up to 100ml
Solution has conductivity of 624pS, should be kept on ice and stored at 4°C.
2.5. SDS solution
10 or 20g sodium dodecyl sulphate is dissolved in 100ml of distilled water to make a 10
or 20% solution. The solution should be kept at room temperature as SDS precipitates
below 10°C.
2.6. Staining solution
The staining solution is composed of:




H20 up to 1L






H20 up to 2L
Store at room temperature
2.8. Bromophenol blue 0.001%
Stock solution lOmg lOOmf1 sample treatment buffer with 2% SDS and a 10-fold
dilution in sample treatment buffer with 2% SDS is used.
2.9. Loading dye/ Volume adjusting buffer
STB with 2% SDS and 0.001% bromophenol blue.
Store at -20°C.
2.10. Low molecular weight markers
The protein molecular weight markers were all obtained from Sigma. They were mixed
with STB with 20% SDS to obtain the optimal concentrations recommended by the
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Abstract
Burkholderia cepacia is now recognised as a life-threatening pathogen among several groups of immunocompromised patients. In this
context, the proposed large-scale use of these bacteria in agriculture has increased the need for a better understanding of the genetics of the
species forming the B. cepacia complex. Until now, little information has been available on the bacteriophages of the B. cepacia complex.
Transducing phages, named NS1 and NS2, were derived from the lysogenic B. cepacia strains ATCC 29424 and ATCC 17616. The
frequency of transduction per phage particle ranged from 1.0X 1CT8 to 7.0 X 10~6 depending on the phage and recipient strain used. The
host range of NS1 and NS2 differed but in each case included environmental and clinical isolates, and strains belonging to several species
and genomovars of the B. cepacia complex. The host range of both phages also included Pseudomonas aeruginosa. Some B. cepacia complex
isolates were sensitive to the well-characterised P. aeruginosa transducing phages. B3, F116L and G101. The lytic activity of NS1 and NS2
was inhibited by B. cepacia lipopolysaccharide suggesting that this moiety is a binding site for both phages. The molecular size of the NS1
and NS2 genomes was approximately 48 kb. © 2000 Federation of European Microbiological Societies. Published by Elsevier Science
B.V. All rights reserved.
Keywords: Burkholderia cepacia: Bacteriophage; Transduction; Genomovar; Pseudomonas aeruginosa
I. Introduction
Burkholderia (previously Pseudomonas) cepacia was first
described in 1950 as the phytopathogen responsible for
bacterial rot of onion bulbs [1], In the 1960s, seminal
taxonomic studies by Stanier and colleagues [2] high¬
lighted the organism's extraordinary metabolic ability to
degrade a wide range of organic compounds. Inherent re¬
sistance to antibiotics and survival in nutritionally limited
environments were also exemplified by the organism's use
of penicillin G as a sole carbon source [3] and its role as a
major bacterial contaminant of space shuttle water sup¬
plies [4] and bottled drinking water [5],
In the last two decades, B. cepacia has emerged as a life-
threatening human pathogen, in particular as a cause of
* Corresponding author. Tel.: +44 (131) 650 3165;
Fax: +44 (131) 650 6653; E-mail: snzula@ed.ac.uk
intractable life-threatening pulmonary infections in pa¬
tients with chronic granulomatous disease and cystic fibro¬
sis [6] or undergoing treatment in intensive care units [7],
Recently, attention has focused on the taxonomy of
B. cepacia for reasons which will become apparent. In
1992, the new genus Burkholderia was introduced with
Burkholderia cepacia named as the type species [8], Inte¬
grated genotypic and polyphasic taxonomy [9,10] showed
that isolates presumptively identified as B. cepacia com¬
prise several genomic species, or genomovars. Three ge¬
nomovars have been awarded species status as they can
be distinguished phenotypically: genomovar II (Burkhol¬
deria multivorans), genomovar IV (Burkholderia stahilis)
and genomovar V (Burkholderia vietnamiensis). These
three species together with genomovars I, III and VI pres¬
ently constitute the B. cepacia complex. Unless otherwise
indicated, the term B. cepacia will be used in this report to
refer to all members of the complex.
Interest in the taxonomy of B. cepacia arises not only
from the organism's role as a plant and human pathogen
but ironically from intense debate on the potential human
hazards associated with plans to exploit the antifungal and
0928-8244/00/520.00 © 2000 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.
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metabolic properties of these organisms as agricultural
biopesticides and bioremediators [11-14]. B. cepacia can
repress many soil-borne plant pathogens and thus improve
germination and crop yields [15]. Its striking metabolic
potential can also be exploited in the bioremediation of
environmental sites contaminated with toxic organic pes¬
ticides and herbicides. Regulatory agencies in North
America are presently faced with the task of providing
Solomon-like judgements on licence applications to per¬
form field trials of candidate biopesticide strains. Use of
B. cepacia on an agricultural scale would involve large
quantities of bacteria and, as noted in a recent report of
the United States Environmental Protection Agency
(http://www.epa.gov/oscpmont/sap/1999/july/fi-
nalrptl.pdf), introduces the potential hazard of horizontal
gene transfer between biopesticide strains and other mem¬
bers of the B. cepacia complex, including strains with po¬
tential to cause human infections.
Transduction is a major mechanism by which genetic
exchange could be facilitated between members of the
B. cepacia complex, furthermore, some of the difficulties
in genetic manipulation of B. cepacia [16], including vector
markers based on antibiotic resistance, could be resolved
by the availability of recombination systems based on
transducing phage. There are few published studies on
B. cepacia phage, and none recent enough to take account
of the major developments in B. cepacia taxonomy. To
our knowledge, the only previous report of a B. cepacia
transducing phage is that of Matsumoto et al. [17]. The
aim of our study was to search for evidence of lysogeny
within the B. cepacia complex and to investigate any
phages isolated. We report here the biological properties
of two B. cepacia transducing phages, NS1 and NS2; their
host ranges include several groups within the B. cepacia
complex and Pseudomonas aeruginosa. We also report the
sensitivity of B. cepacia to several classic P. aeruginosa
transducing phages.
2. Materials and methods
2.1. Bacteria and phage strains
The strains used in this study included 38 environmental
and clinical isolates of the B. cepacia complex. Also in¬
cluded were the 30 well-characterised strains of the B.
cepacia strain panel [16] which contains type strains and
representatives of the major genomic species belonging to
the B. cepacia complex [9]. Identification of all isolates was
confirmed by the API 20 NE system (bioMerieux, Marcy
TEtoile, France) and their genomovar and species status
identified by whole cell protein analysis and DNA:DNA
hybridisation using methods previously described [9], In
addition, 42 strains of P. aeruginosa were screened as po¬
tential hosts for phages NS1 and NS2. To ensure a lack of
clonal relationship, isolates were fingerprinted by pulsed
field gel electrophoresis (PFGE, CEIEF, Bio-Rad Labora¬
tories Inc.) using protocols described previously for
B. cepacia [18] and P. aeruginosa [19], Three isolates
(J2315, BC7 and K56-2) were already known to be clonal
[16] but were included in the B. cepacia complex strain
panel as geographically distinct representatives of the ma¬
jor epidemic lineage ET12 [6,20], Resistant mutants of
strains ATCC 53267 (ATCC 53267R), ATCC 29424
(ATCC 29424R) and C2973 (C2973R) with minimum in¬
hibitory concentrations (MICs) of ceftazidime of 8 pg
ml-1 were used for transduction studies. Cultures were
preserved in 10% skimmed milk at —70°C.
2.2. Media
All cultures were grown in nutrient broth+0.5% yeast
extract (NBYE) at 37°C in an orbital incubator at 140
rpm. Soft agar for phage experiments contained nutrient
broth with 0.3% (w/v) agar.
2.3. Isolation of bacterial mutants
Spontaneous bacterial mutants were isolated by spread¬
ing 100 pi of overnight broth cultures (approximately 108
cfu mfi') on the surface of iso-sensitest agar (Oxoid) con¬
taining antibiotic at concentrations ranging from the MIC
to 32 times the MIC. After incubation at 37°C in air for 48
h, mutational frequencies were calculated from results ob¬
tained with the highest concentration of antibiotic on
which resistant mutants were detected. The mutants were
cultured again on the medium containing the same con¬
centration of antibiotic and maintained in skimmed milk
at —70°C.
2.4. Isolation and propagation of bacteriophages
Overnight NBYE cultures of B. cepacia were harvested
at 3200 Xg for 30 min and the supernatants filtered (Milli-
pore: pore size 0.2 pin) and screened for the presence of
phage by spotting onto bacterial lawns using a multipoint
inoculator.
High-titre phage preparations for transduction were
prepared as follows: 100 pi of a phage preparation, con¬
taining approximately 103 plaque-forming units (pfu
ml"1), was added to 2.5 ml of molten soft nutrient agar,
previously seeded with 100 pi of an overnight culture of
the donor strain. The mixture was then overlaid on nu¬
trient agar and allowed to set. After 18 h at 37°C, overlays
showing semi-confluent lysis were transferred into 10 ml
phage buffer (10 mM Tris-HCl, pH 8.0, 10 mM MgCF)
[17]. The lysate was then vortexed, centrifuged at 3200Xg
for 30 min and the supernatant filtered. Phage titres were
determined as pfu ml"1 by incorporating diluted filtrate in
soft agar overlays using TNM buffer (Tris 0.01 M pH 7.4.
NaCl 0.15 M, MgSCC 0.01 M) [21]. Stock preparations
were maintained at 4°C.
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2.5. Host range of phages against B. cepacia and
P. aeruginosa
Stock phage solutions, diluted in phage buffer to ap¬
proximately 108 pfu ml-1, were spotted on to lawns of
B. cepacia and P. aeruginosa using a multipoint inoculator
and examined for lytic activity after 24 h at 37°C.
2.6. Purification ofphage DNA
Phage DNA was extracted using the method described
by Matsumoto et al. [17]. Genome size of unrestricted
DNA was estimated by PFGE (initial and final pulse times
of 5 and 20 s, 170 V at 14°C for 19 h) incorporating a X
ladder DNA PFGE standard kit (New England Biolabs,
Hitchin, Hertfordshire, UK).
2.7. Extraction of lipopolysaccharide (LPS)
B. cepacia LPS was extracted using the aqueous phenol
method of Westphal and Luderitz [22] as modified by
Hancock and Poxton [23].
2.8. Neutralisation of phage activity by LPS
The effect of pre-incubation with LPS on phage activity
was determined using a modification of the method de¬
scribed by Govan [24], Phage preparation (0.5 ml), con¬
taining approximately 103 pfu ml-1, was mixed with 0.5
ml of LPS (20 mg ml-1 solution in distilled pyrogen-free
water) and incubated at 37°C for 1 h. Controls comprised
phage and buffer without LPS. The experiment was re¬
peated and the results were calculated as the means of
three experiments.
2.9. Transduction
Transduction experiments were carried out using the
method described by Krishnapillai [21]. Phages NS1 and
NS2 were propagated on the ceftazidime-resistant mutants
of three B. cepacia strains with MICs of 8 (ig ml-1. Phage
lysate (0.5 ml) was added to a phosphate-buffered saline
suspension of the sensitive parent strains ATCC 53267,
ATCC 29424 and C2973 at a multiplicity of I and left
for 20 min at 37°C to allow phage adsorption. The cells
were harvested at 3200 Xg for 30 min, resuspended in
TNM buffer and 100 pi spread on nutrient agar containing
ceftazidime 8 pg ml-1. Transductants were recovered after
incubation at 37°C for 72 h. Controls comprised recipient
strains plus TNM buffer alone.
2.10. Electron microscopy
Phage lysates were centrifuged at 3200Xg to remove cell
debris, and then at 100000Xg for 1 h. The phage pellet
was resuspended in 1 M ammonium acetate. After nega¬
tive staining with 2% (w/v) potassium phosphotungstate
solution (pH 7.0), phage morphology was observed
with a transmission electron microscope (Hitachi type
12A).
3. Results
In preliminary experiments, 38 strains of B. cepacia
from clinical and environmental sources were tested
for lysogeny by employing the same B. cepacia strains as
indicator strains. Two strains, ATCC 29424 (genomovar
V) and ATCC 17616 (genomovar II), proved to be lyso-
genic, providing the phages named NS1 and NS2 respec¬
tively.
3.1. Virological characteristics and morphology of the
phages NS1 and NS2
Plaques of NS1 and NS2 on a host cell lawn were about
1 mm in diameter and either clear or turbid depending on
the host strain. Neither phage was inactivated by treat¬
ment with chloroform. Electron microscopy showed NS1
and NS2 to resemble T-even-like phages with a hexagonal
head and a contractile tail (Fig. 1).
3.2. Transduction
Phages NS1 and NS2 were propagated on three cefta¬
zidime-resistant mutants of B. cepacia and used to infect
the sensitive parent strains. Ceftazidime resistance was
transduced at a frequency ranging from LOxlO-8 to
7.0 X 10~6 per infected cell depending on the phage and
recipient strain; these compared to spontaneous mutation
frequencies between undetectable and 6.8X 10~". Similar
results were obtained in three replicate experiments.
Fig. 1. Electron micrograph of NS2 (X 56 000).
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Table 1
Isolates of the B. cepacia complex sensitive to NS1 and NS2
Isolate Genomovar NS1 NS2 Reference
J2540 I + + [9]
C2775 II + + This paper
J2315 III - + [16]
ATCC 17765 III - + [16]
CI 394 III - + [16]
J415 III - + [16]
BC7 III - + [16]
K56-2 III - + [16]
C6433 III - + [16]
PC 184 III + + [16]
CEP511 III + + [16]
LMG 18836 V - + [16]
ATCC 53266 V + + This paper
ATCC 53267 V + + This paper
ATCC 29424 V - + This paper
C2973 V + + This paper
LMG 16232 V + + [16]
3.3. Lytic spectrum of phages NS1 and NS2 against
B. cepacia and P. aeruginosa
Table 1 illustrates B. cepacia strains sensitive to one or
more phages; these strains include environmental and clin¬
ical isolates of the B. cepacia strain panel [16] and repre¬
sentatives of the species and genomovars of the B. cepacia
complex [9]. When combined, the host range of NS1 and
NS2 included B. multivorans and B. vietnamiensis, as well
as genomovars I and III. J2540 was the only genomovar I
strain among 18 strains tested that was sensitive to NS1 or
NS2. Neither phage lysed any of the four B. stabilis strains
tested. Only a few representatives of this group were avail¬
able for investigation and these results are inconclusive;
however, as the genome of this organism is highly con¬
served and shows little diversity on PFGE analyses [10], it
is possible that resistance to NS1 and NS2 may be a char¬
acteristic of B. stabilis. Of particular interest, each of the
seven genomovar III clones in the B. cepacia strain panel,
including the intercontinental epidemic lineage ET12,
showed sensitivity to one or more of the phages. Several
biopesticide candidate strains were also found to be sensi¬
tive to NS1 and NS2; these included ATCC 53266 and
ATCC 53267.
To determine if the host range of B. cepacia phages
extended to other pseudomonads, 42 strains of P. aerugi-
Table 2
Effect of LPS on phage activity
Strain Phage Number of plaque-forming units per ml
Control Phage and LPS Decrease (%)
ATCC 29424 NS2 3620 870 76
C2973 NS1 640 430 33
C2973 NS2 270 130 52
ATCC 53267 NS1 5290 120 98
ATCC 53267 NS2 2050 90 96
nosa were examined for sensitivity to NS1 and NS2. Eight
P. aeruginosa isolates (19%) were lysed by at least one of
the phages, five by both phages (12%), one (2%) by NS1
and two (5%) by NS2.
Sensitivity of P. aeruginosa to B. cepacia phages
prompted an investigation of the corresponding sensitivity
of B. cepacia isolates to P. aeruginosa phages. Of 38
strains of B. cepacia investigated, three strains, one each
of genomovars I, III and V, were found to be sensitive to
four well-characterised P. aeruginosa phages. These in¬
cluded the virulent phage E79, and the transducing phages
B3, F116L and G101 [25],
3.4. Effect of LPS on phage activity
Table 2 shows the effect of pre-incubating NS1 and NS2
with LPS before infecting sensitive strains. Depending on
the phage and host strain, titres of plaque-forming units
decreased by 33-98% compared to controls which had
been pre-incubated with buffer.
4. Discussion
NS1 and NS2 are morphologically similar to the T-even
phages with hexagonal heads and contractile tails. Similar
characteristics were described by Matsumoto et al. [17] for
the transducing phage CP75. The molecular mass of NS1
and NS2 phage genomes was approximately 48 kb, which
is reasonably close to the molecular size of 52 kb reported
for CP75. CP75 or the lysogenic strain PCT1 were un¬
available for comparative studies.
P. aeruginosa and B. cepacia share environmental hab¬
itats and often co-colonise airways of cystic fibrosis pa¬
tients at high bacterial density (109 cfu ml"1). Different
strains of each pathogen may also co-colonise the same
patient. Thus, NS1 and NS2, together with the classic
P. aeruginosa transducing phages F116L, G101 and B3,
have the potential and opportunity to mediate transfer
of virulence and resistance factors between clinical isolates
of two major opportunistic pathogens and environmental
isolates of the B. cepacia complex selected as candidate
biopesticide strains.
Acquisition of virulence factors mediated by transduc¬
tion has been reported in Vibrio cholerae [26] and Strepto¬
coccus pyogenes [27], In V. cholerae, it has been suggested
that transduction contributes to the evolution of epidemic
strains [28], Evidence for the assimilation of foreign DNA
by B. cepacia has been presented by citing the significantly
lower G+C content of insertion sequences when compared
with native DNA [29], It has also been reported that in¬
sertion sequences found in B. cepacia J2315, a representa¬
tive of the genomovar III and epidemic lineage ET12, are
identical to those found in Burkholderia pseudomallei [30],
B. pseudomallei is the highly virulent agent of the tropical
disease melioidosis and shares environmental habitats with
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B. cepacia and P. aeruginosa. There are also reports of
cystic fibrosis patients co-colonised with B. pseudomallei
and B. cepacia on return from holiday in South East
Asia. Further studies are required to determine: (1) if
the host range of NS1. NS2 and the P. aeruginosa trans¬
ducing phages extends to B. pseudomallei and to the
closely related and highly virulent equine and human
pathogen Burkholderia mallei; and (2) if B. cepacia and
P. aeruginosa transducing phages can mediate transduc¬
tion of genes associated with virulence and epidemic
markers between different subpopulations of the B. cepa¬
cia complex and between members of the complex and
other pseudomonads.
The activity of NS1 and NS2 is inhibited by LPS, sug¬
gesting that LPS is a binding site for both phages. An LPS
receptor would explain the sensitivity of P. aeruginosa to
B. cepacia phages since Western blotting and absorption
studies have indicated cross-reactivity in antibodies to the
core LPS of both species [31]. An NS2 receptor located
within core LPS is also supported by previous analyses of
B. cepacia LPS chemotypes which showed that most ge-
nomovar III isolates express only core LPS [32] and our
observation in this study that the majority of genomovar
III isolates were sensitive to NS2.
To our knowledge, this is the first report of B. cepacia
transducing phages the host spectrum of which spans en¬
vironmental and clinical isolates, several subpopulations
within the B. cepacia complex and candidate biopesticide
strains. It is also the first report of the sensitivity of
B. cepacia isolates to well-characterised transducing
phages of P. aeruginosa. Given the present difficulties in
genetic manipulation of multiresistant strains of B. cepa¬
cia, transducing phages could provide a useful mechanism
to study horizontal gene transfer in B. cepacia and other
pseudomonads. Further studies of the bacterial receptors
for NS1 and NS2 could also clarify the relationships of the
LPS chemotypes of B. cepacia and P. aeruginosa.
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